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Crimean-Congo hemorrhagic fever orthonairovirus (CCHFV) is a negative sense 
single stranded RNA virus, capable of causing fatal hemorrhagic fever in humans. 
Currently, an infectious clone system exists for CCHFV, however, owing to the 
high containment level required for experimentation with this virus, its potential is 
limited. Here, a highly efficient infectious clone system was developed for 
recovery of Hazara virus (HAZV), the first such orthonairovirus system able to be 
used in biosafety level 2 facilities, providing a valuable tool for increasing our 
understanding of these viruses.  
 
Mechanisms of viral subversion of cellular trafficking pathways involved in viral 
entry, gene expression, assembly and egress are poorly understood for HAZV 
and CCHFV. The infectious clone system was adapted to express eGFP, 
enabling screening of an siRNA library targeting genes involved in cellular 
trafficking networks via live-cell fluorescent imaging, the first such screen for a 
nairovirus. Screening revealed an important role for subunits of the coat protein 
1 vesicle coatomer (COPI), normally involved in regulation of Golgi / ER cargo 
trafficking. The effect was observed at multiple stages of the HAZV life cycle; an 
early stage prior to and including gene expression, and also a later stage during 
assembly and egress of infectious virus, with COPI-knockdown reducing titres by 
approximately 100-fold. 
 
In addition to gain of function mutations, such as the reporter virus discussed 
above, the infectious clone system represents a powerful tool for exploring the 
role of individual nucleotides, amino acids and entire open reading frames within 
the viral genome. Both CCHFV and HAZV contain a well-documented, highly 
conserved caspase cleavage motif on the apex of the arm domain on the 
nucleoprotein (N). Whilst previous literature has demonstrated this motif to be 
cleaved as purified protein, limited data exists as to its role in the context of viral 
replication in a cellular system. To this end, the infectious clone system described 
above was used to create a panel of mutants targeting this conserved caspase 
cleavage motifs within HAZV N. HAZV bearing an uncleavable DQVE sequence 
rescued efficiently with growth rates equivalent to those of wild-type virus in both 
mammalian and tick cells, showing this site was dispensable for virus 
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multiplication. In contrast, substitution of the DQVD motif with the similarly 
uncleavable AQVA sequence could not be rescued despite repeated efforts. 
Together, these results highlight the importance of this caspase cleavage site in 
the HAZV life cycle but reveal the DQVD sequence performs a critical, as yet 
unknown, role aside from caspase cleavage.  
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1.1 General introduction 
1.1.1  Discovery of CCHFV and HAZV 
Crimean-Congo hemorrhagic fever (CCHF) was first described between 1944 
and 1945 following an outbreak amongst approximately 200 Soviet military 
personnel in the Crimean Peninsula. The disease was initially named Crimean 
hemorrhagic fever (CHF). A viral aetiology was determined after psychiatric 
patients requiring pyrogenic therapy had CHF-like clinical symptoms induced 
following infection with a filterable agent isolated from CHF patients, termed 
Crimean hemorrhagic fever virus (Chumakov, 1945). The viral agent was first 
isolated following inoculation of new-born white mice with samples taken from 
a CHF patient in Astrakhan in 1967. The isolated strain (Drozdov) permitted 
development of antibodies and antigens to enable serological studies and 
comparisons to viruses isolated from outbreaks from various different 
geographical locations (Butenko et al., 1968). Collaboration between M.P 
Chumakov and Jordi Casals identified the virus isolated from Crimea in 1945 
to be antigenically indistinguishable from three stains of Congo virus taken 
from patients in the Congo and Uganda in 1956, resulting in the renaming of 
the virus to Crimean-Congo hemorrhagic fever virus which has since been 
adapted to Crimean-Congo hemorrhagic fever orthonairovirus (CCHFV) 
(Hoogstraal, 1979). The viral agent was also detected at a similar time in 
suspensions generated from Hyalomma plubeum (Hyalomma marginatum), 
identifying ticks as the vector of the virus (Butenko et al., 1968).  
 
Despite the identification and characterisation of CCHFV in the last 50 years, 
similar CCHF-like symptoms have long been documented in areas of 
Tajikistan, dating back to the 12th century. Symptoms included blood in the 
urine, vomit, sputum, rectum and abdominal cavity, with a tough, small 
arthropod responsible for the spread of the disease (Hoogstraal, 1966). More 
recently, CCHF has been recognised under three different names by the 
indigenous population of southern Uzbekistan, which suggests that despite 
the relatively recent advances in knowledge surrounding CCHFV, it has been 
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the responsible agent of human hemorrhagic fever for centuries (Hoogstraal, 
1979). 
 
Hazara orthonairovirus (HAZV) was first isolated in 1970 from the vole Alticola 
roylei in subarctic terrain in the Kaghan Valley in the Hazara district of West 
Pakistan. Early serological tests showed it to be a distinct, but related virus to 
the Crimean and Congo strains that were renamed to CCHFV (Begum, 
Wisseman Jr and Traub, 1970). In line with CCHFV infection, HAZV infection 
of suckling mice progresses in a similar manner, with an often fatal disease 
outcome following intracerebral inoculation, with high viral loads detected in 
the liver and brain tissue (Smirnova et al., 1977). However, there has been no 
evidence of HAZV infecting or causing disease in humans and limited 
information is available regarding its global distribution. 
 
1.1.2 CCHFV and HAZV classification 
CCHFV and HAZV are members of the order Bunyavirales, which was 
established in 2017 to accommodate related viruses exhibiting segmented, 
linear, single-stranded, negative or amibisense RNA genomes (Maes et al., 
2018). Initially 9 families were defined, however this was amended to 12 to 
permit efficient assignment of newly discovered species, most recently with 
the addition of the Leishbuvidae family and recreation of the Tospoviridae 
family in 2019 (Abudurexiti et al., 2019). There are currently around 500 
named isolates within this order, across 287 assigned species, making the 
Bunyavirales one of the largest taxonomic groupings. Prior to the formation of 
the order Bunyavirales, bunyaviruses were classified within the Bunyaviridae 
family, which comprised of 5 genera (Nairovirus, Orthobunyavirus, Hantavirus, 
Phlebovirus and Tospovirus). 
 
Both CCHFV and HAZV are members of the family Nairoviridae and are further 
classified into the orthonairovirus genus along with 13 other viruses (Figure 
1.1). Notable examples from within this genus include Dugbe orthonairovirus, 
the type species of the genus and Nairobi Sheep Disease orthonairovirus 
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(NSDV), which causes 90 % mortality in sheep and goats, causing significant 
economic disruption (Lasecka and Baron, 2014). 
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Family  Genus  Species 
Arenaviridae  Orthonairovirus  Artashat orthonairovirus 
Cruliviridae  Shaspivirus  Chim orthonairovirus 
Fimoviridae  Striwavirus  Crimean-Congo hemorrhagic fever orthonairovirus 
Hantaviridae    Dera Ghazi Khan orthonairovirus 
Leishbuviridae    Dugbe orthonairovirus 
Mypoviridae    Estero Real orthonairovirus 
Nairoviridae    Hazara orthonairovirus 
Peribunyaviridae    Hughes orthonairovirus 
Phasmaviridae    Kasokero orthonairovirus 
Phenuiviridae    Keterah orthonairovirus 
Tospoviridae    Nairobi sheep disease orthonairovirus 
Wupedeviridae    Qalyub orthonairovirus 
    Sakhalin orthonairovirus 
    Tamdy orthonairovirus 
    Thiafora orthonairovirus 
 
Figure 1.1, Classification of Hazara orthonairovirus (HAZV) and Crimean-Congo hemorrhagic fever orthonairovirus (CCHFV) within the 
Bunyavirales order 
Figure shows the taxonomy of HAZV and CCHFV within the Bunyavirales order, Nairoviridae family, orthonairovirus genus. All species within the 
orthonairovirus genus are listed.
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1.1.3 Transmission, vectors and hosts 
CCHFV is a zoonotic infection that is maintained in several species of ixodid 
(hard) ticks through trans-stadial, transovarial and venereal transmission. Whilst 
CCHFV has been isolated from other arthropods, such as biting midges, this is 
believed to be a result of recent feeding on an infected mammal (Causey et al., 
1970). CCHFV is unable to be maintained in soft ticks, experimental infection of 
such ticks demonstrated the virus was unable to spread to tissues or be 
maintained trans-stadially (Shepherd et al., 1989; Durden et al., 1993). The virus 
is amplified during the spring and summer months during blood meals taken by 
ticks on small or large mammalian hosts. As ixodid ticks maintain levels of 
CCHFV throughout their entire life cycle, they are true hosts. Humans only 
transiently maintain levels of CCHFV and do not provide a source of infection for 
ticks and are therefore accidental “dead-end” hosts for the virus (Bente et al., 
2013).  
 
Initial infection of the tick occurs when a bloodmeal is taken from an infected host, 
CCHFV then replicates in the lining of the tick’s midgut, before spreading to 
multiple tissues including the salivary glands and reproductive organs, where 
titres of CCHFV are highest (Nuttall et al., 1994). Infected females may pass the 
virus to offspring by transovarial transmission. Upon hatching, larvae of the 
Hyalomma spp. tick feed on a small mammalian or avian host for their first blood 
meal. Following engorgement, the nymph drops off this small host and following 
molting, develops into the adult form. Adult ticks take a second blood meal on a 
larger animal host and mate whilst feeding. Female ticks subsequently drop off 
and find a suitable location for oviposition, where the cycle then repeats (Estrada-
Peña and de la Fuente, 2014). A schematic of the life cycle of Hyalomma spp. 




Figure 1.2, The natural life cycle of the CCHFV vector, Hyalomma ticks 
The complete life cycle of the Hyalomma spp. tick requires a small and large host. A tick 
infected with CCHFV carries the virus for the full duration of its life cycle and can pass 
the virus vertically to offspring. Humans become infected following a bite with an infected 
tick at any stage of the life cycle, though questing adult Hyalomma ticks are thought to 
be responsible for the majority of human infections. 
 
Infection of hosts can be assessed by serosurveys, which have been the 
traditional method of identifying regions of CCHFV circulation. Direct infections of 
multiple species of wild and domestic animals with CCHFV identified low levels 
of replication in horses, donkeys, sheep, cattle and ostriches (Shepherd et al., 
1987, 1989; Wilson et al., 1990; Zeller, Cornet and Camicas, 1994). Whilst birds 
represent a common target for blood meals for the larvae and nymphs of the 
Hyalomma spp. ticks, there is limited evidence to suggest birds become viraemic 
following contact with an infected tick. Historical records suggest that whilst ticks 
isolated from birds were CCHFV positive, the birds themselves were not thought 
to be hosts for viral replication (Hoogstraal, 1979). Therefore, the likely role of 
birds in transmission of CCHFV is in increasing the global distribution of CCHFV 
positive ticks, rather than as a source for infecting naïve ticks. 
 
Transmission to humans naturally occurs when people are bitten by virally 
infected ticks. The two-host life cycle of Hyalomma spp. ticks may have 
implications on the number of human cases of CCHF. Where there is an 
abundance of both small and large mammalian hosts for Hyalomma spp. ticks, 
infection rates observed in humans are low. However, where there is an 
imbalance in numbers of large hosts compared to small hosts, human cases 
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appear to increase. It is hypothesised that this is the reason for the outbreak 
among Soviet military personnel in the Crimean. Wild hare populations had 
recently proliferated but numbers of livestock had been sharply reduced, leaving 
a lack of non-human large mammalian hosts for Hyalomma spp. ticks to take 
blood meals from. The sudden increase in cases of CCHF seen in the military 
personnel was likely a result of questing Hyalomma spp. ticks feeding on humans 
as an alternative. In addition to tick bites, human transmission can occur during 
contact with virally infected blood or bodily fluids of an infected patient during the 
first seven to ten days of illness.  
 
1.1.4 Epidemiology and global distribution of CCHFV 
CCHFV is the second most widespread medically important arbovirus, after 
Dengue virus, responsible for over 140 outbreaks and more than 6000 cases 
worldwide since its discovery (Appannanavar and Mishra, 2011). Outbreaks have 
occurred across a vast geographical distribution, ranging from China to Africa, 
with recent cases also reported in India, Europe and the Middle East (Hoogstraal, 
1979; Celikbas et al., 2014; Makwana et al., 2015; Spengler, Bergeron and Rollin, 
2016) (Figure 1.3). However, the true geographic distribution of CCHFV is likely 
to be larger than current estimates suggest, due to an absence of surveillance 
systems. Previous first reports of virus, or human cases of CCHF, have coincided 
with the implementation of surveillance systems, supporting a larger distribution 
than is currently known (Mamuchishvili et al., 2015). In addition, cases in endemic 
countries are rising annually, a study into cases of CCHF in Afghanistan between 
2016 and 2018 reported increasing cases year on year, with 163 cases in 2016, 
245 cases in 2017 and 483 cases in 2018. A potential explanation for this 
increase is the Eid-al-Adha festival, in which Muslims sacrifice cattle, sheep, 
goats or camels. For the next 10-15 years this festival is likely to be in the summer 
months when animals are likely to have peak viremia. Historically the festival has 
fallen in autumn or winter, during which fewer animals were infected, and thus 
posed less of an infection threat (Leblebicioglu et al., 2015). 
 
New cases are now also being reported in countries previously unaffected by the 
virus, which may be a result of the increased geographical distribution of the tick 
vector, with Hyalomma ticks detected for the first time in the UK and Norway by 
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the European Centre for Disease Prevention and Control (Jameson et al., 2012; 
Hansford et al., 2019). Additionally, countries have reported imported cases of 
CCHF from patients travelling to and from endemic regions. The UK confirmed 
two cases, one from a patient returning from Afghanistan in 2012 and another 
from Bulgaria in 2014 (Atkinson et al., 2012; Lumley et al., 2014). Given the ease 
of international travel in the modern era, it could be easily expected that imported 
cases could result in countries reporting first cases more frequently.  
 
Figure 1.3, Geographic distribution of Crimean-Congo hemorrhagic fever 
Countries in pale yellow report the presence of Hyalomma Spp. Countries in yellow 
have not reported cases of CCHF, but CCHFV has been isolated from ticks or animals 
in these countries, or serological evidence suggests its presence, in addition to 
presence of Hyalomma Spp. Orange countries report between 4 and 49 cases of 
CCHF per year. Red countries report more than 50 cases of CCHF per year. The 
horizontal line across the top of the map where countries are greyed out represents the 
northernmost limit of distribution of genus Hyalomma ticks. Image was adapted from an 






1.1.5 Diagnosis of CCHF 
Multiple methods of CCHF diagnosis exist, including reverse transcriptase (RT)-
PCR, immunofluorescence assay (IFA), antibody and antigen capture ELISA and 
virus isolation. Due to the biosafety containment level 4 (BSL-4) requirements of 
CCHFV, virus isolation is rarely used as a diagnostic tool. RT-PCR is primarily 
used as it has the highest detection sensitivity at the earliest time point of infection 
(Mazzola and Kelly-Cirino, 2019). However, challenges to RT-PCR diagnosis of 
CCHF arise from the inherent variability in CCHFV genomic sequences, with the 
conserved genomic sequence required for effective RT-PCR not determined for 
all strains of CCHFV (Vanhomwegen et al., 2012; Tezer and Polat, 2015). 
Therefore, the recommended diagnostic approach is a combination of a nucleic 
acid amplification test (NAAT), such as RT-PCR, with an immunological assay, 
such as an ELISA (Drosten et al., 2003; Fernandez-Garcia et al., 2014). Both 
NAATs and immunological approaches require a moderate to high level of 
biological containment infrastructure, which often does not exist at outbreak 
locations of CCHF. Rapid diagnostic tests (RDTs) that can diagnose at the point 
of care (POC) present an attractive option for initial screening in such locations. 
These POC devices are compact, self-contained and involve automated sample 
processing, meaning most healthcare workers can be trained in their use with 
minimal effort. RDTs utilise similar principles as NAATs and immunological based 
assays, combining them with a lateral flow format which enables much faster 
diagnosis, often within an hour of testing. The drawback of RDTs is their lower 
sensitivity of detection (Filippone et al., 2013), especially with immunological 
based options, due to the low serological response observed in severe and fatal 
cases of CCHF.  
 
1.1.6 Clinical manifestations and treatment options 
Humans become infected with CCHFV following a tick bite or contact with 
contaminated livestock, often during the butchering process. Nosocomial 
infections are also widespread and well documented, with healthcare workers 
from Europe, Asia, and Africa all found to have contracted CCHFV (Burney et al., 
1980; Antoniadis and Casals, 1982; Watts et al., 1988). Infection with CCHFV is 
often fatal, with 3-30 % of reported cases resulting in mortality, though previous 
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isolated outbreaks have seen significantly higher fatality rates of 70 % 
(Hoogstraal, 1979; Schwarz, Nsanze and Ameen, 1997; Mardani et al., 2003). 
 
Clinical progression of CCHF can be categorised into 4 distinct phases; 
incubation, pre-hemorrhagic, hemorrhagic and convalescence. The duration of 
these phases varies based on the source of infection, with delivery via tick bite 
resulting in the shortest duration of incubation (3.2 days) versus contact with 
infected blood of livestock (5 days) or humans (5.6 days) (Swanepoel et al., 
1987). The pre-hemorrhagic phase usually lasts an average of 3 days, though 
ranges from 1 to 7 days (Hoogstraal, 1979). During the pre-hemorrhagic phase 
symptoms of fever, headache, myalgia and dizziness are common, with some 
cases also causing diarrhoea, nausea and vomiting (Swanepoel et al., 1987; 
Schwarz, Nsanze and Ameen, 1997; Karti et al., 2004; Bakir et al., 2005). The 
hemorrhagic phase develops rapidly, lasting between 2 and 3 days and has 
associated symptoms of petechiae and appearance of haematomas on mucus 
membranes and skin. Bleeding from the nose, gastrointestinal system, uterus 
and urinary tract are also common, though vaginal, gingival and cerebral 
hemorrhage have been documented (Swanepoel et al., 1987; Ergönül, 2006). 
Convalescence occurs in survivors approximately 10 to 20 days after the first 
signs of illness; however, symptoms in this phase appear inconsistent across 
different outbreaks, including, but not limited to: tachycardia, labile pulse, loss of 
hearing and memory, polyneuritis and temporal complete loss of hair. 
 
Almost 80 years following the first description of CCHF and the later association 
with CCHFV as the cause, supportive care still remains the mainstay of treatment 
for CCHF patients. Currently there are no licensed vaccines or CCHF specific 
therapeutics, however ribavirin has shown potential as an anti-viral, and although 
its efficacy is debated, it is recommended by the World Health Organisation 
(WHO) alongside general supportive care. Ribavirin is a guanosine analogue that 
undergoes phosphorylation within the target cell to ribavirin-triphosphate (RTP) 
(Witkowski et al., 1972). RTP is then incorporated into the replicating RNA strand 
by the viral RNA dependent RNA polymerase (RdRp), as initially demonstrated 
with poliovirus, resulting in inhibition of chain elongation or chain termination and 
has since been used in treatment of Hepatits C virus (Crotty et al., 2000; Maag 
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et al., 2001). A STAT-1 knockout mouse model has previously shown ribavirin to 
have a protective role against CCHFV challenge, with greater success observed 
when administered at early stages of infection and with lower viral titres (Bente 
et al., 2010). However, another study assessing the efficacy of ribavirin and 
favipiravir, another nucleotide analogue also known as T-705, in an interferon 
(IFN) knockout mouse model found that despite a small number of mice surviving 
the CCHFV challenge, the majority succumbed to the disease and ribavirin had 
no significant effect on clinical outcome (Hawman et al., 2018). This study found 
favipiravir to demonstrate statistically significant clinical benefit to subjects with 
CCHF, even when administered later following infection, though a small 
percentage of patients did experience onset of CCHF following conclusion of the 
treatment. 
 
Despite the current lack of a globally approved vaccine, a potential CCHFV 
vaccine candidate has previously been trialled in Bulgaria. A virus preparation is 
grown in neonatal mouse brains then subsequently inactivated via chloroform 
treatment and heating to 58C prior to absorbing it onto aluminium hydroxide 
(Vasilenko, 1976). Between 1953 and 1974, 1105 cases of CCHF were reported 
in Bulgaria with a fatality rate of 17 %. Following an immunisation programme in 
1974, cases over the same period (1974 to 1996) dropped 4 fold to 279 with a 
fatality rate of 11.4 % and annual cases have remained relatively low (<20 cases 
per year) (Christova et al., 2009; Maltezou et al., 2010). However, this has only 
been authorised for use in Bulgaria where it was developed and has not met 
approval standards for other countries with at-risk populations due to safety 
concerns and the associated costs with scaling up production. 
 
Several potential future vaccination options are currently being researched. 
Perhaps the most promising candidate is a virus replicon particle (VRP) 
incorporating the full length S and L genome segments from the IbAr10200 strain 
whilst omitting the M segment, instead directly transfecting in an expression 
plasmid to permit generation and amplification of VRPs. This was recently shown 
to offer heterologous protection versus multiple strains of CCHFV (IbAr10200, 
Oman-97 and Turkey), with 100 % of the interferon /-receptor knockout 
(IFNAR-/-) mice surviving virus challenge with no signs of clinical disease 
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following a single dose of the VRP (Spengler et al., 2019). Whilst other previous 
work has demonstrated complete protection vs CCHFV challenge in IFNAR-/- 
mice, all required multiple doses and not all offered protection against multiple 
strains (Buttigieg et al., 2014; Hinkula et al., 2017; Aligholipour Farzani et al., 
2019; Rodriguez et al., 2019). 
 
1.2 The virus 
1.2.1 Virus structure 
CCHFV and HAZV have a host-derived membrane and present as broadly 
spherical virions approximately 80 to 100 nm in diameter (Martin et al., 1985). 
The structural glycoproteins Gn and Gc protrude through the membrane, 
extending 5 to 10 nm from the surface and are responsible for binding to cellular 
receptors during the entry phase (Bergeron, Vincent and Nichol, 2007). Within 
the virion, the viral genome segments are encapsidated within the viral 
nucleoprotein (N) and RdRp, with at least one copy of each genome segment 
within a single virion. A schematic of the HAZV virion and electron micrographs 
of CCHFV and HAZV are depicted in Figure 1.4, detailing the spherical nature 





Figure 1.4, Schematic diagram and electron micrographs of HAZV and CCHFV 
a) Schematic representation of a HAZV and CCHFV virion showing the glycoprotein 
studded membrane enclosing the three genome segments encapsidated with 
nucleoprotein and a copy of the viral RNA dependent RNA polymerase (RdRp) to form 
an RNP. b) Electron micrograph of HAZV virions, taken from (Punch et al., 2018), scale 
bar 100 nm. c) Electron micrograph of CCHFV virions, taken from (Martin, Lindsey-
Regnery et al. 1985), scale bar 100 nm. 
 
1.2.2 Viral genome structure 
The genome of CCHFV and HAZV is comprised of three single stranded RNA 
(ssRNA) segments, termed small (S), medium (M) and large (L), that encode the 
viral N, glycoprotein precursor (GPC) and RdRp, respectively. The CCHFV S 
segment has been reported to encode an additional non-structural protein (NSs) 
using an ambisense coding strategy (Barnwal et al., 2016). Sequence and amino 
acid conservation vary within CCHFV when geographically diverse strains are 
compared, with 20, 31 and 22 % nucleotide differences and 8, 27 and 10 % amino 
acid differences in the S, M and L segments, respectively (Deyde et al., 2006).  
 
The open reading frame (ORF) of each gene segment is flanked by a non-
translated region (NTR) at the 5' and 3' termini. These NTRs contain cis-acting 
signals that acts as promoters for viral RNA synthesis activities (Matsumoto et 
al., 2019; Mega et al., 2020). NTR sequences are also postulated to have roles 
involved in several additional aspects of the viral lifecycle, including 
encapsidation of viral RNA (vRNA) by N into ribonucleoprotein (RNP) complexes 
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and packaging of these RNPs into virions (Kohl et al., 2006). The length of the 
segment specific NTRs varies, however the 5' NTR in the vRNA is in all cases 
longer than its 3' partner. The terminal nine nucleotides (5'-UCUCAAAGA and 
3'AGAGUUUCU) are entirely conserved between segments and across different 
nairoviruses and may form closed hairpins to enable binding to the viral RdRp as 
shown in related viruses such as La Crosse virus (LACV) (Gerlach et al., 2015).  
 
1.3 The replication cycle of CCHFV and HAZV 
A complete and detailed description of the HAZV and CCHFV lifecycles remains 
unclear, due in part to the classification of CCHFV as a hazard level 4 pathogen, 
requiring BSL-4 facilities for its growth and study. In this section, current 
knowledge surrounding individual aspects of the life cycle of both HAZV and 
CCHFV is discussed.  
 
1.3.1 Binding and entry 
The initial phase of viral replication for enveloped viruses requires an interaction 
between viral and host cell components.  For CCHFV and HAZV, this is thought 
to be mediated by the viral glycoproteins. It is hypothesised that Gc serves as the 
viral component in the interaction (Xiao et al., 2011). Monoclonal antibodies 
against Gc, but not Gn, have been proven effective in preventing CCHFV 
infection during neutralisation assays in vitro. However, this is not consistent with 
in vivo results where monoclonal antibodies against Gn were found to offer more 
protective immunity against CCHFV in mice (Bertolotti-Ciarlet et al., 2005). There 
is little information surrounding the cellular receptor for CCHFV. A functional 
interaction has been suggested between Gc and cell surface nucleolin, a protein 
normally found in the nucleus, via coimmunoprecipitation reactions between 
soluble Gc and CCHFV susceptible cell lines (Xiao et al., 2011).   
 
Following binding, CCHFV uptake into the host cell occurs in a clathrin, pH and 
cholesterol dependent manner, trafficking at least part way through the 
endosomal pathway (Simon, Johansson and Mirazimi, 2009; Garrison et al., 
2013). Dependence on clathrin was demonstrated by inhibition of the clathrin 
heavy chain using Pitstop-2 (PS2). Increasing the concentrations of PS2 
administered to host cells led to reduced infectivity of CCHFV, implicating the 
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requirement of functional clathrin coated pits in CCHFV infection (Garrison et al., 
2013). Further evidence for the role of clathrin mediated endocytosis (CME) was 
provided by siRNA knockdown of the clathrin adaptor protein (AP) 2. AP2 is the 
second most abundant protein in clathrin coated pits and is not known to have 
additional roles outside CME (Blondeau et al., 2004). siRNA-mediated 
knockdown of AP2 subunits inhibited CCHFV infection by ≈ 30 to 40 % (Garrison 
et al., 2013). The role of pH in viral entry has been investigated for both CCHFV 
and HAZV. Treatment of cells with NH4Cl, which prevents maturation of early 
endosomes to late endosomes via neutralisation of the luminal pH, reduced 
CCHFV infectivity in a dose-dependent manner, demonstrating a low pH 
requirement for infection (Garrison et al., 2013). To assess how far through the 
endosomal pathway CCHFV trafficked, dominant negative (DN) forms of Rab5, 
a marker for early-endosomes, and Rab7, a marker for late endosomes were 
transfected into cells prior to infection. Rab5 and Rab7 associate with the 
membranes of their respective vesicles and shuttle cargo via interactions with 
effector proteins (Stenmark et al., 1994; Mukhopadhyay et al., 1997). DN forms 
of Rab5 and Rab7 contain a single amino acid change that renders the protein 
inactive, due to the inability to exchange GTP to GDP. Therefore, a virus requiring 
functional early-endosomes or late-endosomes would be negatively impacted by 
transfection of the respective DN form of Rab. CCHFV infectivity was reduced 
following transfection of DN Rab5 but not for DN Rab7, showing a requirement 
for early, but not late endosomes (Garrison et al., 2013). 
 
For HAZV, entry has been shown to be dependent on pH, potassium 
concentration (K+) and cholesterol (Punch et al., 2018; Charlton et al., 2019). 
Punch et al. identified increased infectivity of HAZV in elevated K+, with an optimal 
pH for infectivity at 7.3. Purification of HAZV particles and subsequent treatment 
at pH 7.3 with high or low K+ concentrations revealed a conformational change in 
the surface glycoproteins via cryo-electron tomography. A hypothesised model 
suggested that under high K+ conditions, either or both of the HAZV glycoproteins 
extend into a fusion ready state (Punch et al., 2018). The HAZV dependence on 
cellular cholesterol was identified in a follow up study by Charlton et al. Here, the 
depletion of cellular cholesterol via treatment with U18666A or using methyl-beta 
cyclodextrin resulted in reduced infectivity of HAZV. Due to the previously 
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described requirement for HAZV fusion on K+ and pH, the role of cholesterol in 
facilitating these conditions was also explored. Priming of HAZV prior to infection 
of cholesterol depleted cells recovered the infection, suggesting the HAZV 
dependence on cholesterol to be linked to establishing the pH and K+ conditions 




There is little information surrounding the specific mechanism for CCHFV or 
HAZV RNA transcription and replication. However, in order to generate additional 
viral proteins and viral RNA, each viral genome segment encapsidated within an 
RNP must act as a template for two distinct RNA synthesis activities (Figure 1.5). 
For generation of viral proteins, the genomic segment must be transcribed into 
translatable mRNA. For the generation of additional viral genomes, the genomic 
segment must be replicated to synthesise full length complementary RNA (cRNA) 
copies for each viral genome segment, which may then act as templates for the 
synthesis of genomic vRNA. The two products, cRNA and mRNA, have distinct 
structures. Whilst the cRNA represents a full-length complementary version of 
the initial vRNA, the mRNA is extended at the 5’ end by the addition of a host-





Figure 1.5, Schematic detailing negative sense gene expression 
Schematic detailing how negative sense genomes act as a template for two discrete 
activities; RNA replication into anti-genomes and mRNA transcription. 
 
Following cell entry and fusion, genomic RNPs are released into the cytosol, 
where the vRNA must serve as a template for the RdRp during primary 
transcription of mRNAs. Translation of mRNA requires a 5’ cap which acts to 
recruit initiation factors and in mediating binding to the 40S ribosomal subunit. 
Sequencing of bunyavirus mRNAs identified non-viral sequences at the 5’ 
termini, suggesting bunyaviruses utilise a cap-snatching mechanism to prime 
viral transcription (Patterson and Kolakofsky, 1984; Collett, 1986). Cap snatching 
occurs following the binding of a cap-binding domain of a viral polymerase to the 
cap structure of a cellular mRNA. Once bound, an endonuclease domain cleaves 
the RNA approximately 10-15 bases downstream of the cap-binding domain, 
generating a capped RNA fragment that can be used to prime viral transcription. 
Whilst unconfirmed for CCHFV, there is evidence that the RdRp contains a Mn2+ 
coordinating residue at position D693 that facilitates the cap snatching process, 
a process described in multiple negative sense viruses including influenza, 
arenaviruses and other bunyaviruses (Dias et al., 2009; Morin et al., 2010; 
Reguera, Weber and Cusack, 2010; Devignot et al., 2015).  
 
At a stage of the replication cycle that is currently undefined, the RdRp can begin 
replication of the input vRNA into cRNA. As the 5’ end of the cRNA is distinct to 
the 5’ end of mRNA, it is likely the pathways involved in their individual production 
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are distinct. Replication of vRNA to generate cRNA is known not to require 
capped primers as mutation of D693, whilst able to prevent RdRp transcription of 
mRNA, has no effect on replication (Devignot et al., 2015).  Replication of vRNA 
is therefore a process that initially requires the replication and encapsidation of 
uncapped vRNA, minimally involving N and the viral RdRp. This process results 
in the generation of cRNA that acts as a template for further amplification of 
vRNAs. During cRNA or vRNA synthesis, N subunits are added to the elongating 
strands to form antigenomic or genomic RNPs, respectively.  
 
1.3.3 Assembly and egress 
As with other stages of the CCHFV replication cycle, there is limited specific 
information available relating to the assembly and egress phases of infection. 
The subcellular localisation of mature glycoproteins can often provide insight into 
the location of viral assembly. A study into the localisation of CCHFV 
glycoproteins Gn and Gc identified Gn to localise to the Golgi, with Gc remaining 
in the ER  following individual expression of both glycoproteins (Bertolotti-Ciarlet 
et al., 2005). Upon co-expression of Gn and Gc, both glycoproteins co-localised 
with the Golgi, suggesting a Golgi localisation signal on Gn, and that Gc may 
localise to the Golgi via an interaction with Gn. Endoglycosidase H (Endo-H) 
treatment is commonly used to monitor post-translation modification of 
glycoproteins in the Golgi apparatus. CCHFV Gn and Gc were both found to be 
sensitive to Endo-H treatment, indicating they are targeted to early compartments 
of the Golgi (Bertolotti-Ciarlet et al., 2005). This is also similar for members of the 
orthohantavirus genus, which suggests a conserved mechanism across multiple 
Bunyaviridae families (Ruusala et al., 1992). 
 
For members of the Bunyaviridae family, evidence supports the Golgi apparatus 
as the site of “virus factories”, in which virus particles assemble, bud and mature 
(Salanueva et al., 2003). The model bunyavirus BUNV, is able to build factories 
surrounding the Golgi, consisting of virally induced tubular structures (Salanueva 
et al., 2003). These structures have both viral and cellular origins and appear to 
be involved in multiple aspects of the viral lifecycle including genome replication, 
transfer of RNPs to assembly sites and viral morphogenesis (Fontana et al., 
2008). Detection of components indicative of viral replication, such as dsRNA, 
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BUNV N and viral polymerase within these structures supported the role of these 
structures as viral factories.   
 
Egress of mature CCHFV virions is dependent on intact microtubules. 
Manipulation of microtubules using nocodazole (NOC) and paclitaxel (PAC) 
resulted in reduced egress of CCHFV, with less extracellular virus detected 
versus untreated controls (Simon et al., 2009). The role of microtubules was 
suggested to be in both CCHFV assembly and egress. The manipulation of 
microtubules with NOC, which disrupts microtubule assembly/disassembly, 
reduced levels of intracellular virus, indicating a requirement of intact 
microtubules in virus assembly. Conversely, treatment with PAC, which acts to 
stabilise microtubules, had no significant impact on intracellular virus levels, 
suggesting that when intact microtubules were available, virus assembly could 
proceed normally (Simon et al., 2009). CCHFV release has been shown to occur 
from the basolateral surface of polarised MDCK cells, with high titres detected 
released from the basolateral surface versus limited titres from the apical surface, 
indicating a preference for basolateral release (Connolly-Andersen, Magnusson 
and Mirazimi, 2007). However, the molecular mechanisms underpinning this 
preference are unknown, but may represent an interaction with a host cell protein, 
which are secreted in a polarised manner. 
 
1.4 Virally encoded proteins 
1.4.1 S segment 
The S segment of HAZV and CCHFV minimally encodes the viral nucleoprotein, 
with CCHFV also recently reported to express an additional NSs using an 
ambisense coding strategy (Barnwal et al., 2016). 
 
1.4.1.1 Structure of HAZV N and CCHFV N 
The structure of both CCHFV and HAZV N have been solved by multiple groups, 
including our own (Carter et al., 2012; Guo et al., 2012; Wang et al., 2012, 2015; 
Surtees et al., 2015). Both CCHFV and HAZV N display extensive similarities in 
structure, with two distinct domains, a globular domain and an arm domain 
(Figure 1.6, a-b). The globular domain of HAZV N is comprised of a central core 
of C-terminal helices 13 to 20, flanked by N-terminal helices 1 to 8. The arm 
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domain is comprised of two long helices, 11 and 12, with two supporting 
helices 9 and 10 (Surtees et al., 2015). The globular domain of CCHFV is 
formed from the central core of C-terminal helices 18 to 29 flanked by N-
terminal helices 1 to 11, with the arm domain formed again by two long helices 
15 and 17 with a trio of supporting helices 12 to 14 (Carter et al., 2012; 
Wang et al., 2012, 2015). 
 
 
Figure 1.6, Comparison of the crystal structures of HAZV N and CCHFV N 
Comparison of the crystal structure of a) HAZV N and b) CCHFV N shows the high 
similarity between the two nairoviral nucleoproteins in structure of both arm and globular 
domains.  
 
The angle of the arm domain in relation to the globular domain is thought to be 
variable due to a flexible linker region between the two domains. In HAZV N the 
two domains are linked by an alpha helix, 13, and an additional disordered loop 
formed of residues 187 to 196 (Surtees et al., 2015). The flexible nature of the 
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arm domain is perhaps displayed most evidently in the crystal structures of 
CCHFV N, all three solved structures, arising from the IbAr10200, Baghdad-12 
and YL04057 strains, present the arm domain in a different orientation (Carter et 
al., 2012; Guo et al., 2012; Wang et al., 2015). These variable positions may have 
functional implications, such as the ability of N to bind RNA. 
 
During formation of the RNP, monomers of the HAZV N and CCHFV N interact 
with other monomers forming oligomers. For HAZV N, 6 residues have been 
identified in this interaction on the arm domain; Leu279, Trp 263, Lys 275, Val271, 
Glu270 and Phe216 and a single residue on the globular domain; Pro355 
(Surtees et al., 2015). The proline residue from the globular domain sits within a 
hydrophobic pocket formed by the 6 residues on the arm domain. This style of 
interaction between arm and globular domains is also observed in CCHFV N 
oligomers, suggesting this interaction may be responsible for the formation of 
long helical chain oligomers of N that may have functional relevance to their role 
in RNP formation (Wang et al., 2012). It is unknown as to whether N binds RNA 
or forms oligomers first during the formation of the RNP. The RNA binding 
potential of both HAZV N and CCHFV N has been explored. Plotting of the 
surface electrostatic potential of HAZV N identified multiple regions of positive 
charge, with two significant areas; a platform located adjacent to the arm domain 
and a crevice on the opposite face of the protein, extending inwards and offering 
protection against degradation for any RNA sequestered within it (Surtees et al., 
2015). Comparisons with CCHFV show conservation of the platform and pocket 
regions (Carter et al., 2012; Wang et al., 2015). Given the flexible nature of the 
arm and the proximity of the platform to the arm domain, it is possible the flexibility 
of the arm may act as a “gate” mechanism, regulating the binding of RNA and 
formation of RNPs. Despite identifying the potential regions RNA could bind, an 
electrophoretic mobility shift assay, which assess DNA/RNA: protein interactions, 
showed weak affinity of CCHFV for a 24 nucleotide ssRNA fragment (Guo et al., 
2012). However, as this study utilised purified monomeric CCHFV N; it is possible 
either CCHFV N oligomers bind RNA more readily. Furthermore, the 
complementarity of the 5’ and 3’ NTRs suggests an interaction resulting in 
formation of a dsRNA panhandle structure that circularises the vRNA is possible. 
In vitro analysis of the ability of CCHFV to bind to this dsRNA structure 
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demonstrated a high affinity interaction specifically between the stalk domain of 
CCHFV N and vRNA panhandle, with CCHFV N able to bind to both HAZV and 
CCHFV vRNA, but not vRNA from the related Andes virus of the Hantavirus 
genus (Jeeva et al., 2019). 
 
1.4.1.2 Additional roles of HAZV N and CCHFV N 
In addition to the formation of RNPs, as described in section 1.4.1, previous 
research has identified both HAZV N and CCHFV to express caspase-3 cleavage 
motifs, 269DQVD272 and 266DEVD269 respectively, located on the tip of the arm 
domain on a flexible loop that links the two helices. The exact biological role of 
this motif is unclear, however in-vitro analysis of purified active caspase-3 with 
purified HAZV N or CCHFV N demonstrated the ability of N to be cleaved into 
two products of approximate mass 20 and 32 kDa (Carter et al., 2012; Wang et 
al., 2012; Surtees et al., 2015). It is therefore expected that N acts a substrate 
decoy in a similar manner to the Junin nucleoprotein, which via expression of 
multiple caspase motifs is able to reduce levels of caspase 3 cleavage and 
thereby delay progression of apoptosis (Wolff, Becker and Groseth, 2013). 
Interference with immune system pathways is a tactic employed by many viral 
families, multiple viruses have evolved mechanisms to both promote or down-
regulate the induction of apoptosis. For viruses that delay apoptosis, examples 
include inhibition of the pro-apoptotic tumour-suppressor p53 by the DNA virus 
SV40 and the direct inhibition of effector caspases by baculovirus p35 protein, 
which following cleavage remains irreversibly bound to the active site of the 
caspase (Zhou et al., 1998; Ali and DeCaprio, 2001). 
 
In addition to interacting with host cell proteins, HAZV N and CCHFV N, alongside 
other Bunyavirales members, have been shown to interact with cellular nucleic 
acids. CCHFV N has previously been shown to display intrinsic nuclease activity 
in the presence of Mn2+, Co2+ or Mg2+ cations on both single and double stranded 
DNA, in a sequence nonspecific manner. This nuclease activity was specific to 
DNA, as attempts to digest single or double stranded RNA were unsuccessful. 
Responsible amino acids for this activity were identified as Y374, R384, E387, 
K411, H453 and Q457 via site-directed mutagenesis, each with variable 
significance of impact on the endonuclease activity (Guo et al., 2012). These 
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residues sit within a positively charged pocket in the globular domain of CCHFV. 
Further structural analyses on HAZV, Kupe virus (KUPV) and Erve virus (ERVEV) 
all identified similar positively charged pockets, however in ERVEV a loop region 
folds over the entrance to the pocket, blocking solvent access. This structural 
blockade correlated with endonuclease activity, both KUPV and HAZV displayed 
similar levels of endonuclease activity to CCHFV, whilst ERVEV demonstrated 
significantly lower enzymatic activity (Wang et al., 2012). 
 
In addition to N, the S-segment of CCHFV has also recently been reported to 
express a second protein, NSs (Barnwal et al., 2016). The ORF of CCHFV NSs 
expresses a 150 amino acid product coded in a positive sense, overlapping the 
ORF of CCHFV N. Ectopic expression of CCHFV NSs resulted in activation of 
apoptotic pathways, with the detection of the characteristic apoptotic makers 
active caspase 3/7 and cleaved poly(ADP-ribose) (PARP). Mutagenesis of NSs 
determined the residues responsible for apoptosis activation to be Leu127 and 
Leu13, which triggered apoptosis via association with the mitochondrial 
membrane and disruption of the membrane potential, resulting in the release of 
cytochrome C into the cytoplasm. No such evidence exists for expression of NSs 
in HAZV, however an ORF in a similar position does exist and could present an 
interesting study to identify if NSs expression is a shared feature between these 
viruses.  
 
Expression of NSs is not unique to CCHFV within the Bunyavirales. The type 
species of the family, bunyamwera virus (BUNV) NSs is required for efficient 
BUNV replication in mosquito cells (Szemiel, Failloux and Elliott, 2012). BUNV 
NSs also counteracts the immune response, via delaying interferon regulatory 
factor 3 mediated apoptosis, preventing cell death in the early stages of BUNV 
infection (Kohl et al., 2003). Rift Valley Fever Virus (RVFV) NSs also interacts 
with cellular factors, with the ability to shut off host cell transcription via interaction 
with the transcription factor IIH (Le May et al., 2004). For non-human viruses, 
members of the Tospoviridae also express an NSs. Tomato spotted wilt 
orthospovirus (TSWV) encodes NSs using an ambisense strategy and has been 
identified as a virulence factor both in host plant cells and the insect vector. TSWV 
NSs is injected into plants in the saliva of infected thrips, where it interferes with 
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the RNA silencing or antiviral RNAi response (Kormelink et al., 1991; Nagata et 
al., 1999).  
 
1.4.2 M segment 
The M segment encodes the GPC, a large, 1689 amino acid polyprotein that is 
processed via complex post-translational modifications to yield the structural 
glycoproteins Gn and Gc and in the case of CCHFV, the non-structural 
glycoproteins GP160, GP85, GP38 and NSm, GPmuc and proGc (Figure 1.7, a) 
(Sanchez, Vincent and Nichol, 2002; Sanchez et al., 2006; Altamura et al., 2007). 
It was reported that HAZV encodes three structural glycoproteins within the GPC 
of apparent molecular weights 84, 45 and 30 kDa, however this has not been 
confirmed since (Foulke, Rosato and French, 1981). 
 
1.4.2.1 GPC processing  
The GPC is heavily glycosylated to facilitate cleavage by host cell proteases to 
yield the structural and non-structural products. This enables members of the 
proprotein convertase family of serine proteases to process the GPC (Bergeron, 
Vincent and Nichol, 2007). The N-terminal region of the GPC contains a signal 
peptide that directs synthesis to the secretory pathway. The exact termini of this 
signal peptide are strain specific, with signalase cleavage predicted to occur in 
the region of amino acids 21-27, dependant on strain (Sanchez, Vincent and 
Nichol, 2002). The signal peptide is located within a highly variable mucin-like 
domain (MLD). The MLD of CCHFV, strain Matin, is encoded by amino acids 1-
248, the five C-terminal residues of this domain (243-248) are highly variable in 
relation to the remainder of the M ORF, with 23.8 to 56.4% amino acid difference 
among strains, resulting from a nucleotide variability of 14.3 to 37.2% (Papa et 
al., 2002; Sanchez, Vincent and Nichol, 2002). The signal peptide is predicted to 
be aa 1 to 24 and is removed in the secretory pathway (Sanchez, Vincent and 
Nichol, 2002). Complete processing of the CCHFV GPC requires multiple cellular 
proteases and extensive co- and post-translational modifications. Further 
sequence analysis of the GPC revealed 5 transmembrane domains and 10 N-
linked glycosylation sites, with 3 present in Gc, 1 present in Gn, 2 in GP38 and 4 




A series of primary cleavage events to the GPC generate preGn, NSm and preGc. 
These occur close to the 2nd and 4th transmembrane domain and are reported to 
be due to the action of intramembrane cleaving proteases (iCLIPs) (Sanchez, 
Vincent and Nichol, 2002; Altamura et al., 2007) (Figure 1.7, a). These products, 
preGn, NSm and preGc, are then trafficked to the Golgi where the MLD of preGn 
is O-glycosylated and subsequently cleaved early in the secretory pathway, either 
in the ER or on route to the cis-Golgi, by the subtilisin kexin isozyme-1/site-1 
proteases (SKI-1/S1P) at a specific RRLL motif generating GP160/85 and Gn 
(Vincent et al., 2003) (Figure 1.7, b). The protease responsible for the cleavage 
event resulting in generation of mature Gc from preGc is unknown, however the 
presence of the motif RKPL, which is the responsible cleavage site of the 
Guanarito arenavirus by SKI-1/S1P, suggests a similar protease may act on 
CCHFV preGc (Rojek and Kunz, 2008). GP160/85 is processed further in the 
trans-Golgi network (TGN) by furin at a RSKR motif located between the GP38 






Figure 1.7, Processing of the CCHFV glycoprotein precursor by cellular proteases 
a) CCHFV GPC is expressed as a 1689 amino acid polyprotein from which all structural 
and non-structural glycoproteins are derived. Primary cleavage of GPC is a result of the 
action of iCLIPs and signal peptidases (red arrows). b) Primary cleavage generates the 
non-structural intracellular preGn, NSm and preGc proteins. Cleavage by SKI-1/S1P 
(green arrow), SKI-1/S1P-like (black arrow) and furin (blue arrow) yields the structural 
proteins Gc and Gn, non-structural secreted proteins GP160/85 and GP38 and the 
uncharacterised GPmuc and proGc proteins. 
 
1.4.3 L Segment 
The L segments of HAZV and CCHFV are both approximately 12 kb in length, 
containing a 11835 nucleotide ORF, a 76 nucleotide 3’ NTR and a 253 nucleotide 
5’ NTR (Kinsella et al., 2004). The ORF encodes a polyprotein approximately 448 
kDa, making it significantly larger than related bunyavirus L proteins (Honig, 




The N terminal region of the RdRp encodes a functional ovarian tumor (OTU)-
like protease domain, with additional roles in deubiquitination and immune 
evasion (Frias-Staheli et al., 2007). This OTU domain was shown to be 
dispensable for RNA replication in a minigenome system, but was essential for 
recovery of infectious virus, explained in more detail in section 1.5 (Bergeron et 
al., 2010; Scholte et al., 2017). This domain was further identified to suppress the 
cellular immune response by acting as an IFN antagonist, following studies 
identifying the RdRp bound to interferon stimulated gene (ISG) 15 and ubiquitin 
(James et al., 2011). 
 
At the time of writing, no full length orthonairovirus L protein structure has 
successfully been solved by x-ray crystallography. The polymerase of the related 
LACV was solved by electron microscopy and x-ray crystallography, complexed 
with the 5’ and 3’ NTRs (Gerlach et al., 2015). Interestingly, despite the 
complementary nature of the terminal 9 bases of the 5’ and 3’ NTRs, the solved 
structure showed the 5’ NTR forming a stem-loop structure and binding to the 
RdRp in a distinct location to the 3’ NTR, in a similar manner previously identified 
for influenza virus (Pflug et al., 2014). Binding of the NTRs to the polymerase in 
this way, rather than using complementary Watson-Crick base pairing to form a 
“pan-handle” structure between 5’ and 3’ NTRs suggests an alternative 
mechanism for circularisation of RNPs in the Bunyavirales order. In addition, the 
structures of the Lassa and Machupo arenavirus polymerases have been solved 
and shown to display similar architecture to LACV and influenza virus 
polymerases (Peng et al., 2020).  
 
1.5 Nairoviral reverse genetics systems 
In classical, “forward”, genetics the starting point is a mutant phenotype. 
Researchers work backwards from the phenotype and identify the mutation 
responsible for it, thereby associating the phenotype to a gene. With reverse 
genetics, advances in recombinant DNA technologies and DNA sequencing 
enabled these forward genetics approaches to be reversed, allowing a 
researcher to begin with a gene of interest, insert mutations within it and analyse 
gene function from the resulting phenotype. Due to the reversion of classical 
genetics, this approach has been termed “reverse genetics”. This approach can 
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be applied to virology to understand the role of viral genes and non-coding 
regions during replication, immune evasion and additional host-pathogen 
interactions. Reverse genetics systems are especially useful in uncovering the 
basics of viral genome transcription, replication, assembly and egress, whilst also 
permitting mutational analysis and the development of reporter viruses. 
Minigenome systems have been developed for multiple bunyaviruses, namely, 
BUNV, Uukuniemi virus, Hantaan virus, RVFV and LACV (Dunn et al., 1995; Flick 
and Pettersson, 2001; K. Flick et al., 2003; Klemm et al., 2013). 
 
For HAZV and CCHFV, a number of different reverse genetics systems exist. For 
CCHFV, a minigenome system, virus-like particle (VLP) system and infectious 
clone system have all been reported and used to uncover detailed information 
surrounding CCHFV replication that will be discussed further in the following 
sections (Bergeron et al., 2010, 2015; Devignot et al., 2015; Zivcec et al., 2015). 
For HAZV, at the outset of this project, no minigenome, VLP or infectious clone 
systems had yet been described. However, in 2019 a minigenome system was 
successfully developed and reported for HAZV, allowing detailed study into viral 
transcription (Matsumoto et al., 2019). 
 
1.5.1 Minigenome system 
Minigenome systems for negative sense viruses use a genome-like reporter RNA 
flanked by viral NTRs encapsidated by N, allowing recognition and transcription 
by the viral RdRp. The minigenome system therefore enables study into gene 
expression and genome replication. As the viral coding regions are replaced with 
reporters, the system is non-infectious and as such can be used in low 
containment facilities. 
 
The first report of a CCHFV minigenome system was published in 2003, where 
the CCHFV S segment was transcribed by pol I and rescued via coinfection with 
a helper virus. This reporter encoding S segment was also packaged into CCHFV 
virions, representing the first recombinant CCHFV system (R. Flick et al., 2003). 
A more comprehensive CCHFV minigenome system was developed in 2010, 
where CCHFV coding regions for S, M and L segments were replaced with eGFP 
and Gaussia luciferase coding regions. Initially, the viral NTRs flanking the 
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reporters were found to contain sufficient signals for transcription, replication and 
packaging, following superinfection of BSR-T7/5 cells with CCHFV following 
transfection of the minigenome reporter. This initial study using a helper-virus 
also identified a gradient in efficiencies between the CCHFV S, M and L segment 
NTRs, with L having the highest and S the lowest signal (Bergeron et al., 2010). 
Further developments of the system in the same study removed the requirement 
of the helper virus. Transfection of the CCHFV RdRp and CCHFV N, as opposed 
to a superinfection, alongside the S, M or L minigenome RNAs showed the 
segment specific NTRs supported similar levels of replication, suggesting the 
gradient in signal observed with the earlier superinfection was linked to variable 
packaging efficiencies across the segment specific NTRs (Bergeron et al., 2010). 
The minigenome system also demonstrated its use in screening anti-viral 
compounds that affect the genome replication phase of infection. Ribavirin, 
previously described in section 1.1.6, was shown to have a dose dependent 
inhibitory effect on CCHFV in cell culture models (Bergeron et al., 2010).  
 
The HAZV minigenome system, in which the HAZV coding regions for the S, M 
and L segments were replaced by Renilla luciferase, was first described in a study 
exploring the role of complementarity and sequence in NTRs during viral 
transcription (Matsumoto et al., 2019). The study identified that in addition to the 
terminal 9-11 nucleotides, termed promoter element (PE) 1, a second region 
directly adjacent to PE1 was also required for efficient transcription. This region, 
termed PE2, contains an initial region of non-complementary bases at positions 
12 to 15/16 from the genome end, followed by a region of at least 9 
complementary bases. Mutational analysis identified the non-complementary 
region to be critical, with the 3’ and 5’ ends independently changed to give 
complementary base pairing with the opposite end resulting in severely reduced 
reporter signal. Furthermore, the region of complementarity following this initial 
region was shown to be both sequence and complementarity specific (Matsumoto 
et al., 2019). This revealed a significant difference between NTRs of the 
Nairoviridae and other Bunyaviruses, in which no region of ssRNA exists 
following PE1. It is hypothesised that this ssRNA region enables flexibility 
between PE1 and the dsRNA sequence of PE2, potentially enabling it to bind to 




Figure 1.8, CCHFV minigenome system schematic 
The CCHFV minigenome system comprises of a reporter encoded on a minigenome 
plasmid and three support (“helper”) plasmids, L, NP and T7 encoding the viral 
polymerase, nucleoprotein and T7 RNA polymerase downstream of an RNA pol II 
promoter. The minigenome plasmid encodes a reporter, such as NanoLuc, Renilla or 
Gaussia luciferase flanked by the 5’ and 3’ viral non-translated regions (NTRs) from 
either the S, M or L genome segment. Co-transfection of support plasmids provides the 
corresponding viral proteins for transcription of vRNA from the minigenome plasmid. This 
vRNA is encapsidated by viral proteins expressed from the support plasmids into 
genomic RNPs that permit transcription of mRNA and its translation into the reporter 
protein capable of generating a luminescent signal that can be detected. 
 





1.5.2 VLP system 
The VLP system expands upon the principles of the minigenome system by co-
expression of viral glycoproteins alongside the viral NTR flanked reporter RNA 
sequences, viral N and polymerase. This leads to self-assembly of 
transcriptionally competent VLPs that can be internalised into fresh cells, allowing 
study of assembly, attachment and entry processes.  
 
Whilst no such system currently exists for HAZV, a CCHFV VLP system was 
described in 2015 (Devignot et al., 2015). Using the previously established 
minigenome system as a basis, the secreted Gaussia luciferase previously used 
was exchanged for Renillia luciferase due to its suitability for a VLP system. 
Additionally, passage of the VLP system through cells expressing N, the RdRp 
and GPs allows propagation of the VLP stocks alongside examination of genome 
replication, secondary transcription, particle assembly and release. The VLP 
system was employed in this study to identify the endonuclease domain of the 
CCHFV RdRp involved in cap snatching for mRNA during mRNA transcription. 
Substitution of D693 to an inactive alanine prevented the synthesis of mRNA, 
whilst still permitting genome replication and assembly of RNPs (Devignot et al., 
2015). 
 
A follow up study describing an improved VLP system in 2015 built upon the 
original CCHFV VLP system, but incorporated NanoLuc as the reporter and 
utilised codon-optimised support plasmids for the RdRp and GPs (Zivcec et al., 
2015). Rather than try to gain knowledge of CCHFV replication, this study utilised 
the VLP system to screen antiviral drugs and neutralising antibodies in a high-
throughput manner. Neutralisation of CCHFV VLPs by mAbs could differentiate 
strain specific and broad acting mAbs with varying effectiveness, whilst small 
compound inhibitors such as ribavirin and chloroquine demonstrated more 
consistent inhibition between the two compounds (Zivcec et al., 2015). The ability 
to screen CCHFV inhibitors for multiple stages of virus replication, without the 




Figure 1.9, CCHFV virus-like particle system schematic 
The CCHFV virus-like particle system is composed of the minigenome plasmid, encoding 
a reporter flanked by non-translated regions (NTRs) from either S, M or L segments, and 
four support (“helper”) plasmids. The support plasmids encode the T7 RNA polymerase 
and viral nucleoprotein, RNA dependent RNA polymerase (RdRp) and glycoprotein 
precursor (GPC) downstream of an RNA pol II promoter. These viral proteins and T7 
RNA polymerase drive transcription of vRNA from the minigenome plasmid, which is 
subsequently encapsidated in N and a copy of the RdRp to form genomic RNPs. 
Translation of mRNAs expressed by support plasmids yields the required proteins for 
packaging genomic RNPs into VLPs capable of infecting recipient cells. Following 
infection, the genomic RNPs are released into the cytoplasm and express the 
minigenome, resulting in generation of a luminescent signal from the encoded reporter. 
 
Figure adapted from (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848600/) 
 
1.5.3 Infectious clone 
The CCHFV infectious clone system permits the recovery of infectious 
recombinant CCHFV (rCCHFV), meaning all precautions and high containment 
facilities associated with working with CCHFV are required. The infectious clone 
system represents the most comprehensive model available for study of the viral 
replication cycle, as the produced recombinant virus must minimally complete all 
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the basic stages of CCHFV replication for successful recovery of virus. However, 
introduction of a mutation that prevents completion of any critical stage will 
prevent recovery of the virus, with no indication as to which stage the mutation 
interrupted. In these cases, the systems described in sections 1.5.1 and 1.5.2 
can be used to elucidate the effects on individual stages.   
 
rCCHFV was recovered in 2015, via transfection of plasmids expressing positive 
sense RNAs associated with the full length S, M and L segments in combination 
with codon optimised expression plasmids for N and the RdRp (Bergeron et al., 
2015). The system was used to explore non-structural glycoprotein processing 
during CCHFV infection by substitution mutagenesis of the furin-like proprotein 
convertase RSKR cleavage site to a cleavage resistant ASKA motif. Increased 
WT rCCHFV production was observed in furin expressing cells over the cleavage 
deficient ASKA mutant. This suggested that whilst furin cleavage at the RSKR 
was not essential for rCCHFV recovery, it  enhanced virion production (Bergeron 
et al., 2015). The ability to recover viruses from cloned complementary DNA 
allows such precisely determined genomic sequences to be incorporated into 
infectious virions with relative ease. Whilst this technology exists for CCHFV, 
there is no similar system for any member of the Nairoviridae that can be used at 





Figure 1.10, CCHFV infectious clone system schematic 
The CCHFV infectious clone system comprises of 3 plasmids, each containing the entire 
sequence from one of the S, M and L genome segments and 3 support (“helper”) 
plasmids encoding the T7 RNA polymerase, viral nucleoprotein and RNA dependent 
RNA polymerase (RdRp) downstream of a T7 RNA pol II promoter. Following 
transfection of all plasmids, T7 polymerase drives transcription of the genomic plasmid 
generating cRNA which is subsequently encapsidated by viral proteins, encoded on the 
support plasmids, into antigenomic RNPs. Antigenomic RNPs form a template for 
replication of genomic RNPs which assemble with viral proteins to form infectious virions. 
 





1.6 Apoptotic response to HAZV / CCHFV infection 
Apoptosis forms a key part of the immune response against a variety of 
physiological and pathophysiological stimuli, including viral infection. It permits 
regulation of the immune response by deletion of self-killing immune cells through 
cytotoxic killing (Ekert and Vaux, 1997). Two distinct apoptotic pathways have 
been described, the intrinsic pathway, which is activated by intracellular stimuli 
and the extrinsic pathway, which is activated by extracellular stimuli. Both intrinsic 
and extrinsic pathways ultimately result in disruption of the mitochondrial 
membrane, permitting the release of pro-apoptotic proteins such as cytochrome 
c (Liu et al., 1996). Release of cytochrome c, alongside others, leads to activation 
of caspases, a family of cysteine proteases. Two groups of caspases exist initially 
as inactive pro-caspases, the initiator pro-caspases 8, 9 and 10, which function 
to activate the second family of executioner pro-caspases 3, 6 and 7 through 
cleavage. Activation of executioner caspases triggers the execution phase of 
apoptosis, which results in cell death as a result of cleavage of cellular substrates 
such as PARP by caspase 3. PARP plays a critical role in a number of essential 
cellular processes such as DNA repair, transcription and replication (Morales et 
al., 2014). Therefore, cleavage of PARP by caspase 3 can act as a useful 
biomarker for apoptotic activity through generation of unique PARP fragments. 
 
Viruses must employ mechanisms to subvert or delay the apoptotic response to 
complete their replication cycles. The baculovirus p35 protein, following a 
cleavage event, is able to bind irreversibly to the active site of caspases, 
preventing further progress of the apoptotic pathway (Zhou et al., 1998). Within 
the Bunyavirales, LACV and BUNV also regulate apoptosis at an early stage 
through expression of NSs (Kohl et al., 2003; Blakqori et al., 2007). CCHFV 
infection has previously been reported to induce apoptosis in mammalian cell 
lines, with detectable activation of the executioner caspase 3 (Karlberg, Tan and 
Mirazimi, 2011). Furthermore, caspase mediated cleavage of CCHFV N has been 
shown to occur at a conserved DEVD motif on the apex of the arm domain by 
multiple groups (Karlberg, Tan and Mirazimi, 2011; Carter et al., 2012; Wang et 
al., 2012). Expression of active caspase 3 and detection of DNA fragmentation 
can be detected 48 hours post-infection with CCHFV, with levels rising to 72 
hours at which point visible cytopathic effect (CPE) was observed. Whilst the 
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exact mechanism in which CCHFV triggers apoptosis is unclear, infection with 
UV-inactivated CCHFV failed to illicit an apoptotic response, suggesting induction 
was replication dependent. CCHFV induced ER stress, as indicated by activation 
of the unfolded protein response, may also be responsible for activation of the 
intrinsic apoptotic response (Rodrigues et al., 2012). It is likely that CCHFV 
infection induces apoptosis through multiple pathways and therefore must be 
able to modulate these induced pathways in order to complete the replication 
cycle prior to cell death. 
 
1.7 Project aims 
Reverse genetics systems, such as those involving the generation of an 
infectious clone, facilitate and accelerate research of the target organism. 
Previously, a rescue system for the highly pathogenic CCHFV was established, 
though due to the high containment facilities required, the usefulness of such a 
system is limited. Such a system in HAZV would prove invaluable to nairovirus 
research, with no current infectious clone systems available for a BSL-2 member 
of this family. Therefore, the initial aim of the project was to develop an infectious 
clone system for HAZV, to act as a model system for CCHFV.  
 
Following development of an infectious clone system for HAZV, the aim was to 
utilise the system to increase knowledge and understanding surrounding 
nairoviral replication. Previous infectious clone systems have incorporated 
reporter genes to facilitate live-cell imaging, which could prove a useful means of 
screening potential therapeutics. The ability of the infectious clone system to 
identify critical residues involved in virus replication, due to their inability to be 
recovered following knockout mutagenesis, would also provide valuable insight 
into the roles of the viral proteins in virus replication. In this sense, a further aim 
of the project was to utilise the infectious clone system to further our 
understanding of the HAZV N interaction with caspases. By creation of a panel 
of mutants in which the caspase site was altered, the requirement of the DQVD 
motif, and additional caspase motifs present on HAZV N, during viral replication 





The final aim of the project was to design and subsequently validate the 
development of a reporter strain of HAZV expressing eGFP. As with the WT 
infectious clone system, no such reporter system exists for a BSL-2 nairovirus 
member and would prove invaluable in high-throughput screening, such as 
antivirals. In regards to this project, the system was designed in order to screen 
a large panel of host factors involved in entry, in order to identify those utilised by 
HAZV. 
 
In summary, the aims of this project were to develop an infectious clone system 
for HAZV, then modify it to increase our understanding of HAZV replication, via 
mutagenesis of conserved regions of interest, or gain of function mutations such 





2 Materials and methods 
2.1 Materials 
2.1.1 Vectors 
Full-length cDNAs representing the S, M, and L segments were synthesized by 
R. A. Surtees (Genewiz) using the HAZV strain JC280 (GenBank accession 
numbers M86624.1, DQ813514.1, and DQ076419.1, respectively) as reference 
and were incorporated into the pMK-RQ plasmid, resulting in the generation of 
pMK-RQ-S, pMK-RQ-M, and pMK-RQ-L, respectively, able to express S, M, and 
L segment-specific RNAs. Modifications were performed upon receipt as per 
section 2.2.1 to remove an additional unrequired promoter. The T7 polymerase 
expressing pCAG-T7pol (Addgene plasmid number 59926) was a gift from Ian 
Wickersham. The eGFP-P2A containing pUC57-Kan-eGFP-P2A was 
synthesized and purchased (Genewiz), prior to insertion into pMK-RQ-S. 
Sequences for all plasmids can be found in appendix 1.1. 
 
2.1.2 Bacterial cell lines 
Plasmid DNA constructs were amplified through competent Escherichia coli (E. 
coli) cells. Strains used were either DH5alpha (New England Biolabs) for work 
involving pMK-RQ-S or JM109 cells (Promega) for work involving pMK-RQ-M and 
pMK-RQ-L. 
 
2.1.3 Mammalian cell lines 
SW13 cells, derived from a human adrenal cortex carcinoma line, were used in 
experimental procedures and for propagation of viral stocks. BSR-T7 cells, 
derived from a baby hamster kidney cell line that constitutively express T7 
polymerase, were used in transfections. A549 cells, derived from the human 
alveolar basal epithelium, were used in experimental procedures. Huh7 cells, 





2.1.4 Tick cell lines 
HAE/CTVM9 cells, derived from the tick Hyalomma anatolicum, were used in 
experimental procedures and were a kind gift from Dr Lesley Bell-Sakyi, The 
University of Liverpool. 
 
2.1.5 Hazara virus strain 
The HAZV strain JC280 used in this project was supplied as an infectious cell 
culture supernatant from Dr Emma Punch. Sequences of the cRNAs associated 
with this strain for the S, M and L segments are available from GeneBank with 
the respective accession numbers; M86624.1, DQ813514.1, DQ076419.1 
 
2.2 General methods 
2.2.1 Manipulation of recombinant DNA 
2.2.1.1 Bacterial transformations 
For DH5alpha cells, both plasmids and cells were thawed on ice immediately 
prior to transformation. 5 ng of plasmid was added to 50 μl of DH5alpha cells and 
incubated on ice for 30 minutes. The transformation mixture was then heat 
shocked at 42 C for 30 seconds. Eppendorf tubes were then cooled on ice for 2 
minutes before 450 μl of 37 C SOC media was added to each reaction. The 
transformation mixture was then incubated at 37 C for 1 hour with shaking. The 
mixture was then split into 20 μl and 100 μl aliquots to spread on antibiotic 
selective kanamycin / ampicillin LB media plates and incubated overnight at 37 
C. 
 
For JM109 cells, both plasmid and cells were thawed on ice immediately prior to 
transformation. 100 ng of plasmid DNA was added to 65 μl of JM109 cells and 
incubated on ice for 30 minutes. The transformation mixture was then heat 
shocked at 42 ºC for 30 seconds. Eppendorf’s were then cooled on ice for 2 
minutes before 300 μl of room temperature LB broth was added to each reaction. 
The transformation mixture was then incubated at 30 ºC for 1 hour with shaking. 
The mixture was then split into 300 μl and 50 μl aliquots to spread on antibiotic 
selective kanamycin / ampicillin LB media plates. Plates were then incubated 




2.2.1.2 Starter cultures 
Single colonies were picked from antibiotic selective LB plates and used to 
inoculate 5 mL LB broth containing the appropriate antibiotic (kanamycin 50 
μg/mL or ampicillin 50 μg/mL). Cultures were incubated at 30C for 8 hours with 
shaking. These were then scaled up to either 10 mL (mini-prep), 50 mL (midi-
prep) or 100 mL (maxi-prep) cultures and incubated overnight at 30C or 37C 
for JM109 and DH5alpha cell lines respectively. 
 
2.2.1.3 Plasmid DNA amplification 
Overnight cultures of 100 mL LB with kanamycin at a concentration of 50 μg/mL 
were pelleted by centrifugation at 5000 rpm for 15 minutes. A Plasmid Miniprep, 
Midiprep or Maxiprep kit (Qiagen) was used to isolate the plasmid DNA from the 
pelleted bacteria according to the manufacturer’s protocol, where isolation of 
plasmid DNA is based on the alkaline lysis method followed by isopropanol 
precipitation. Concentration of plasmid DNA was identified following elution in 
ddH2O using a NanoDrop 1000 (Thermo Scientific) by spectrophotometry. 
 
2.2.1.4 The polymerase chain reaction (PCR) 
Following first strand synthesis of extracted viral RNA, sequences of interest were 
amplified by PCR to permit sequencing confirmation of mutations in recovered 
virus. PCR reactions were performed in a 25 μL reaction volume using the Q5 
High-Fidelity 2X Master Mix (New England Biolabs), containing 25 ng template 
DNA, and 0.5 μM forward and reverse primers. Reaction cycles were carried out 
as follows; initial denaturation at 98C for 5 minutes, 35 cycles of denaturation at 
98C for 10 seconds, primer annealing at 50-72C (primer specific) for 30 
seconds, extension at 72C for 30 s/kb, then a final extension at 72C for 2 
minutes. PCR products were then purified using the Monarch® PCR & DNA 
Cleanup Kit (New England Biolabs) according to manufacturers’ instructions.  
 
2.2.1.5 Reverse transcription quantitative PCR (RT-qPCR) 
RNA was harvested from cells of interest via Trizol extraction. Briefly, cells were 
washed in nuclease free phosphate buffered saline (PBS) then resuspended in 
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TRI reagent™ (Invitrogen), chloroform was then added, mixed vigorously and left 
at room temperature for 2 minutes. Samples were centrifuged at 12,000 g and 
the resulting aqueous phase was collected and added to isopropanol to 
precipitate RNA for 5 minutes at room temperature. Samples were spun at 12,000 
g and the resulting pellet was washed in ice cold 75 % EtOH prior to resuspension 
in nuclease free H2O. qPCR was carried out using the One step MESA GREEN 
qRT-PCR MasterMix for SYBR® Assay (Eurogentec) according to the 
manufacturer’s instructions, with samples normalised to GAPDH expression. 
Primer sequences used can be found in Table 2.1. 
 
2.2.1.6 Agarose gel electrophoresis   
DNA was examined for quality and purity, or purified from 1 % agarose gels 
composed of 0.5 g agarose, 50 mL of 1 x TAE buffer (40 mM Tris-acetate, 1 mM 
ethylene-diamine-tetraacetic acid (EDTA)) and SYBR Safe DNA stain (Life 
Technologies) diluted 1:10,000. Samples were mixed with 6 X DNA loading dye 
(New England Biolabs) and ran alongside the Quick-load 2-Log DNA Ladder 
(New England Biolabs) at 110 V for 1 hour in 1 X TAE buffer 
 
2.2.1.7 Site directed mutagenesis 
Generation of mutant plasmids incorporating deletions, small insertions and/or 
substitutions was achieved using the Q5 site-directed mutagenesis kit (New 
England Biolabs), according to the manufacturer’s instructions, with all mutant 
plasmid sequences confirmed via sequencing (Genewiz). Primers used in 
generation of mutant sequences can be found in appendix 1.2. 
 
2.2.1.8 Restriction digests 
Restriction digests were carried out using the indicated restriction enzymes (New 
England Biolabs) using the manufacturer’s instructions. Briefly, 1 µg of DNA was 
digested using 1 µL of restriction enzyme in a 50 µL total volume at 37°C for 1 
hour. Restriction digestion products were then purified via agarose gel 
electrophoresis followed by gel extraction using the NEB Gel extraction kit (New 





Ligations were carried out in 20 µL total reaction volumes containing: 3:1 molar 
ratio of insert: vector DNA, 1 x Ligase Reaction Buffer (30 mM Tris-HCl (pH 7.8), 
10 mM MgCl2, 10 mM DTT and 1 mM ATP; Promega) and 1 unit of T4 DNA 
Ligase (New England Biolabs). Ligase reactions were incubated at room 
temperature for 1 hour or 4 °C overnight, then transformed into DH5alpha cells. 
 
2.2.2 Cell culture methods 
2.2.2.1 Mammalian cell culture 
SW13, A549 and Huh7 cells were all maintained at 37C with 5 % CO2 in 
humidified incubators with Dulbecco’s modified Eagle’s medium (DMEM, Sigma-
Aldrich) supplemented with 10 % foetal bovine serum (FBS, Invitrogen), 100 
IU/mL penicillin and 100 g/mL streptomycin. Cell lines were passaged every 2 
to 3 days using trypsin-EDTA (Sigma) based on the level of confluency.  
 
2.2.2.2 Arthropod cell culture 
HAE/CTVM9 cells were maintained in L15 medium containing 20 % FBS, 10 % 
tryptose phosphate broth, 2 mM L-glutamine, 100 IU/mL penicillin and 100 µg/mL 
streptomycin at 30 C and passaged as required every fortnight. 
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Primer Direction Sequence (5’ to 3’) Supplier 
HAZV S segment  Forward CAA GGC AAG CAT TGC CAC AC IDT1 
HAZV S segment Reverse GCT TTC TCT CAC CCC TTT TAG GA IDT 
GAPDH  Forward TGT GGT CAT GAG TCC TTC CAC GAT Sigma Aldrich 
GAPDH Reverse AGG GTC ATC ATC TCT GCC CCC TC Sigma Aldrich 
COPA Forward CCA CTA TCA GAA TGC CCT ATA CC IDT 
COPA Reverse CCA CAA ACC CAT CTT CAT CC IDT 
COPB1 Forward ACA GAGA GAA AGA GGC AGC AGA IDT 
COPB1 Reverse GCA AGG TATA CAC TGG TTT GGT TC IDT 
COPB2 Forward GTG GGG ACA AGC CAT ACC TC IDT 
COPB2 Reverse GTG CTC TCA AGC CGG TAG G IDT 
Table 2.1, List of primers and associated sequences used in qPCR 




2.2.3.1 TransIT-LT1 mediated transfection of BSR-T7 cells with a single 
plasmid 
Twelve-well plates were seeded with 1x105 BSR-T7 cells/well 1 day prior to 
transfection in 1 mL DMEM supplemented with 2.5 % FBS. 24 hours later, 
cells were transfected with 1 g of the indicated cDNA and 2.5 l Mirus 
TransIT-LT1 (Mirus Bio) transfection reagent per g DNA in 200 L Opti-MEM 
(Life Technologies) following a 20 minute incubation period at room 
temperature. Cells were then incubated at 37 C for 24 hours prior to collection 
of total cell lysate for analysis. 
 
2.2.3.2 TransIT-LT1 mediated transfection of BSR-T7 cells with WT 
rHAZV cDNAs 
Six-well plates were seeded with 2x105 BSR-T7 cells/well 1 day prior to 
transfection, 
in 2 mL DMEM supplemented with 2.5 % FBS, 100 U/mL penicillin and 100 
g/mL streptomycin. 16 to 24 hours later, cells were transfected with a 
transfection mixture containing 1.2 g pMK-RQ-S, pMK-RQ-M, and pMK-RQ-
L and 0.6 g pCAG-T7pol, 2.5 l Mirus TransIT-LT1 transfection reagent per 
microgram of DNA and 200 l Opti-MEM. This transfection mixture was 
applied to cells following a 20 minute incubation of the mixture at room 
temperature. At 24 hours post transfection media containing the transfection 
mix was removed and replaced with fresh DMEM supplemented with 2.5 % 
FBS, 100 U/mL penicillin and 100 g/mL streptomycin.  A control sample, in 
which transfection of pMK-RQ-L was omitted, was set up alongside each 
experiment as a negative control. Supernatant was harvested at 72, 96 and 
120 hours post transfection and examined for presence of virus. 
 
2.2.3.3 TransIT-LT1 mediated transfection of BSR-T7 cells with mutant 
rHAZV cDNAs 
For mutant recovery, the same transfection protocol was followed as 
described in section 2.2.3.2, with the mutated cDNA used in the place of the 
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corresponding WT cDNA. In addition to the negative control omitting pMK-RQ-
L, a full WT rHAZV recovery was carried out alongside each mutant recovery 
to provide a positive control. 
 
2.2.3.4 Reverse transfection of Silencer™ Human Membrane Trafficking 
siRNA library 
The Silencer™ Human Membrane Trafficking siRNA Library (Thermo Fisher 
Scientific, 0.25 nmol) was initially prepared prior to use. 96 well plates 
containing stock siRNAs were briefly centrifuged, reconstituted in 125 L 
nuclease free H2O and mixed via thorough pipetting to generate a stock plate 
of 2 M. Working stocks were prepared via combining 50 L of the stock plate 
with 50 L nuclease free H2O, diluting the stock 2 fold, in a 96 well plate, to 
achieve a working stock concentration of 1 M (1 pmol / L). Plates were 
stored at -80 C for long term storage and number of freeze thaw cycles was 
recorded. 
 
Reverse transfection of the siRNAs was carried out as follows; trypsinised 
SW13 cells in DMEM containing 2.5 % FBS and 100 U/mL penicillin and 100 
g/mL streptomycin were counted using a hemocytometer and used to make 
a cell suspension containing 1 x 105 cells/mL. A master mix containing 0.3 L 
Lipofectamine® RNAiMAX reagent (Invitrogen) and 16.7 L Opti-MEM per well 
as required was created and 17 L of this master mix was pipetted into each 
well of a 96-well plate. 3 L of working stock siRNA (1 M) was pipetted into 
the transfection master mix and gently pipetted up and down to ensure good 
distribution and final concentration of 3 pmol of siRNA per well. 100 L of the 
1 x 105 cell suspension was then applied per well, to give a final count of 1 x 
104 cells per well. Cells were incubated with the transfection mix for 24 hours 
at 37C, then 60 L of the media was removed and replaced with 140 L of 
fresh DMEM containing 2.5 % FBS, 100 U/mL penicillin and 100 g/mL 
streptomycin to dilute out any potential toxic effects of the siRNAs or 
transfection reagent. 6 hours post-dilution, media was removed and cells were 
washed in PBS prior to infection with rHAZV(eGFP) at a MOI of 0.25 in 100 
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L of DMEM containing 2.5 % FBS, 100 U/mL penicillin and 100 g/mL 
streptomycin.  
 
2.2.3.5 Reverse transfection of COPI specific siRNAs 
To validate the knockdown observed in the siRNA screen, siRNAs specific to 
COPA, COPB1 and COPB2 were purchased (Ambion) and reverse 
transfected into SW13 cells. Briefly, 75 pmol of siRNA was mixed with 4.5 L 
Lipofectamine® RNAiMAX in 200 L Opti-MEM and incubated at room 
temperature for 20 minutes. Following incubation, the transfection mix was 
added dropwise to a 6 well plate and overlaid with 2 mL of cell suspension 
containing 1 x 105 cells/mL in 2.5 % DMEM. 24 hours post transfection, media 
was changed to fresh 2.5 % DMEM for 6 hours then infected with rHAZV at a 
MOI of 0.1. 24 hours post infection lysates were collected for analysis via 
western blot or qPCR. 
 
2.2.4 Analysis of protein expression 
2.2.4.1 Preparation of whole cell lysate 
For preparation of cell lysates, monolayers were washed twice in ice-cold 
PBS, followed by incubation in ice-cold RIPA buffer (150 mM sodium chloride, 
1.0 % NP-40 alternative, 0.1 % SDS, 50 mM Tris [pH 8.0]) and agitated for 
120 s. Cells were then harvested via cell scraping and were transferred to 
prechilled Eppendorf tubes, after which lysates were centrifuged at 20,000 X 
g for 15 min to pellet insoluble material. Supernatant was then collected and 
stored at -20 C prior to analysis 
 
2.2.4.2 SDS polyacrylamide gel electrophoresis (SDS PAGE) 
Proteins were separated on a 5 mL 12 % SDS-polyacrylamide resolving gel 
comprised of 4 mL 30 % bis-acrylamide, 2.5 mL 1.5 M Tris-HCl pH 8.8, 3.3 mL 
ddH2O, 100 L 10 % SDS, 100 L 10 % ammonium persulphate (APS), 10 L 
TEMED and a 5 % stacking gel containing 0.83 mL 30 % bis-acrylamide, 0.63 
mL 1M Tris-HCl pH 6.8, 50 L 10 % SDS, 50 L 10 % APS and 5 L TEMED. 
Protein samples were mixed 1:1 with 2 X denaturing sample buffer (60 mM 
Tris pH 6.8, 25 % (v/v) glycerol, 2 % (w/v) SDS, 5 % β-mercaptoethanol, 0.01 
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% (w/v) bromophenol blue) supplemented with 50 mM DTT, then denatured 
via heating to 95C for 10 minutes immediately prior to loading. Samples were 
then loaded into gels alongside the Color Prestained Protein Standard, Broad 
Range (11-245 kDa) (New England Biolabs) ladder and electrophoresis was 
performed in SDS running buffer (25 mM Tris, 192 mM glycine, 0.1 % (w/v) 
SDS) at 180 V for 1 hour. 
 
2.2.4.3 Western blot analysis 
Proteins were transferred from SDS PAGE gels (section 2.2.4.2) to 
fluorescence-compatible polyvinylidene difluoride (FL-PVDF) membranes 
(Millipore) using a Trans-Blot semi-dry cell (Bio-Rad) in Towbin buffer (25 mM 
Tris, 192 mM glycine, 20 % (v/v) methanol) for 1 hour at 15 V. FL-PVDF 
membranes were blocked in 1:1 Odyssey® Blocking Buffer in TBS, TBS (50 
mM Tris-HCl pH 7.5, 150 mM NaCl) for 1 hour at room temperature with gentle 
rocking. Blocking buffer was then replaced with primary antibody diluted to the 
appropriate concentration in 1:1 Odyssey® Blocking Buffer in TBS, TBS-T (50 
mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 % Tween 20) for 1 hour at room 
temperature with gentle rocking. A full list of primary antibodies and associated 
concentrations used to detect immobilised proteins is provided in Table 2.2.   
 
FL-PVDF membranes were extensively washed in TBS, then incubated with 
the appropriate fluorescently labelled secondary antibody at a 1:10,000 
dilution under the same conditions as for the primary antibody incubations. FL-
PVDF membranes were washed three times in TBS-T, once in water, then 
fluorescently labelled secondary antibodies were directly visualised using a 
LiCor Odyssey Sa Infrared imaging system (LiCor). 
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Target Species Supplier Dilution 
Actin Mouse Sigma Aldrich 1:10000 
Caspase 3 Rabbit Cell Signaling Technologies 1:1000 
Caspase 7 Rabbit Cell Signaling Technologies 1:1000 
Caspase 9 Mouse Cell Signaling Technologies 1:1000 
Cleaved caspase 3 Rabbit Cell Signaling Technologies 1:1000 
Cleaved caspase 7 Rabbit Cell Signaling Technologies 1:1000 
Cleaved caspase 9 Rabbit Cell Signaling Technologies 1:1000 
Cleaved Poly ADP-ribose polymerase  Rabbit Cell Signaling Technologies 1:1000 
GAPDH Mouse GeneTex 1:10000 
Enhanced Green fluorescent protein (eGFP) Rabbit BioVision 1:1000 
Hazara nucleoprotein (HAZV N) Sheep In-house1 1:3000 
Poly ADP-ribose polymerase Rabbit Cell Signaling Technologies 1:1000 
Table 2.2, List of primary antibodies used during the project 
Table displays antibodies used during the project, detailing their targets, host species, supplier and dilution used at during 




2.2.4.4 Immunofluorescence microscopy 
Trypsinised SW13 cells were seeded onto 16 mm round glass coverslips (VWR) 
in a 12-well plate at 5 x 104 cells/well and incubated at 37C. 16-24 hours later, 
cells were infected at a MOI of 0.1 in DMEM containing 100 U/mL penicillin and 
100 g/mL streptomycin for 1 hour at 37C. Following infection, media was 
removed and cells were washed in PBS, DMEM containing 2.5 % FBS, 100 U/mL 
penicillin and 100 g/mL streptomycin was then applied and returned to incubate 
at 37C for a further 24 hours. At this point media was removed and cells were 
washed twice in PBS prior to fixation in 4 % paraformaldehyde in PBS (v/v) for 
10 minutes at room temperature. Following fixation, cells were washed twice in 
PBS and then incubated in permeabilization buffer (0.1 % Triton-X100 [v/v], 1 % 
BSA [w/v] in 1X PBS) for 15 minutes at room temperature. Cells were then 
blocked in blocking buffer (1 % BSA [w/v] in 1X PBS) for 45 minutes then 
incubated with the required primary antibody at a specified dilution for 1 hour at 
room temperature. Cells were washed three times in PBS then incubated with 
the corresponding secondary AlexaFluor® antibody (Life Technologies, 1:500 in 
blocking buffer) for 1 hour at room temperature in a light protected vessel then 
washed three times with PBS. Coverslips were then mounted onto glass slides 
with the addition of ProLong Gold Antifade Reagent with DAPI (Thermo Fisher 
Scientific), sealed and stored at 4C. Images were then taken on the LSM 700 or 
LSM 880 confocal microscope and processed using Zen (Blue Edition) software. 
 
2.2.4.5 Detection of fluorescent rHAZV 
The IncuCyte® Live Cell Imaging System (Essen BioSciences) was used to detect 
infection by rHAZV(eGFP) or rHAZV(eGFP-LFAA). SW13 cells were infected as 
described in section 2.2.5.1 and imaged at indicated time points to permit 
analysis of total green cell count or total integrated intensity of eGFP (TIIE) over 
time. Captured images were analysed using the associated software for 
fluorescent protein expression. The fluorescent thresholds for analysis were 
determined using control wells and were used to identify fluorescent positive 




2.2.5 Virological techniques 
2.2.5.1 Virus infections 
SW13, A549, BHK or Huh7 monolayers were infected with HAZV at the specified 
multiplicity of infection (MOI) in serum-free DMEM (SFM) at 37 C. After 1 hour, 
the inoculum was removed and cells washed in PBS, fresh DMEM containing 2.5 
% FBS, 100 U/mL penicillin and 100 g/mL streptomycin was then applied for the 
duration of the infection.  
 
Infections of HAE/CTVM9 cells of tick origin were carried out at a MOI of 0.01 in 
a similar manner to mammalian cell infections, but with an incubation temperature 
of 30 C and using L15 media containing 20 % FBS, 10 % tryptose phosphate 
broth, 2 mM L-glutamine, 100 IU/mL penicillin and 100 µg/mL streptomycin. 
 
During recovery of recombinant virus, reinfections were carried out as follows; 
Six-well plates were seeded with 2x105 SW13 cells/well, 1 day prior to infection, 
in 2mL DMEM supplemented with 10 % FBS, 100 U/mL penicillin and 100 g/mL 
streptomycin. Cell supernatants from transfected BSR-T7 cells (section 2.2.3) 
were collected 72, 96, and 120 hours post transfection, and 300 L supernatant 
was passaged for 48 hours in a 6 well plate of SW13 cells grown in DMEM 
supplemented with 10 % FBS, 100 U/mL penicillin and 100 g/mL streptomycin.  
 
2.2.5.2 Virus growth curves 
To assess viral fitness over time, 2x106 SW13 cells were seeded into 75 cm2 
flasks one day prior to infection in 8 mL DMEM supplemented with 10 % FBS. 24 
hours later, virus was used to infect flasks at the specified MOI in 5 mL SFM for 
1 hour with shaking, an aliquot of the infection media was collected to permit 
back-titration, ensuring equal MOI comparisons were made. Following infection, 
media containing virus was removed, cells were washed with PBS and 7 mL 
DMEM supplemented with 2.5 % FBS was reapplied and returned to incubated 
at 37 C for the remainder of the experiment. At 24 hour intervals, 200 L 
supernatant was removed and stored at -80 C until all samples had been 
collected and stored in a similar manner. Following collection of all timepoints, 





2.2.5.3 Virus purification 
For propagation of virus stock, 4 x 175 cm2 flasks were seeded with 3x106 BHK 
cells, one day prior to infection in 25 mL DMEM supplemented with 10 % FBS. 
24 hours later, WT rHAZV was used to infect flasks at a MOI of 0.001 in 5 mL 
SFM for 1 hour with shaking. Following infection, media containing virus was 
removed, cells were washed in PBS and 15 mL DMEM supplemented with 2.5 % 
FBS was reapplied and flasks were incubated at 37 C for 72 hours with 
occasional shaking. Following incubation, supernatant containing virus was 
removed and clarified at 4500 X g for 30 minutes, passed through a 0.45 M filter 
then re-clarified as above. Clarified and filtered supernatant was then loaded 
above a 20 % sucrose cushion and spun at 150,000 X g for 3 hours. Following 
centrifugation, supernatant was removed and the tube was inverted to permit air-
drying of the pellet prior to overnight resuspension in 1 mM MgCl2 and 1mM CaCl2 
at 4 C with shaking. 
 
2.2.5.4 Viral titration 
Determination of virus titers was achieved through plaque assays. Supernatant 
was collected at the time titration was required and serially diluted by a factor of 
10 from neat to create dilutions of 10-1 to10-6 to infect fresh monolayers of SW13 
cells in a 6-well plate. Following infection, medium containing virus was removed, 
cells were washed in ice cold PBS and a 1:1 ratio of 2.5 % FBS DMEM to 1.6 % 
methylcellulose (Sigma) was reapplied, and cells were returned to incubate for a 
further 6 days prior to fixing and staining with crystal violet (13.5 % formaldehyde, 
2.5 % crystal violet, 20 % ethanol). Plaques formed where HAZV had replicated 
and caused CPE and were counted, and virus titers were determined using the 
equation; 
 
𝑝𝑓𝑢 ∕ 𝑚𝐿 =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠





2.2.5.5 Generation of cDNA from infectious virus 
Viral RNA was extracted from virus containing cell-free supernatant using the 
QIamp viral RNA kit (Qiagen) and subsequently treated with DNase to remove 
any contaminating DNA. A cDNA copy was generated using the ProtoScript II 
reverse transcriptase kit (New England Biolabs), according to the manufacturer’s 
instructions. Amplification of the cDNA was carried out using PCR, as described 
in section 2.2.1.4. To rule out plasmid carryover from transfection media, a no 
reverse-transcriptase control was also carried out in the same manner as 
described, with the omission of the reverse transcriptase. 
 
2.2.5.6 rHAZV(eGFP) MOI optimisation 
SW13 cells were seeded at 1x104 cells/well in a 96-well plate and incubated at 
37C for 24 hours to replicate conditions generated according to the siRNA 
reverse transfection protocol. Media was then removed and cells were infected 
with rHAZV(eGFP) at range of MOIs (0.1, 0.25 and 1.0) in SFM containing 100 
U/mL penicillin and 100 g/mL streptomycin. Cells were incubated for a further 
48 hours at 37C with hourly imaging using the IncuCyte® Live Cell Imaging 
System to detect the number of eGFP positive cells. 
 
2.2.5.7 Quantifying viral expression levels using eGFP signal 
Following a 24 hour infection, GFP fluorescence intensity was determined using 
the IncuCyte® Live Cell Imaging System as a measure of virus infectivity. Total 
green integrated intensity (GCU x m2/image) was first normalised to confluency 
per well, then analysed as a percentage of the total green integrated intensity in 
positive control wells containing virus but omitting siRNA and transfection 
reagent. Normalised values within each technical repeat were averaged and then 
averaged across two biological repeats. Statistical analyses were performed 
using an unpaired, two-tailed Student’s t-test assuming variance in standard 




2.2.6 Inhibitor studies 
2.2.6.1 Inhibition of retrograde transport 
Trypsinised A549 cells were seeded into 12 well plates at 1x105 cells/well and 
incubated at 37C. 16 to 24 hours later, cells were pretreated with brefeldin A 
(BFA) at the indicated concentrations for 45 minutes in SFM prior to infection with 
rHAZV or rIAV at a MOI of 0.1 for 1 hour at 37C. Following the infection period, 
media containing virus was removed and cell monolayers washed three times 
with PBS. Fresh 2.5 % DMEM was then reapplied containing the indicated 
concentration of BFA for a further 24 hours. At this point lysates were collected 
and analysed via western blot (2.2.4.3).  
 
2.2.6.2 Inhibition of caspases 
SW13 monolayers were pretreated for 45 min with 20 μM Z-FA-FMK or Z-VAD-
FMK in SFM at 37°C prior to infection with HAZV at a MOI of 0.1. Following 
infection, virus and inhibitor were removed, cells were washed three times in 
PBS, and 2.5% FBS-DMEM containing 20 μM Z-FA-FMK was reapplied. At 24, 
32, and 48 hour time points, total cell lysates were harvested and prepared for 
western blotting. 
 
2.2.6.3 Viability assays 
Trypsinised A549 cells were seeded into 96 well plates at 1x104 cells/well and 
incubated at 37C. 16 to 24 hours later, cells were treated with inhibitor at the 
indicated concentrations for 1 hour 45 minutes in SFM, to replicate the pre-
treatment and infection timings. After this period 100 L of fresh 2.5 % DMEM 
was then reapplied containing the indicated concentration of inhibitor for a further 
24 hours. At this point the CellTitre 96® AQueous One Solution Cell Proliferation 
Assay (Promega) was used to measure cell viability according to the 
manufacturer’s instructions. Briefly, 20 L was added to each well and returned 
to incubate for a further 4 hours, at which point absorbance was measured at 490 
nm using a plate reader (Tecan) and used to determine viability via comparison 





3 Development of a Hazara virus infectious clone 
3.1 General introduction 
The ability to perform detailed genetic analysis of any virus is dramatically 
increased by the provision of a reverse genetics system, which allows any 
nucleotide or amino acid residue to be specifically altered, allowing any resulting 
change in phenotype to be identified. Such a system has been developed for 
CCHFV (Bergeron et al., 2015), which has been exploited to expand the current 
understanding of nairovirus molecular and cellular biology (Scholte et al., 2017; 
Welch et al., 2017). However, the classification of CCHFV as a hazard group 4 
pathogen presents additional and significant experimental hurdles, such as the 
requirement of BSL-4 facilities, which significantly increase experimental cost and 
study times. Therefore, there is an urgent need to generate similar systems in 
related, lower containment level nairoviruses such as HAZV to provide a platform 
to study the function of the viral genes and genetic elements. A HAZV infectious 
clone system would also enable the recovery of so-called ‘gain of function’ 
viruses, such as incorporation of reporter genes to facilitate efficient analysis of 
virus growth kinetics. Any findings of interest discovered in the HAZV infectious 
clone system could then be replicated in CCHFV, streamlining the discovery 
process and therefore reducing the length of time required to make significant 
advances into our knowledge of CCHFV replication. 
 
The first recovery of an infectious RNA virus from cDNA occurred in 1981, with 
the successful recovery of poliovirus (Racaniello and Baltimore, 1981). Since 
then, multiple RNA viruses from a broad range of families have had reverse 
genetics systems developed enabling rapid advances in understanding. Due to 
the inability of negative sense RNA viruses to have their genomes directly 
translated into proteins and the requirement of the genome to be associated with 
viral N to be replication competent, advancement of reverse genetics systems for 
this group of viruses has been slower, with the first such development published 
in 1994, for the recovery of infectious rabies virus (Conzelmann and Schnell, 
1994; Schnell, Mebatsion and Conzelmann, 1994). In the years since, multiple 
infectious clone systems have been set up for multiple members of the 
Bunyavirales order across four of the five families; The Hantaviridae family are 
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the only group to have no such system, despite repeated attempts to recover 
recombinant virus. BUNV, CCHFV and RVFV all have well established infectious 
clone systems (Bridgen and Elliott, 1996; Bridgen et al., 2001; Bird, Albariño and 
Nichol, 2007; Bergeron et al., 2015). These systems have enabled discovery of 
many features surrounding the viral lifecycles, including the previously described 
processing mechanisms of the GPC of CCHFV in section 1.4.2.1 and BUNV 
requirement of cellular proteases such as furin and signal peptide peptidase 
(Bergeron et al., 2015; Shi et al., 2016). However, despite multiple members of 
the Bunyavirales order having infectious clone systems established, no hazard 
group 2 members of the Nairoviridae currently have such systems. Reverse 
genetics systems provide an invaluable means to study the role of individual 
nucleotides, amino acids, entire genes and NTRs by enabling targeted 
mutagenesis, via manipulation of the DNA source. These reverse genetics 
approaches allow the user to decide on the region for mutation and then identify 
any resulting phenotypic effect, rather than relying on the forward genetics 
method of sequencing naturally occurring mutants and working backwards from 
phenotype to identify the responsible mutations. This dependence of forward 
genetics on mutations resulting in a viable phenotype limits the study into critical 
elements of the viral genome.   
 
Recovery of infectious negative sense viruses can be achieved via the use of 
DNA plasmids expressing positive or negative sense primary RNA transcripts 
corresponding to viral genome segments. The previously described rescue 
system for recovery of rCCHFV utilised plasmids expressing positive sense 
primary RNA transcripts. Upon transfection of a positive sense plasmid into a T7 
polymerase expressing cell line, such as BSR-T7 cells, T7 RNA polymerase 
recognises the T7 promoter positioned upstream of the gene of interest and 
begins transcription, generating either translatable mRNAs or antigenomic 
vRNAs from a single transcription reaction. Being directly translatable, the 
mRNAs are able to drive translation of the viral products. In the case of HAZV, 
they permit translation of HAZV N and L, which are critical for packaging the 
antigenomic vRNAs forming antigenomic (coding) RNPs which can act as 
replication templates to generate genomic (non-coding) RNPs that can 
subsequently be packaged into maturing virions (Figure 3.1). When mutations 
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are introduced that remain viable for virus replication, the infectious clone system 
has the advantage of being able to study the impact of the viable mutation across 
all aspects of the viral lifecycle. The fundamental drawback occurs when an 
alteration, such as large insertions, deletions or mutations to critical amino acids, 
prevent the virus from carrying out any essential part of the viral lifecycle. In cases 
where this occurs, recovery of infectious virus is not possible and the only 
conclusion that can be drawn is that the alteration affected a critical domain of 
the viral genome or prevented the virus from carrying out an essential phase of 
the lifecycle. In these situations, alternatives, such as the mini-genome and VLP 
systems, are well suited to the necessary further genetic analysis (Bergeron et 
al., 2015; Devignot et al., 2015; Matsumoto et al., 2019).  
 
The aims of this chapter were as follows; 
 
1. Generate an infectious clone for rHAZV 
2. Compare rHAZV growth to that of the parental virus 
3. Demonstrate the ability of the infectious clone to incorporate mutations 
 
Successful completion of these aims would yield a valuable tool for studying 
HAZV and by extension other members of the Nairoviridae family, in a more 
efficient manner without the need for high level containment facilities. More 
specifically, it would provide an excellent model for increasing understanding the 
replication cycle and pathogenicity of CCHFV, in which initial characterization of 
orthonairovirus properties would be performed using HAZV with selected 




Figure 3.1, Schematic of rHAZV rescue workflow 
Plasmid cDNAs representing HAZV segments are transfected into actively replicating 
BSR-T7 cells. The action of both endogenous and exogenous T7 RNA polymerase 
drives primary transcription of RNAs that represent S, M and L segment antigenomes, 
which also act as templates for translation of viral structural and non-structural proteins. 
Translated viral proteins then associate with primary T7 RNA polymerase transcripts to 
form positive sense antigenomic RNPs, which are in turn replicated by the HAZV RdRp 
to form negative sense genome segments. These genomes then act as templates for 
either mRNA transcription or RNA replication, permitting accumulation of negative sense 
RNPs and viral proteins, subsequently resulting in assembly of infectious virions which 
then exit the cell and can be collected in the supernatant. 
 
3.2 Plasmid design 
The infectious clone system requires transfection of a copy of the viral genome, 
carried either on a bacterial plasmid, or on an in-vitro transcript derived from it 
into cultured cells. The use of plasmid DNA in recovery of CCHFV is described 
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in sections 1.5.3 and 3.1. The use of plasmid DNA in infectious clone systems 
has multiple advantages over transfection of RNA. Firstly, as the plasmid is 
continuously transcribed within the cell, more copies are generated from a cDNA 
plasmid than a finite amount of RNA. Also, the direct use of a cDNA plasmid 
removes the requirement for in-vitro transcription and subsequent purification of 
RNA, reducing the time and costs involved with infectious clone recovery. Finally, 
DNA has increased stability over RNA and therefore handling, storage and 
transfection of plasmid DNA over RNA is made more reliable. 
 
Plasmids for the recovery of HAZV had previously been designed within our 
group to express positive sense primary viral RNA transcripts corresponding to S 
(Figure 3.2, a), M (Figure 3.2, b) and L (Figure 3.2, c) segments, with each 
segment cDNA encoding both viral 5' and 3' NTRs flanking the ORF encoding 
the associated viral gene. Upstream of the 5' NTR, a bacteriophage T7 RNA 
polymerase promoter sequence was included to permit transcription within a T7 
polymerase expressing cell line, in our case BSR-T7 cells. Directly downstream 
of the 3' NTR a hepatitis delta virus ribozyme (HDR) sequence and T7 terminator 
sequence were included to terminate transcription and permit self-cleavage of 
the resulting RNA product. This HDR cleavage event is a transesterification 
reaction, which generates products with either a 2’, 3’-cyclic phosphate or 5’-
hydroxyl termini (Ferré-D’Amaré and Scott, 2010). Therefore, via the use of the 
HDR in our system, we are able to exactly define the 3’ end of our transcribed 
RNA sequence. A kanamycin resistance gene and origin of replication were both 
incorporated to permit selection of bacterial colonies following transformations 
and provide an initiation sequence for replication of dsDNA. The designed inserts 
for S, M and L segments were then incorporated into the pMK-RQ backbone to 
generate pMK-RQ-S, pMK-RQ-M and pMK-RQ-L respectively. 
 
Plasmids expressing positive sense primary RNA transcripts, including directly 
translatable mRNAs, were utilised over those expressing negative sense RNA 
transcripts, despite the negative sense polarity of the HAZV genome.  This is as 
the uncapped positive sense T7 transcripts generated by T7 polymerase have 
previously been shown in other bunyavirus recovery systems to be sufficient in 
initiating viral replication (Lowen et al., 2004; Bergeron et al., 2015). In addition, 
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should the use of support plasmids be required, utilising plasmids expressing a 
positive sense RNA corresponding to the viral genome segments eliminates 
issues arising from dsRNA formation between complementary negative sense 
RNA genome transcripts and the positive sense RNA support transcripts. 
 
 
Figure 3.2, Design of cDNAs for recovery of recombinant rHAZV 
Schematic representation of cDNA plasmids designed for expression of HAZV S (a), M 
(b) and L (c) segments. Virus-encoded proteins are flanked by their respective non-
translated regions (NTRs). T7 promoter (T7P, T7T) and terminator sequences drive 
primary transcription in transfected cells, with the hepatitis delta virus ribozyme (HDR) 
responsible for generating a defined 3’ terminus. A kanamycin resistance gene (KanR), 
origin of replication (Ori) and multiple cloning site (MCS) were included to permit plasmid 
amplification, cloning and antibiotic selection. 
 
Modification following receipt of the plasmids was carried out to remove an 
additional unnecessary T7 promoter that was identified in the backbone of each 
plasmid following sequencing. Presence of this secondary T7 promoter would 
result in extension of the viral 3’ NTR sequence by 51 bases, changing its terminal 
nucleotide sequence, which would likely have a significantly negative effect on 
60 
 
rescue efficiency. Therefore, primers were designed back to back, flanking the 
additional promoter region and it was removed via site-directed mutagenesis 
(SDM). As an initial test to check whether the mutagenesis had the desired 
outcome, restriction digests were performed on each plasmid. pMK-RQ-S was 
digested with KpnI and PstI, pMK-RQ-M was digested with KpnI and XhoI and 
pMK-RQ-L was digested with XhoI, NcoI and EcoRI. These digests generate a 
predicted set of cleavage products, listed in Figure 3.3, that allowed an initial 
check of SDM success. Following this initial check, the plasmids were fully 
sequenced, including the backbone, to ensure complete confidence in the source 
material for the infectious clone system. 
 
Figure 3.3, Restriction digest confirmation of plasmid identity 
a) Expected sizes of products generated following restriction digest of pMK-RQ-S, pMK-
RQ-M and pMK-RQ-L. pMK-RQ-S was digested with KpnI and PstI, pMK-RQ-M was 
digested with KpnI and XhoI and pMK-RQ-L was digested with XhoI, NcoI and EcoRI. b) 
A 2 % agarose gel was used to separate the products of the restriction digests outlined 
in part (a) for pMK-RQ-S (*), pMK-RQ-M (**) and pMK-RQ-L (***). 
 
Due to the availability of HAZV N antisera, confirmation that pMK-RQ-S could 
express the correct virally encoded products was achieved by transfection of 
pMK-RQ-S into BSR-T7 cells and analysing expression of HAZV N compared to 
a WT HAZV infection of SW13 cells via western blot. BSR-T7 cells were 
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transfected at 60-70 % confluency with 1.5 g pMK-RQ-S and 3.75 L TransIT-
LT1 and returned to a 37C incubator for 24 hours. For the WT HAZV infection, 
60-70 % confluent SW13 cells were infected at a MOI of 0.1 and incubated at 
37C for 24 hours. Following the transfection and infection, total cell lysate was 
collected, lysed in RIPA buffer, clarified via centrifugation then analysed via 
western blot (Figure 3.4). Utilising anti-HAZV N serum, visualisation of a band at 
approximately 54 kDa, representing full length HAZV N was achieved following 
transfection, with a similar molecular weight band also detected in lysates 
collected from the WT HAZV infection, as expected. In addition to the 54 kDa 
product, a slightly smaller HAZV N specific product was detected in both 
transfected and infected cell lysates, potentially representing a cleavage or 
degradation product, suggesting that the HAZV N expressed by pMK-RQ-S was 
a similar molecular weight and able to be processed in the same way as HAZV 
N.  
 
Figure 3.4, Confirmation of HAZV N expression from pMK-RQ-S 
Comparison of HAZV N expressed via transfection of the pMK-RQ-S plasmid into BSR-
T7 cells versus HAZV infection of SW13 cells. BSR-T7 cells were transfected at 60-70 
% confluency using the TransIT-LT1 transfection reagent. SW13 cells were infected at a 
MOI of 0.1 in SFM for 1 hour prior to washing and reapplication of 2.5 % DMEM. 
Following a 24 hour incubation period, total cell lysate for both SW13 cells and BSR-T7 
cells was collected and analysed for HAZV N expression via western blot using HAZV N 
antisera. A negative control of BSR-T7 cells with no virus added was also included to 




3.3 Optimising transfections 
In order to generate recombinant virus, the efficiency of delivering cDNAs into the 
BSR-T7 cell line was optimised to increase chances of successful recovery of 
infectious virus. Despite protocols being provided by manufacturers for efficient 
use of their transfection reagents, inherent variability in the conditions required 
for efficient transfection into both closely related and different cell lines, requires 
optimisation prior to commencing experiments (Rose, 2003).  Factors such as 
transfection reagent, ratios of DNA mass to reagent quantity and inclusion of 
additional plasmids to aid transcription were all explored.  
 
3.3.1 Transfection reagent 
In the recovery of infectious CCHFV, the Mirus Bio transfection reagent, TransIT-
LT1, was used to transfect cDNA plasmids into BSR-T7 cells (Bergeron et al., 
2015). To ensure this reagent was optimal for cDNA plasmids encoding HAZV 
genome segments, we compared it to Lipofectamine 2000, the most heavily cited 
transfection reagent available at the time of writing. 
 
Equal amounts of pMK-RQ-S were transfected into 60-70 % confluent BSR-T7 
cells using either the TransIT-LT1 or Lipofectamine 2000 reagents according to 
the manufacturer’s instructions, 24 hours post transfection lysates were 
harvested and analysed via western blot (Figure 3.5, a). Detection of HAZV N 
was used as a marker of transfection efficiency to permit effective comparison 
between the two. A non-transfected control was included and levels of GAPDH 
were also measured to confirm equal loading of samples. Densitometry 
performed on independent triplicate repeats showed expression of pMK-RQ-S 
via Lipofectamine 2000 to have a mean expression rate 30 % lower than that 
using TransIT-LT1 and was therefore chosen as the reagent of choice in all future 





Figure 3.5, Selection of transfection reagent 
a) Comparison of HAZV N expression levels with either TransIT-LT1 or Lipofectamine 
2000 (Lipo 2000) transfection reagent. 1.5 μg of pMK-RQ-S was transfected into BSR-
T7 cells at ≈ 60-70 % confluency using each transfection reagent at the manufacturers 
indicated ratio. At 24 hours post transfection cell lysates were collected for analysis by 
western blot analysis using HAZV N antisera. GAPDH expression levels were also 
examined, using antisera, as a loading control. b) Densitometric analysis of HAZV N 
expression in part (a) using ImageJ plotted using GraphPad Prism software. 
 
3.3.2 Ratio of transfection reagent to cDNA 
Following selection of a reagent, optimisation of the ratio of transfection reagent 
to plasmid DNA was explored to minimise the volume required to achieve 
effective plasmid expression. This minimises not only cost, but also toxic effects 
to the cells that are an inherent side-effect of transfection reagents. This allows 
cells to remain healthy and thereby increase expression. 
 
A range of ratios of DNA to TransIT-LT1, including a negative control of 0:1, from 
1:1 to 1:3.5 were used to transfect 60-70 % confluent BSR-T7 cells. Following a 
24 hour incubation period, lysates were harvested and HAZV N expression 
analysed via western blot (Figure 3.6, a). As with the transfection reagent 
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optimisation, HAZV N expression was used as a marker of transfection efficiency 
to permit comparison between ratios. Levels of GAPDH were also analysed to 
confirm equal loading of samples. Densitometry showed HAZV N expression to 
plateau at ratios of 2.5 and above (Figure 3.6, b), with no significant benefit arising 
from further addition of reagent. Expression of HAZV N at a DNA/transfection 
reagent ratio of 1:1 was used as baseline expression and the other ratios 
compared to this value. The mean relative expression values were determined 
via independent triplicate repeats for ratios 1:2 (1.88), 1:2.5 (2.43), 1:3 (2.45) and 
1:3.5 (2.23). For this reason, a ratio of 1:2.5 of plasmid DNA to TransIT-LT1 was 
used for further transfections. 
 
Figure 3.6, Optimising ratio of transfection reagent to cDNA  
a) Determination of optimal cDNA to TransIT-LT1 ratio for transfection of pMK-RQ-S into 
BSR-T7 cells, measured via expression of HAZV N, using the TransIT-LT1 transfection 
reagent at 60-70 % confluency according to the product protocol. At 24 hours post 
transfection cell lysates were collected for analysis by western blot analysis with HAZV 
N antisera, GAPDH expression levels were also examined, using antisera, as a loading 
control. b) Densitometric analysis of HAZV N expression in part (a) using ImageJ plotted 




3.3.3 Inclusion of exogenous T7 polymerase 
Previous reports have indicated the fluctuation and unreliable nature of T7 
polymerase expression within BSR-T7 cells (Albariño et al., 2009). Previous 
recovery of infectious CCHFV was also aided by inclusion of a T7 polymerase 
expression plasmid, with no associated negative side effects observed (Bergeron 
et al., 2015). Therefore, to increase the efficiency of recovery of HAZV, we aimed 
to ensure maximal expression of our HAZV genome cDNAs via increased 
expression of T7 polymerase using a T7 RNA polymerase expression plasmid.  
 
For these reasons, we trialled the inclusion or omission of pCAGGS-T7pol, a T7 
polymerase expression plasmid under the control of both a chicken actin 
promoter and T7 promoter, alongside transfection of pMK-RQ-S. To ensure fair 
comparison the same amount and ratio of DNA to transfection reagent was 
maintained across the experiment. After 24 hours following transfection of either 
pMK-RQ-S or pMK-RQ-S segment plus pCAGGS-T7pol into BSR-T7 cells, 
lysates were harvested and analysed via western blot (Figure 3.7, a). A non-
transfected control was included and levels of GAPDH were also detected to 
confirm equal loading of samples. As with previous optimisations, HAZV N 
expression was used as a marker of transfection efficiency to permit comparison 
between samples, with GAPDH also included to ensure equal loading of samples. 
Densitometric analysis using ImageJ was used to compare expression of HAZV 
N, with omission of pCAGGS-T7pol used as baseline expression (Figure 3.7, b). 
Independent triplicate repeats revealed inclusion of the T7 expression plasmid to 





Figure 3.7, Optimisation of T7 polymerase expression 
a) Comparison of expression of HAZV N with or without pCAG-T7pol, 1.5 μg pMK-RQ-S 
and +/- 1 μg pCAG-T7pol were transfected into BSR-T7 cells at 60-70 % confluency. At 
24 hours post transfection cell lysates were collected for analysis by western blot 
analysis with HAZV N antisera, GAPDH expression levels were also examined, using 
antisera, as a loading control b) Densitometric analysis of HAZV N expression in part (a) 
using ImageJ plotted using GraphPad Prism software. 
 
3.4 Recovery of WT rHAZV 
An attempt was then made to recover infectious recombinant HAZV (rHAZV) 
using the optimisations identified in sections 3.3.1, 3.3.2 and 3.3.3. BSR-T7 cells 
were transfected with pMK-RQ-S, pMK-RQ-M and pMK-RQ-L alongside 
pCAGGS-T7pol at 50-60 % confluency, this is referred to as a “complete” 
transfection from herein. Additional transfections in which pMK-RQ-L was omitted 
were also included, to act as recovery controls incapable of generating infectious 
virus, this is referred to as a “control” transfection from herein. Despite the 
previously described rCCHFV system supplementing the individual genome 
segment specific cDNAs with support plasmids expressing the CCHFV N and 
CCHFV RdRp, recovery of rHAZV was attempted without the HAZV equivalents 
in an attempt to reduce the number of plasmids required to a minimum, thus 
reducing the complexity of transfection (Bergeron et al., 2015). Further reasoning 
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for omission of support plasmids was provided by the rescue of BUNV from 
cDNA, which had previously incorporated the use of support plasmids alongside 
plasmids expressing full length antigenomic vRNAs; In a subsequent follow-up 
paper, attempts to recover infectious virus without addition of support plasmids 
proved successful, demonstrating the possibility of rescuing members of the 
order Bunyavirales without additional transfection of support plasmids (Bridgen 
and Elliott, 1996; Lowen et al., 2004). A lower confluency of cells was used versus 
the transfection optimisations previously described in section 3.3 to allow for 
amplification of cell numbers within the time frame of the rescue experiments. 
Attempts made with higher confluency cells were met with visible CPE, potentially 
due to a combination of over confluency, toxicity arising from transfection reagent 
and virus-induced CPE. At regular time intervals post transfection, namely 72, 96 
and 120 hours, supernatant was harvested from BSR-T7 cells and used to infect 
fresh monolayers of SW13 cells for a further 48 hour infection, following this 
infection, supernatant was harvested and stored for downstream applications 
(Figure 3.8). In addition, supernatant samples were also harvested from the 
transfected BSR-T7 cells at the 72, 96 and 120 hour time points and used to 
titrate virus levels to assess the optimal time to harvest recovered virus following 
transfection of the plasmid DNA into BSR-T7 cells. 
 
 
Figure 3.8, Schematic detailing recovery of rHAZV 
Rescue of rHAZV was achieved by BSR-T7 cell transfection of plasmids pMK-RQ-S, 
pMK-RQ-M and pMK-RQ-L designed to express small (S), medium (M), large (L) 
genome segments, respectively, alongside a T7 RNA polymerase expression plasmid 
pCAG-T7pol (T7). At the indicated timepoints, supernatant was used to infect fresh 
SW13 cell monolayers for 48 hours, when supernatants and cell lysates were harvested 
for downstream application and analysis. 
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Following the 48 hour SW13 cell infections, lysates were collected and analysed 
for expression of HAZV N as a marker of viral transcription and translation by 
SDS PAGE and western blotting. Significant amounts of HAZV N were detected 
after the 48 hour infections set up using supernatant collected 96 and 120 hours 
post transfection arising from the complete rescue attempt (Figure 3.9, a, lanes 
1-4). Supernatant at each of these time points was collected and stored at −80C 
for future downstream applications. As expected, no HAZV N was detected in any 
of the SW13 cells infected with supernatant collected from control transfected 
BSR-T7 cells (Figure 3.9, a, lanes 5-8). Titre of infectious rHAZV was determined 
via plaque assay, with increasing titre of rHAZV detected in the supernatant taken 
from transfected BSR-T7 cells at 72, 96 and 120 hours post transfection (Figure 
3.9, b), extensive CPE of the BSR-T7 cells created difficulties with collection of 
supernatant past this point. It is important to note that the titre following 
transfection should not be used as a measure of viral fitness; the requirement of 
multiple plasmids to be transfected into a single cell may lead to some cells 
acquiring the required cDNAs for virus production much sooner than others. 
However, in all recoveries of rHAZV, the titre of infectious virus generated peaked 
at day 5 post transfection, in a similar manner to recovery of rCCHFV (Bergeron 
et al., 2015). Interestingly, rCCHFV was only recoverable in the presence of 
support plasmid expressing the RdRp, whereas our data shows HAZV not to 
require the inclusion of any supports, potentially due to differences in length of 
the L segment, though this was not explored further. However as previously 
mentioned, the ability of HAZV to be recovered without the use of support 
plasmids is not unique to the Bunyavirales order (Lowen et al., 2004). Plaque 
assays, which rely on viral lysis of cells in localised areas, also confirmed the 
infectious nature of the virus produced from cDNAs (Figure 3.9, c), allowing 
downstream comparisons to parental virus to be carried out at equal MOI to 
ensure accurate conclusions to be drawn on their phenotypes. Taken together, 
the expression of viral products coupled with presence of CPE in the plaque 
assays shows successful recovery of a rHAZV infectious clone that, to our 




Figure 3.9, Recovery of WT rHAZV 
a) Detection of HAZV N post-transfection (p.Tr) of BSR-T7 cells and subsequent 48 hour 
post-infections (p.Inf) by western blot using HAZV N antisera. Supernatant samples 
collected from transfected BSR-T7 cells at 96 hours post transfection were used to infect 
monolayers of SW13 cells. At 48 hours post infection, lysates were collected and 
analysed by SDS-PAGE. Recovery of rHAZV using S, M and L rescue expressing 
plasmids (‘complete’) was carried out alongside control transfections in which L segment 
plasmid was omitted. Detection of GAPDH abundance by western blotting was included 
as a loading control. b) Titre of infectious rHAZV released into supernatant at 72, 96 and 
120 hours post transfection of ‘complete’ and control plasmids was assessed via plaque 
assay. c) Representative plaque assays at 10-1 to 10-3 dilutions from rHAZV titration in 
part (b). Serial dilutions were generated from virus harvested 120 hours post infection 
and used to infect SW13 cell monolayers for 1 hour prior to addition of a methyl cellulose 
overlay. Cells were then fixed and stained 6 days post infection and counted. 
 
Following successful titration of virus via the plaque assay method, quantitative 
polymerase chain reaction (qPCR) was carried out to confirm that the virus 
causing the plaque assay CPE was rHAZV. Primers were designed to be specific 
to the S segment of HAZV (5’ CAA GGC AAG CAT TGC ACA AC 3’ and 5’ GCT 
TTC TCT CAC CCC TTT TAG GA 3’) and a set of standard RNA was transcribed 
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in vitro to permit quantification of S segment copies. Following an infection of 
SW13 cells with rHAZV at a range of MOIs including mock, 0.01 and 0.1 total 
RNA was isolated via Trizol extraction and analysed via qPCR. Detection of the 
in-vitro transcribed RNA was as expected, with relative threshold cycle values (ct) 
increasing as the copy number of RNA decreased (Figure 3.10, a). Consistent 
with expected results, the RNA isolated from the highest MOI infection of 0.1 had 
the lowest ct values, followed by the 0.01 MOI infection (Figure 3.10, b). 
Unfortunately, amplification of RNA did occur in RNA isolated from the mock 
infected SW13 cells. However, the ct values corresponding to the mock infected 
cells were outside the range of the RNA standards and is therefore possibly a 
result of non-specific binding of primers. As a control to ensure total cellular RNA 
was consistent between samples, primers against GAPDH were designed and 
incorporated into the qPCR assay. Primer sequences can be found in Table 2.1. 
As expected, ct values for all samples were similar, demonstrating a similar 
concentration of starting material was present in the samples (Figure 3.10, c). 
Inclusion of the GAPDH also permitted normalisation of the data relative to the 
0.10 MOI infection. Consistent with the 10 fold reduction in MOI, RNA isolated 
from the 0.01 MOI infection contained approximately 7 % of the S segment 
specific RNA detected in the 0.10 MOI infection, consistent with expectations 
(Figure 3.10, d).  
Having an established qPCR system may prove beneficial in future experiments 
where mutations incorporated into the recovered virus affect its ability to form 
plaques, providing an alternative and faster means of titration. In addition, when 
used in combination with cellular lysates rather than supernatants it could provide 
useful information on viral transcription levels and is therefore a valuable tool in 




Figure 3.10, qPCR detection of HAZV S segment RNA 
qPCR readout for (a) in vitro transcribed S RNA using HAZV S primers. RNA extracted 
from SW13 cells infected at 0.1, 0.01 and mock infected MOIs using (b) HAZV S segment 
primers and (c) using GAPDH primers. Axis display fluorescence versus cycle number, 
threshold was automatically determined by qPCR software. d) Normalised S segment 





3.5 Comparison of recombinant HAZV to parental strain JC280 
To permit accurate conclusions to be drawn about the parental strain from the 
infectious clone, the recombinant virus must be confirmed as a suitable model for 
the parental strain. To this end, rHAZV was compared directly against in-house 
parental HAZV stocks, examining both fitness and plaque morphology.  
 
Briefly, to examine the growth profiles of HAZV and rHAZV, SW13 cell 
monolayers were infected at an equal MOI of 0.001 in SFM for 1 hour. At this 
time infection media was removed, cells were washed in PBS and fresh media 
was reapplied. Supernatant samples were harvested at 24, 48, 72 and 96 hours 
post infection, at which point and viral titre was determined via plaque assay. 
Plotting of infectious titre versus time displayed both HAZV and rHAZV to share 
similar growth profiles, with both titres increasing from the point of infection until 
72 hours post infection, with titres observed to be approximately 1-2 x 106 pfu / 
mL, after this point, virus titre began to drop off in a similar manner with both 
HAZV and rHAZV (Figure 3.11, a).  
 
As virus titre was determined via plaque assay, it also permitted analysis of 
plaque morphologies for both HAZV and rHAZV. Plaque morphology is a useful 
measure of viral fitness as variation in dimensions, clarity and intensity of staining 
can all indicate altered fitness. As with the growth profiles of the two viruses, 
plaque morphologies were similar (Figure 3.11, b), presenting as circular, with 
well-defined edges and a "bullseye" centre. This bullseye forms when the initially 
infected cells are not killed to the same degree to subsequently infected cells 
surrounding them, leaving a portion of cells still able to take up the crystal violet 
stain. As to why the initially infected cells are not killed by rHAZV or HAZV 
remains unknown, but may be linked to the reduced viral load initially present in 
the infection. These data both supported the rHAZV infectious clone as a suitable 




Figure 3.11, Comparison of rHAZV to parental strain 
a) Titre of infectious rHAZV (circle data points) and its parental strain of HAZV (square 
data points) harvested at 24 hour intervals up to 96 hours post infection of SW13 cells 
at an equal MOI of 0.001. b) Representative plaque assays from the 10-1 to 10-3 dilutions 
used to determine titre of infectious HAZV and rHAZV in (a) showing similar plaque 
morphology in both instances. Serial dilutions were generated from virus harvested 24 
hours post infection and used to infect SW13 cell monolayers for 1 hour prior to addition 
of a methyl cellulose overlay. Cells were then fixed and stained with crystal violet 6 days 
post infection and plaques counted.  
 
3.6 Confirmation of the cDNA source of rHAZV 
In order to confirm the origin of the rescued HAZV as having a cDNA source, 
rather than as a laboratory contaminant, site directed mutagenesis (SDM) was 
conducted on pMK-RQ-S resulting in the insertion of a “silent” mutation as a 
genetic marker, which was a Hind III restriction site at nucleotide position 723 via 
switching of guanine to thymine, giving the new plasmid termed pMK-RQ-S-
nG723T. This change was silent at the amino acid sequence level, as evidenced 
by the resulting codon changing from CTG to CTT, both encoding leucine 
residues (Figure 3.12, a). Following recovery of the mutant rHAZV, primers were 
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designed to flank this region at position 415 and 1217 in the S genome to permit 
PCR amplification of an 800 bp sequence of DNA, following RNA extraction and 
first strand synthesis, that could then be examined for the restriction site via 
sanger-sequencing or restriction digest (Figure 3.12, b). 
 
Figure 3.12, Overview of insertion of a HindIII restriction site to S segment cDNA 
a) Table showing the change (underlined) to both DNA sequence of the HAZV N ORF 
and the resulting amino acid sequence. b) Schematic showing the location of the inserted 
Hind III restriction site into the S-segment ORF.  
 
The plasmid containing the nG723T mutation, pMK-RQ-S-nG723T, was then 
utilised in mutant recovery in place of pMK-RQ-S alongside control and complete 
recoveries as previously described in section 3.4. As expected, the silent nature 
of the mutagenesis meant no phenotypic effect was observed and the nG723T 
mutant rescued alongside the WT recovery, with strong HAZV N expression 
detected in both transfected BSR-T7 cells and the subsequent infections of SW13 
cells using supernatant harvested at 96 and 120 hour post transfection (Figure 
3.13, a). Following recovery and subsequent amplification to generate high titre 
virus, an RNA extraction, first strand synthesis and PCR amplification using the 
primers described above permitted isolation of an 800 bp fragment of DNA. 
Restriction digest using Hind III cleaved the fragment isolated from 
rHAZV(nG723T) into 300 and 500 bp fragments, whilst the fragment isolated from 
WT rHAZV remained intact (Figure 3.13, b). A control omitting the reverse 
transcription stage was also included to rule out possible plasmid contamination 
as the source of the PCR amplified DNA. This proved beyond reasonable doubt 




Figure 3.13, Recovery and confirmation of a silent mutant rHAZV 
a) Detection of HAZV N by western blotting following transfection (p.Tr) of BSR-T7 cells 
and subsequent 48 hour infections (p.Inf). Supernatant samples collected from 
transfected BSR-T7 cells at 96 hours post transfection were used to infect monolayers 
of SW13 cells. Following a 48 hour infection, lysates were collected and ran on SDS-
PAGE. Recovery of rHAZV containing a HindIII restriction site (rHAZV(G723T)) was 
carried out alongside a complete and control recovery of rHAZV. Detection of GAPDH 
abundance was included as a loading control. b) A 2 % agarose gel was used to separate 
the products of the Hind III restriction digest of the dsDNA generated following RNA 
extraction of rHAZV and rHAZV(nG723T) containing supernatants, first strand synthesis 
and PCR amplification of viral genetic material. A control reaction in which no reverse 
transcriptase was added to the reaction mixture (“No-RT”) was also included to rule out 
plasmid carryover as the source of the amplification. 
 
3.7 Chapter summary and discussion 
In this chapter, an infectious clone system was designed, optimised and utilised 
to generate infectious rHAZV from positive sense cDNAs in a robust manner. 
Previous work has developed a similar system for CCHFV, however due to the 
highly pathogenic nature of this virus, the CCHFV system requires restrictive 
containment level 4 protocols (Bergeron et al., 2015). The classification of HAZV 
as a hazard level 2 pathogen permits its use in much more easily accessible BSL-
2 facilities and, given it is the first orthonairovirus of this hazard level to be 
recovered from cDNAs, represents a major advance in the study of 
orthonairovirus molecular and cellular biology. The potential uses of an infectious 
clone system for HAZV are broad; the above described system for CCHFV has 
already been utilised to increase understanding on glycoprotein processing, the 
requirement of the OTU domain and more recently in aiding anti-viral discovery 
(Bergeron et al., 2015; Scholte et al., 2017; Welch et al., 2017). Recovery 
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systems are not just limited to small scale changes to the viral genomes; the 
RVFV infectious clone system was utilised to generate a NSm deficient virus, 
demonstrating NSm to be dispensable for both virulence and lethality (Bird, 
Albariño and Nichol, 2007). Another important aspect of an infectious clone is its 
ability to aid vaccine development. Attenuation of domains critical for viral 
pathogenesis, or alteration of the optimal replication temperature or additional 
host requirements, has already been explored in both RVFV and respiratory 
syncytial virus (RSV) in pursuit of vaccine candidates (Collins et al., 1995; Smith 
et al., 2018). With extensive similarities between HAZV and CCHFV, aside from 
the shared human pathology, incorporation of the CCHFV antigen into a HAZV 
virion could present an interesting vaccine candidate, assuming the pathogenic 
domains of CCHFV are not a result of an overlapping region with the antigenic 
section. 
 
The system developed in this chapter has been demonstrated to be highly 
efficient, generating titres of rHAZV over 1.2x105 in primary transfected 
supernatants, which can be used to further create higher titre stocks through a 
second round of passaging once the titre of the initial stock has been determined. 
Furthermore, the recovery of WT rHAZV was successful in 100 % of rescues 
using the sequence confirmed pMK-RQ-S/M/L and pCAGGS-T7pol plasmids, 
with a minimum of 5 recoveries attempted, demonstrating the robust and 
repeatable nature of the system. To test the ability of the infectious clone system 
to tolerate mutations, and also to confirm the source of the infectious virus as 
cDNA and not contaminating cDNA, a silent mutation was inserted, resulting in 
the generation of a Hind III restriction site. Following recovery of this mutant virus, 
the altered cDNA source was confirmed, and contamination ruled out, via RT-
PCR and restriction digest. This ability to tolerate mutations, with high efficiency 
and repeatability of recovery will greatly aid recovery of mutant viruses with 
attenuated fitness and permit identification of mutations resulting in fatal 
phenotype.  
 
This system will provide the basis of the following 2 chapters, which will utilise 
the WT system and adapt it to incorporate additional features and to explore the 
effects of mutations to the WT sequence on viral pathogenesis. 
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4 Generation of a fluorescent reporter virus 
4.1 General introduction 
Following the successful recovery of a WT recombinant clone for HAZV, detailed 
in chapter 3, the ability to modify the viral genome sequence was explored further. 
In addition to studying the importance of individual nucleotides, amino acids, 
NTRs and ORFs of the virus, the recombinant system can also be manipulated 
to add additional features to the virus. To this end the HAZV S segment 
expression plasmid pMK-RQ-S was modified to incorporate an eGFP ORF linked 
to HAZV N via a porcine teshovirus-1 2A peptide linker (P2A) self-cleaving 
sequence, creating pMK-RQ-S-eGFP (Figure 4.1). This construct permits 
expression of both eGFP and HAZV N as independently translated proteins from 
a single mRNA transcribed from the same viral genome segment.  
 
It was decided to co-express eGFP and HAZV N from the same gene segment 
as it prevented the virus simply excluding an additional eGFP segment during 
packaging, due to the critical requirement of HAZV N in HAZV infection. The 
independent expression is a result of a ribosomal skipping event which occurs 
between the terminal glycine and proline residues in the P2A peptide, with no 
peptide bond forming during the continuation of translation, ensuring expression 
of the downstream gene (Donnelly et al., 2001). Independent expression of both 
eGFP and HAZV N has multiple advantages. Firstly, as the final viral product is 
expressed without any additional residues, it should function as a WT viral 
protein, resulting in minimal loss of fitness to HAZV overall. Secondly, the 
untagged form of eGFP is not limited to regions where HAZV N localises to, 
allowing its expression to be ubiquitous within the cell, aiding detection of eGFP 
positive cells. Previous studies have successfully incorporated P2A linkers into 
recombinant virus systems, perhaps the most relevant example being in CCHFV, 
where a ZsGreen1 (ZsG) fluorescent marker was introduced in a similar manner, 
which permitted screening of a number of potential anti-viral compounds in an 
efficient and quantitative manner (Welch et al., 2017). The CCHFV infectious 
clone expressing ZsG led to the identification of 2’-deoxy-2’flurocytidine as a 
potent inhibitor of CCHFV replication, with efficacy higher than ribavirin or 
favipiravir (Welch et al., 2017). Given the similarities between HAZV and CCHFV, 
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and the lower containment level required for HAZV propagation, rHAZV(eGFP) 
presents an attractive means of assessing candidate compounds for CCHFV, 
without the high-level containment laboratory requirements. 
 
It is worth noting that an inherent disadvantage to the P2A linker compared with 
post-translational cleavage systems arises from the imperfect nature of the 
ribosomal skipping event. During the ribosomal skipping event three potential 
outcomes are observed. The desired outcome is a successful skipping event 
resulting in two independently translated products, however previous studies 
have also identified cases where the skipping does not occur, giving a single 
polyprotein. Additionally, cases have been reported where the ribosome falls off 
the mRNA during translation at the glycine to proline site, leading to expression 
of only the first ORF, in our case eGFP (Liu et al., 2017). Taking these factors 
into account, with many translation events occurring, a skew in gene expression 
occurs, with ORFs upstream of the P2A linker regions sometimes having higher 
expression rates than the downstream versions, a study examining expression of 
fluorescent reporters in bi-, tri- and tetra-cistronic vectors found that expression 
of the fluorophores decreased with progression towards the end of the construct 
(Liu et al., 2017). 
 
The aims of this chapter were as follows; 
 
1. Develop an rHAZV infectious clone expressing eGFP 
2. Validate rHAZV(eGFP) as a suitable reporter for rHAZV infection 
3. Utilise the reporter virus to screen a panel of membrane trafficking factors 
4. Follow up any significant results to uncover original findings on HAZV 
infection 
 
Successful generation of an eGFP expressing HAZV infectious clone would 
enable multiple avenues of investigation into many aspects of HAZV infections in 
addition to those mentioned above and would therefore be a valuable tool in 




4.2 Plasmid design 
To generate a cDNA plasmid encoding the eGFP-P2A ORF upstream of HAZV 
N, a cDNA was commercially synthesised and purchased (Genewiz) encoding 
the eGFP-P2A nucleotide sequence in a pUC57-Kan backbone, hereby known 
as pUC57-eGFP-P2A. The full sequence for this insert can be found in appendix 
1.1.4. The purchased synthesised sequence for eGFP-P2A included a 5’ EcoRI 
and 3’ NotI restriction site to permit ligation into pMK-RQ-S. The S segment was 
chosen to express both HAZV N and eGFP due to its small size and prior 
availability of a marker, antiserum against HAZV N. As HAZV is able to package 
the much larger M and L segments, it was hypothesised that there would be no 
issues extending the length of the S segment RNP, the only factor that may be 
an issue would be fitting the enlarged RNP into a virion alongside M and L RNPs. 
However, as incorporation of a larger S segment RNP in the CCHFV fluorescent 
clone had no significant impact on viral fitness, it was assumed similar results 
would be observed in HAZV (Welch et al., 2017). 
 
To facilitate ligation of the eGFP-P2A insert from pUC57-eGFP-P2A into pMK-
RQ-S, SDM was carried out on pMK-RQ-S to insert an EcoRI and NotI restriction 
site at the 5’ end of the HAZV N ORF, immediately after the 3’ end of the NTR, 
resulting in generation of pMK-RQ-S(Eco/Not). Following transformation of the 
plasmids after SDM, colonies were isolated, grown up and the DNA purified to 
permit sequence validation of the insertion of both restriction sites in the correct 
orientation. Upon confirmation, pUC57-eGFP-P2A and pMK-RQ-S(Eco/Not) 
were digested with EcoRI and NotI and relevant bands excised and purified 
following agarose gel electrophoresis. These digestion products were then used 
in a T4 ligation reaction to generate the plasmid displayed in Figure 4.1. A final 
set of SDM reactions were then carried out to remove the EcoRI and NotI 
restriction sites flanking the insert, to ensure HAZV N was kept in frame with the 
eGFP ORF, resulting in generation of pMK-RQ-S-eGFP. Confirmation of SDM 





Figure 4.1, eGFP S segment schematic 
Schematic of S segment plasmid design incorporating the eGFP ORF (green) 
immediately downstream of the 3’ NTR (orange) and upstream of the HAZV N ORF 
(blue). Transcription of this plasmid by T7 RNA polymerase generates a positive sense 
antigenome. The P2A linker sequence (red) was inserted between the eGFP and HAZV 
N ORFs in frame to permit translation of both gene products. The amino acid sequence 
of the P2A linker is indicated below the schematic. A hepatitis delta virus ribozyme (HDR) 
ensured correct 3’ end formation of transcribed RNAs. The entire transcriptional unit is 
under control of T7 promoter (T7P) and T7 terminator (T7T) sequences (white). 
 
To confirm the correct expression of HAZV N following generation of pMK-RQ-S-
eGFP, lysates collected from a WT rHAZV infection of SW13 cells were run 
alongside BSR-T7 cell lysates collected 24 hours following transfection with pMK-
RQ-S-eGFP. Comparisons were made to ensure the P2A linker was correctly 
generating an untagged form of HAZV N, therefore the transfected lysates should 
contain a similar sized HAZV N to those of the rHAZV infected lysates. As seen 
in (Figure 4.2), HAZV N observed in transfected cell lysates was indistinguishable 
from WT rHAZV infected lysates, demonstrating that pMK-RQ-S-eGFP 
expression of HAZV N results in a product that is the same observed molecular 




Figure 4.2, Western blot confirmation of correct HAZV N expression from pMK-RQ-
S-eGFP  
Comparison of HAZV N expressed by WT rHAZV during infection of SW13 cells (WT) 
versus expression of HAZV N following transfection of the pMK-RQ-S-eGFP plasmid into 
BSR-T7 cells (eGFP). BSR-T7 cells were transfected at 60 - 70 % confluency using the 
TransIT-LT1 transfection reagent. SW13 cells were infected at a MOI of 0.1 in SFM for 
1 hour prior to washing and reapplication of 2.5 % DMEM. Following a 24 hour incubation 
period, total cell lysate for both SW13 cells and BSR-T7 cells was collected and analysed 
for HAZV N expression via western blot using anti HAZV N serum. A negative control in 
BSR-T7 cells with no virus added was also included to identify specific bands (*) from 
non-specific bands (**). Relevant molecular sizes are indicated in kDa. 
 
4.3 Recovery of rHAZV-eGFP 
The pMK-RQ-S-eGFP construct described in section 4.2 was synthesised and 
transfected alongside pMK-RQ-M and pMK-RQ-L into BSR-T7 cells at 50-60 % 
confluency. As with the WT rHAZV system described in section 3.4, a control 
recovery was set up with the omission of the pMK-RQ-L. As with recovery of WT 
rHAZV, supernatants were collected at 72, 96 and 120 hour time points following 
transfection and used to infect fresh monolayers of SW13 cells. Following a 48 
hour infection, cell lysates were collected and analysed via western blot for the 
presence of HAZV N that would indicate successful recovery of rHAZV (Figure 
4.3). Presence of a HAZV N specific band in both re-infections of SW13 cells 
using supernatant harvested at 96 and 120 hours post transfection indicated 
successful recovery of rHAZV(eGFP) and WT rHAZV utilising the engineered 
pMK-RQ-S-eGFP plasmid and WT pMK-RQ-S plasmid respectively. To ensure 
the virus was able to generate eGFP, western blot analysis using an eGFP 
antibody was also carried out. Detection of a band specific to eGFP was observed 
in lanes corresponding to the initially transfected BSR-T7 cells and in the SW13 
cells re-infected with supernatant harvested at 120 hours post transfection 
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(Figure 4.3). Critically, detection of both HAZV N and eGFP was observed at their 
expected molecular weights, confirming their independent expression and ruling 
out an eGFP-HAZV N polyprotein expression system.  
 
Figure 4.3, Western blot analysis of transfected and infected cell lysates confirms 
recovery of rHAZV(eGFP) 
Detection of HAZV N and eGFP following transfection (p.Tr) of BSR-T7 cells and 
subsequent 48 hour infections of SW13 cells (p.Inf) using supernatant samples collected 
from transfected BSR-T7 cells at 72, 96 and 120 hours post transfection. Following 
infection, lysates were collected and analysed via western blot. Recovery of rHAZV 
containing the eGFP-P2A ORF was carried out alongside a WT rHAZV and control 
recovery of rHAZV omitting the L segment. Detection of GAPDH abundance was 
included as a loading control.  
 
To confirm the fluorescent nature of the recovered rHAZV(eGFP), the 48 hour re-
infection of SW13 cells, using supernatant harvested from BSR-T7 cells at 120 
hours post-transfection, was carried out in the IncuCyte live cell imaging system. 
This enabled images to be taken and analysed for green cell count every hour 
throughout the infection (Figure 4.4, a). Representative images from the time 
course at 0 and 48 hours post infection for complete and rHAZV(eGFP) are 
provided showing the highly fluorescent nature of the virus (Figure 4.4, b). No 
visible fluorescence was observed in wells infected with WT rHAZV (Complete), 
indicating fluorescence was an attribute unique to the eGFP expressing virus. 
Analysis of total green cell count per well showed a two-step increase of eGFP 
positive cells, the first occurring between 15-20 hours post infection and the 
second at 40-45 hours post infection (Figure 4.4, a). The observation of a two 
step increase allows the estimation of the length of the infectious cycle in SW13 
cells to be approximately 20 to 25 hours. This can be further supported by the 
detection of infectious virus in the supernatant at 24 hours post infection, as 
previously shown in Figure 3.11 As expected, in both the control and WT rHAZV 
infections, no eGFP positive cells were detected, with minor fluorescence visible 
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from 40 hours onwards, likely as a consequence of auto-fluorescence from dying 
cells as the cell culture becomes over confluent. The ability to indirectly measure 
viral activity in real time, by observing eGFP levels, will provide an excellent tool 
for analysing the effect of siRNAs on viral infection, streamlining the sample 





Figure 4.4, Confirmation of the fluorescent nature of rHAZV(eGFP) via live cell 
imaging 
a) Graphical representation of green cell count over time during the 48 hour re-infection 
of SW13 cells using supernatant harvested from BSR-T7 cells 120 hours post 
transfection. Analysis was carried out using the IncuCyte® live cell imaging system and 
plotted using GraphPad Prism. b) Demonstration of the fluorescent nature of 
rHAZV(eGFP) shown in images taken at 0 and 48 hours post infection from the 
experiment carried out in (a) from rHAZV and rHAZV(eGFP) infections. Scale bar 
represents 300 µM. 
 
Titre of supernatant harvested from BSR-T7 cells 120 hours post-transfection 
was measured via plaque assay in SW13 cells to permit further propagation of 
the virus stock at a known MOI to generate a larger titre in future experimentation 
(Figure 4.5). Visualisation of plaques 6 days post infection also confirmed the lytic 
nature of rHAZV(eGFP), as was previously observed with WT rHAZV in section 
85 
 
3.4. Taken together, this demonstrated successful recovery of a rHAZV mutant, 
capable of expressing eGFP independently of viral proteins that can be used for 
multiple applications, including streamlining screening of siRNAs without the 
need for western blotting, immunofluorescence or qPCR-based techniques.  
 
Figure 4.5, Plaque assay of rHAZV(eGFP) 
Representative plaque assays of rHAZV(eGFP) used to titre virus also show lytic nature 
of the recovered recombinant reporter virus. Images show dilutions from 10-1 to 10-6 in 
SW13 cells stained 6 days post infection. 
 
4.4 Comparison to WT rHAZV 
The nature of the P2A linkage of eGFP to HAZV N in rHAZV(eGFP) should result 
in independent expression of both proteins and therefore have little or no effect 
on the viral lifecycle, however previous evidence has suggested this linker is not 
100 % efficient in generating two independent products of translation (Liu et al., 
2017). To ascertain whether the inserted eGFP ORF was having an effect on 
virus growth kinetics, comparison of rHAZV(eGFP) and WT rHAZV was required 
in order to validate rHAZV(eGFP) as a model system. To achieve this, the 
multistep growth kinetics for WT rHAZV and rHAZV(eGFP) was compared in 
SW13 cells infected at an equal MOI of 0.01. At regular 24 hour intervals post 
infection, supernatant samples from each infection were harvested and used to 
titre infectious virus in supernatants via plaque assay. Comparison of viral titres 
displayed a marginal increase in viral titre for WT rHAZV versus rHAZV(eGFP) 
(Figure 4.6, a). However, the growth profile remained consistent between both 
strains, peaking at 72 hours post infection, then decreasing at subsequent 
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timepoints. Mean values for plaque forming units per mL (PFU / mL) were as 
follows; 24 hours: 5400 (rHAZV) and 3750 (rHAZV(eGFP)), 48 hours: 310,000 
(rHAZV) and 80,500 (rHAZV(eGFP)), 72 hours: 440,000 (rHAZV) and 190,000 
(rHAZV(eGFP)), 96 hours: 90,000 (rHAZV) and 44,500 (rHAZV(eGFP)), 120 
hours: 30,000 (rHAZV) and 7850 (rHAZV(eGFP)). This observed difference 
between the WT and reporter viruses may be a result of allocation of cellular 
resources away from expression of viral products during synthesis of eGFP 
during rHAZV(eGFP) infection, resulting in generation of fewer infectious virions. 
The increased length of the S segment, due to the inclusion of the eGFP and P2A 
sequences, will result in slower transcription and translation times. Previous 
reports have also identified lower expression of proteins downstream of P2A 
linker sequences, potentially due to the disadvantages associated with P2A 
linkers identified in section 4.1, which could result in translation of less HAZV N 
(Liu et al., 2017). These explanations would point to the ability of rHAZV to 
produce a higher number of infectious particles than rHAZV(eGFP), rather than 
a difference in fitness between the fully assembled particles produced by either 
virus. Plaque morphology remained largely similar for rHAZV and rHAZV(eGFP), 
with only a slight loss of clarity (Figure 4.6, b). However overall, rHAZV and 
rHAZV(eGFP) displayed similar growth properties and phenotype, demonstrating 




Figure 4.6, Multi-step growth kinetics of rHAZV vs rHAZV(eGFP) shows similar 
growth profiles 
a) Graphical representation of titres of infectious supernatant harvested at 24, 48, 72, 96 
and 120 hours from SW13 cells infected with either rHAZV or rHAZV(eGFP) at a MOI of 
0.01. Error bars represent a minimum of three technical repeats. Plotted using GraphPad 
prism. b) Representative plaque assays taken from samples used to calculate data in 
(a), Images show SW13 cells stained 6 days post infection with either rHAZV or 
rHAZV(eGFP). A mock infected was included as a negative control. 
 
The location of the eGFP ORF upstream of HAZV N within the S segment 
encoding cDNA should rule out exclusion of eGFP were it to be expressed on a 
unique viral genome segment due to the critical requirement of HAZV N to the 
viral lifecycle. However, due to the error prone nature of the viral RdRp 
(Steinhauer, Domingo and Holland, 1992), it is possible that mutations could go 
unchecked within the eGFP ORF, as expression of eGFP is not essential for virus 
replication.  In this case, rHAZV(eGFP) may become capable of infecting cells 
without expression of functional eGFP, which may result in false negative results 
following analysis of eGFP derived signals. To determine whether this required 
addressing, a comparison of eGFP positive cells to HAZV N positive cells was 
performed. This was achieved by infection of SW13 cells with rHAZV(eGFP) and 
imaging via immunofluorescence microscopy, targeting HAZV N with antisera 
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and eGFP using its natural fluorescence. Visualisation of images taken showed 
all eGFP positive cells contained a HAZV N signal. This suggests that no 
mutations affecting critical regions of eGFP had occurred (Figure 4.7). However, 
this experiment was carried out with passage 5 rHAZV(eGFP), which is relatively 
low and therefore this potential for loss of eGFP signal should be closely 
monitored following extensive passage of the virus. Further evidence for stability 
of the insert is shown by the recombinant CCHFV infectious clone expressing 
ZsG, in which analysis of the ZsG-P2A insertion showed no mutations at passage 
10 (Welch et al., 2017). Therefore, as long as the virus is used at low passages, 
this reporter strain will no doubt prove invaluable to future studies, providing a 
means of assessing viral infection in an efficient and easy manner. 
 
Figure 4.7, Confirming co-expression of eGFP and HAZV N in infected SW13 cells 
Tile scan of 5 x 5 immunofluorescent images of rHAZV(eGFP) infected SW13 cells 
stained using HAZV N antisera, taken on a Zeiss LSM880 confocal microscope using 
x40 magnification. Nuclei are shown in blue (DAPI), HAZV N is shown in red, eGFP 
signal is shown in green and a combined merged image is displayed. Scale bar 




4.5 Growth kinetics of eGFP HAZV in multiple cell lines 
At the time of writing, no previous studies have extensively analysed the growth 
profile of HAZV in multiple cell lines. Given the ability of rHAZV(eGFP) to be used 
with live cell imaging on the IncuCyte® live cell imaging system, the mammalian 
cell lines SW13, A549, Huh7 and BHK were infected with rHAZV(eGFP) at a MOI 
of 0.01 and relative growth was examined via hourly detection of eGFP positive 
cells for 48 hours. SW13 cells, originating from a human adrenal cortex 
carcinoma cell line, are commonly described in the literature for HAZV research, 
with multiple groups reporting data using this cell line (Surtees et al., 2015; Hover 
et al., 2016; Matsumoto et al., 2019). A549 cells, originating from the 
adenocarcinomic human alveolar basal epithelium, have been extensively used 
in study of the BUNV, the model species of the Bunyavirales order, having been 
used to uncover the dependence of this family of viruses on ion channels and 
cholesterol during the entry stages of infection (Hover et al., 2016; Charlton et al., 
2019). Huh7 cells, derived from a human hepatocellular carcinoma, are more 
commonly used for CCHFV research and were used during recovery of the WT 
and fluorescent clones for CCHFV (E. Bergeron 2015, S. R. Welch 2017). The 
BHK cell line, originating from baby hamster kidney cells, was used as it 
originates from a small mammal, which represent natural hosts of CCHFV during 
its lifecycle (Spengler, Bergeron and Rollin, 2016). In addition, previous members 
of our group have achieved the highest titres of virus from the BHK cell line during 
purification of HAZV, though why this line specifically is able to generate such 
high titres of virus is unknown (Punch et al., 2018). 
 
Following infection of the indicated cell lines, images were taken hourly and total 
green cell count per well was analysed on the IncuCyte® live cell imaging system 
and plotted versus time (Figure 4.8, a, b). As expected, rHAZV(eGFP) was able 
to replicate efficiently in all four cell lines, as evidenced by detection of eGFP 
positive cells in all four infections. Despite all cell lines supporting rHAZV(eGFP) 
growth, the growth profiles varied significantly. In SW13 cells, eGFP was first 
detected approximately 13 hpi and increased until 48 hpi, with a mean green cell 
count of 125,621. Interestingly, at 9 hpi, A549 cells provided the shortest time 
before eGFP detection, in line with previous data in which HAZV translation 
90 
 
products were detected prior to 10 hpi (Punch et al., 2018). However, following a 
rapid period of growth between 9 and 27 hpi, the total green cell count then 
gradually began to decrease, from a mean green cell count of 37,906 at 27 hpi 
to 30,589 at 48 hpi. Further research into the immune response within this cell 
line may yield answers as to this apparent halt in virus production. The BHK cell 
line displayed a similar growth profile to the SW13 cells, however despite the 
initial detection of fluorescence occurring earlier at the 10 hpi timepoint, total 
growth at the 48 hpi timepoint was lower, with a final mean green cell count of 
53,449. This slowed growth in BHK cells versus that observed in the SW13 cell 
line may provide a longer window in which the cell is able to release virus before 
CPE is observed, which might provide an explanation to the high titres observed 
whilst using this cell line. Huh7 cells also permitted earlier detection of eGFP 
positive cells than the SW13 cells, with signal also detected at 10 hpi. However, 
despite only varying from the SW13 by 3 hours, the speed of subsequent 
infections was much faster with a steady increase in detectable green cells 
occurring up to 48 hpi, resulting in an infected cell count of 127,260.  
 
The utility of rHAZV(eGFP) into facilitating examination of virus growth within 
multiple cell lines simultaneously with minimal sample processing highlights the 
potential of rHAZV(eGFP) to be used as a tool to further knowledge into HAZV 
infection. In a follow up publication to the development of ZsG expressing 
CCHFV, the CCHFV reporter was used to identify tissue tropism and the early 
cell targets during an in-vivo experimental system (Welch et al., 2019). Similar 
experiments using rHAZV(eGFP) are feasible and may provide an insight into the 
differences in pathogenesis between HAZV and CCHFV despite their large 




Figure 4.8, Differential growth profiles of rHAZV(eGFP) infection in a range of cell 
lines 
a) Representative images of infected SW13, A549, BHK and Huh7 cell lines by 
rHAZV(eGFP) at 0.01 MOI 0 and 48 hours post infection taken on the IncuCyte® live cell 
imaging system. Scale bar represents 300 µM. b) Graphical representation of green cell 
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count over time during the 48 hour infection of SW13, A549, BHK and Huh7 cell lines 
with rHAZV(eGFP) at a MOI of 0.01. Analysis was carried out using the IncuCyte® live 
cell imaging system and plotted using GraphPad Prism. 
 
4.6 Identifying host membrane trafficking factors involved in HAZV 
multiplication 
Following establishment of the reporter system in sections 4.1 to 4.4, 
rHAZV(eGFP) was used to aid understanding of HAZV infection. In order to gain 
a greater understanding of the host membrane trafficking factors with importance 
to the HAZV lifecycle, rHAZV(eGFP) was utilised in a siRNA screen targeting 142 
independent genes associated with a range of cellular membrane trafficking 
factors. Each gene was targeted by three independent siRNA sequences to 
improve detection reliability. A full list of gene names and the associated siRNA 
sequences can be found in appendix 1.3. The use of rHAZV(eGFP) over WT 
rHAZV enabled a more-streamlined workflow, removing the need for fixation, 
permeabilization and antibody staining of the reverse transfected cells and, 
should it be required, permitted live cell imaging during the course of the infection. 
  
In order to generate high quality data, the optimal MOI for infection of 96 well 
plates, in which the screening would take place, was established. SW13 cells 
were infected at a range of MOIs (0, 0.1, 0.25 and 1) with rHAZV(eGFP) and 
infection was allowed to progress for 48 hours. Consistent with the previous 
infections using rHAZV(eGFP), fluorescence was observed in all infected wells, 
with no detectable fluorescence in the mock infected wells (Figure 4.9, a). As 
expected, increasing the MOI correlated with increased green cell count, with the 
highest green cell count in the highest MOI (1) and the lowest green cell count in 
the lowest MOI (0.10) (Figure 4.9, b). An MOI of 0.25 was chosen as a suitable 
for the siRNA screen due to the presence of approximately 1500 infected cells at 
24 hours post infection. The 24 hour timepoint was used over the later timepoint 
of 48 hours to minimise the risk of the siRNAs degrading during the infection and 
also to reduce the stress on the cells during the experiment, preventing them from 
becoming over confluent. Whilst having more infected cells would give a more 
reliable output for analysis during the screen, the lower 0.25 MOI was chosen 




Figure 4.9, Infection at multiple MOIs identifies an optimal MOI of 0.25 for infection 
of 96 well plates 
a) Detection of eGFP signal over a 48-hour infection with rHAZV-eGFP at MOIs of 1, 
0.25 and 0.1. A control MOI of 0 was included to rule out non-specific fluorescence. 
Following infection cells were incubated in the IncuCyte® live cell imaging system at 37C 
and images collected every hour for 48 hours. Scale bar represents 300 µM. b) Graphical 
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representation of green cell count over time during the 48 hour infection for each MOI. 
Analysis carried out using the IncuCyte® live cell imaging system software and plotted 
against time using GraphPad Prism software with error bars representing three 
independent repeats.  
 
The siRNA screen utilised a reverse transfection protocol, outlined in the 
materials and methods section 2.2.3.4,  in which cells were seeded over the top 
of the pre-mixed transfection mixture containing OptiMEM, Lipofectamine 
RNAiMax and a unique siRNA. Suitable controls were determined, including cells 
infected (Virus) and mock infected (Mock) with rHAZV(eGFP) and no reagents or 
siRNA, cells infected with rHAZV(eGFP) in the presence of Lipofectamine 
RNAiMax (Control) and cells infected with rHAZV(eGFP) in the presence of 
Lipofectamine RNAiMax and a non-specific scrambled siRNA primer 
(Scrambled). eGFP expression in the control and scrambled tests was found to 
be insignificant compared to the virus control, and therefore any effect observed 
with the gene specific siRNAs can reliably be deemed a target specific effect.  
 
Due to the large number of siRNA probes included in the screen, reliable 
comparisons between the plates were essential. To this end, each plate 
containing siRNA probes against specific genes also contained a full set of 
control wells, this enabled a relative value for TIIE to be calculated, which was 
then averaged across a minimum of three independent experiments. Results 
were then plotted against the virus control, which was set at a baseline of 1.0, 
gene specific siRNAs that significantly affected rHAZV(eGFP) were then 
identified and ranked based on their ability to knockdown the TIIE when averaged 
across the three unique siRNAs against each gene, with the top 25 hits listed in 
Table 3. 
 
It is worth noting that the design of rHAZV(eGFP) only permits deductions on 
stages of rHAZV infection up to and including translation as after this point eGFP 
is not incorporated into the viral products due to its independent expression. 
Whilst it is unable to identify the specific stage at which infection is perturbed, it 
encompasses virus binding, entry into the endosomal pathway, uncoating, fusion, 
replication and translation phases. Also, the 24 hour duration of the siRNA screen 
infection phase is limited to detection of a single round of infection, therefore 
siRNAs targeting genes linked to virus assembly, maturation and exit would not 
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be identified by this system in any case. Extending the duration of the screen 
would permit examination of further infection rounds, however information 
surrounding the stability of the siRNAs in media for longer than 24 hours was 
unavailable therefore, in combination with the data surrounding the optimal MOI, 
the decision was made to keep to a 24 hour infection period. 
 
The results of the siRNA screen can be found in full in appendix 1.4. Consistency 
was largely similar between unique siRNAs targeting the same gene, though 
there were cases in which one of the three siRNAs displayed a substantial 
difference in TIIE. In these cases, it highlights the importance of triplicate siRNAs 
against each gene, with a minimum of 4 experimental repeats.  
 
Initial analysis of the results identified a number of families of genes that either 
affected rHAZV(eGFP) or played no role in its infection. Families of genes such 
as syntaxins, coatamer protein complex I (COPI) components, vesicle associated 
membrane proteins (VAMPs) and synpatogamins all demonstrated significant 
knockdown of TIIE following infection with rHAZV(eGFP). Conversely, other gene 
families displayed little to no effect on the TIIE caused by infection. Interestingly, 
despite the previously described entry mechanism of CCHFV as clathrin 
mediated endocytosis (Garrison et al., 2013), no effect on TIIE was observed 
following siRNA knockdown of clathrin light or heavy chain components. 
Similarly, no effect was observed following knockdown of the clathrin adaptor 
complex 1 and 3.  
 
The top five genes that displayed the largest effect on rHAZV(eGFP) infection, 
measured via TIIE, were COPA (26.04 %), COPB2 (56.69 %), COPB1 (70.67 %), 
AP2B1 (70.72 %), VAMP1 (72.21 %) and FAM62B (72.23 %) (Table 3). With 
three of the top five hits linked to COPI components, it was decided to pursue this 
family of genes further. Whilst the other gene families may well represent 
interesting avenues of investigation, due to time constraints they were not 
pursued further than the initial screen. 
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Gene ID siRNA 1 siRNA 2 siRNA 3 Avg. all 
COPA 31.18% 24.13% 22.82% 26.04% 
COPB2 43.03% 23.72% 103.31% 56.69% 
COPB1 68.28% 80.33% 63.40% 70.67% 
AP2B1 65.15% 63.45% 83.57% 70.72% 
VAMP1 77.16% 66.05% 73.43% 72.21% 
FAM62B 62.91% 82.48% 71.30% 72.23% 
VPS13B 89.40% 51.05% 77.82% 72.76% 
STX18 68.75% 83.03% 69.71% 73.83% 
VPS33B 83.04% 81.98% 57.82% 74.28% 
EHD2 59.58% 87.51% 76.92% 74.67% 
ARHGAP10 74.70% 68.96% 81.25% 74.97% 
AP2A2 80.49% 75.21% 69.78% 75.16% 
STX17 67.27% 87.59% 78.28% 77.71% 
SYT17 89.74% 73.37% 74.82% 79.31% 
COPZ2 64.69% 80.32% 93.43% 79.48% 
STXBP1 83.38% 59.11% 97.98% 80.16% 
COPG1 45.03% 93.74% 102.70% 80.49% 
STX1B 83.26% 88.50% 70.07% 80.61% 
HUWE1 71.20% 71.90% 99.66% 80.92% 
VAMP7 84.95% 69.97% 88.39% 81.10% 
COPE 70.86% 90.84% 82.79% 81.50% 
COPG2 80.33% 81.40% 87.50% 83.08% 
SYT3 70.47% 85.51% 93.55% 83.18% 
AP1S3 107.01% 93.64% 49.21% 83.28% 
FAM62C 62.01% 86.58% 103.29% 83.96% 
     
Table 3.1, Table of selected siRNA targets resulting in highest knockdown of total 
integrated intensity of eGFP signal 
Table format of the top 25 hits from the siRNA membrane trafficking screen, ranked via 
percentage of total integrated intensity of eGFP versus the control. Each percentage for 
the unique siRNAs (1-3) represents an average of four independent experimental 




4.7 COPI components are important for HAZV infection 
COPI complexes are primarily involved in retrograde transport from the Golgi 
apparatus to the ER, however they have also been shown to have roles in 
anterograde transport, endosomal transport and expression of cell surface 
receptors and lipid composition (Aniento et al., 1996; Misselwitz et al., 2011; 
Wang et al., 2015). They are formed from seven subunits, , , , , , , and . 
In addition to vesicular transport between the Golgi and ER, during retrograde 
transport, COPI complexes can also form tubular structures, which have been 
linked to anterograde transport between Golgi cisternae (Yang et al., 2011). The 
role of COPI components in the endosomal pathway has also been proven. The 
 and ε subunits were found to be present on endosomes in a pH dependent 
manner and acted to regulate endosomal membrane transport (Aniento et al., 
1996). The distribution of cholesterol, a lipid required by HAZV and BUNV during 
endosomal escape, and the Rho GTPases Cdc42 and Rac1, can be influenced 
by COPI components, showing the broad range of roles COPI components is not 
limited simply to retrograde transport within the cell (Misselwitz et al., 2011; 
Charlton et al., 2019). 
 
COPI vesicles are distinct from COPII vesicles, which are responsible for 
anterograde transport from the ER to the Golgi apparatus (Figure 4.10). COPI 
vesicles form upon detection of a KKXX or KDEL motif, for membrane bound and 
soluble proteins respectively. The GPC of HAZV encodes five such KKXX motifs, 
four of which are located in the coding region for Gc (KKIS, KKIC, KKFS and 
KKDA) with two each side of the predicted transmembrane domain, placing them 
in a potentially accessible position for COPI vesicle formation. It is unknown 
whether COPI binds directly or indirectly to the KKXX motif, however the resultant 
high local abundance of COPI causes curvature of the Golgi membrane, which 





Figure 4.10, COPI and COPII vesicle schematic 
COPI vesicles function to transport cargo from the Golgi apparatus to the ER, known as 
retrograde transport, whilst COPII vesicles transport cargo from the ER to the Golgi 
apparatus, known as anterograde transport 
 
Analysis of TIIE signal identified multiple genes encoding COPI subunits as 
important to viral infection. COPA, COPB1, COPB2 and COPE all resulted in a 
significant knockdown of eGFP signal in at least two of the three siRNAs against 
each gene (Figure 4.11). siRNA knockdown of COPA had the largest effect on 
eGFP signal with all three unique siRNAs against COPA displaying ~70 to 80 % 
reduction versus the untreated control (siRNA 1 = 0.311 (p=0.0003), siRNA 2 = 
0.241 (p=<0.0001), siRNA 3 = 0.228 (p=0.0001)). COPB1 knockdown also 
caused significant reduction of eGFP signal with all three siRNAs, but to a lesser 
degree, displaying ~20 to 40 % reduction versus the untreated control (siRNA 1 
= 0.682 (p=0.0127), siRNA 2 = 0.803 (p=0.0078), siRNA 3 = 0.634 (p=0.0008)). 
COPB2 knockdown reduced eGFP signal significantly in 2 of 3 siRNAs (siRNA 1 
= 0.430 (p=0.0289), siRNA 2 = 0.237 (p=0.0009), siRNA 3 = 1.033 (p=0.6497)), 
as did COPE knockdown ((siRNA 1 = 0.709 (p=0.0043), siRNA 2 = 0.908 
(p=0.2701), siRNA 3 = 0.828 (p=0.0146)).  
 
Conversely those genes associated with COPII vesicles were not as critical to 
rHAZV(eGFP) infection, with only SAR1A knockdown having a statistically 
significant effect on TIIE signal in two of three siRNAs (siRNA 1 = 0.893 
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(p=0.1153), siRNA 2 = 0.817 (p=0.0256), siRNA 3 = 0.873 (p=0.0123), though 
even with this significance, the knockdown effect was much less at ~10 to 20 % 
reduction versus the untreated control (Figure 4.12). 
 
Figure 4.11, COPI associated genes are important for HAZV infection 
Histogram of the relative fold change in total integrated intensity of eGFP signal in SW13 
cells infected with rHAZV(eGFP) at a MOI of 0.25 following independent reverse 
transfection of triplicate siRNAs (siRNA 1 – orange bars, siRNA 2 - green bars, siRNA 3 
- blue bars) against the subunits of the coatomer protein complex 1 (COPI). Transfection 
reagent only and scrambled siRNA controls were included for reference. Error bars 
represent data from 4 experimental repeats. Plotted using GraphPad Prism. 
 
 
Figure 4.12, COPII associated genes are not required for HAZV infection 
Histogram of the relative fold change in total integrated intensity of eGFP signal in SW13 
cells infected with rHAZV(eGFP) at a MOI of 0.25 following independent reverse 
transfection of triplicate siRNAs (siRNA 1 – orange bars, siRNA 2 - green bars, siRNA 3 
- blue bars) against the subunits of the coatomer protein complex 2 (COPII). Transfection 
reagent only and scrambled siRNA controls were included for reference. Error bars 




The finding that knockdown of many components of the COPI vesicle negatively 
impacted TIIE was a strong indicator as to the importance of these factors in the 
viral lifecycle. Before conclusions could be made in respect of this, validation of 
the screen was required. Confirming knockdown of virus gene expression 
alongside knockdown of the genes targeted by the siRNAs was carried out using 
qPCR and western blotting. The siRNAs against COPA, COPB1 and COPB2 
were selected for validation as they represented the three highest hits on the 
screen. In addition, the -COP in combination with -COP and -COP form a 
subcomplex that forms the backbone of the COPI cage, therefore by validating 
the role of the core structure of the vesicle, the role of the additional COPI 
subunits also gain credibility. To enable validation, a larger volume of one of the 
triplicate siRNAs for each of COPA, COPB1 and COPB2 was purchased from the 
same supplier as the siRNA membrane trafficking library, with the same 
sequence as used in the screen. This enabled knockdown of each target in a 
larger format that would facilitate the validation experiments. As rHAZV(eGFP) 
had identified a smaller pool of target siRNAs, the validation was carried out with 
WT rHAZV to rule out eGFP as a contributing factor to COPI linked inhibition of 
HAZV. To ensure the siRNAs were successfully knocking down their target 
genes, qPCR was also used to target COPA, COPB1 and COPB2 in treated and 
untreated cells following knockdown of the COPI specific targets in SW13 cells. 
As expected, all three siRNAs displayed knockdown of the target genes versus 
the untreated controls (Figure 4.13, a).  
 
Validation of the effect of the siRNA knockdown on rHAZV was then assessed. 
SW13 cells were infected with WT rHAZV according to the same timings and 
concentrations used in the initial screen. After 24 hpi the supernatant was 
removed and the cells lysed in Trizol reagent to maintain the integrity of RNA in 
the lysate whilst solubilising cellular components. RNA was subsequently 
extracted via a phenol chloroform extraction and analysed via qPCR using the 
One step MESA GREEN qRT-PCR kit. Primers used in the development of the 
qPCR system for rHAZV, detailed in Chapter 3, were used to detect the S 
segment of HAZV as an indicator of virus infection with primers against GAPDH 
also included to permit normalization between replicates. Analysis of the 
normalized data confirmed the findings of the screen, with COPA, COPB1 and 
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COPB2 knockdown all resulting in significant decreased copy number of HAZV 
S segment RNA versus an untreated control (Figure 4.13, b). Further validation 
of the siRNA screen and qPCR results was achieved via western blotting of cell 
lysates collected following the same experimental procedures as the siRNA 
screen (Figure 4.14, a). As expected, knockdown of COPA, COPB1 and COPB2 
resulted in reduced expression of HAZV N, however to a much lesser extent than 
seen at the transcriptional level (Figure 4.14, b).  
 
Figure 4.13, qPCR confirmation of siRNA screen results using WT rHAZV 
a) Normalised HAZV S segment copy number isolated from SW13 cells transfected with 
siRNAs targeting COPA, COPB1 and COPB2 then infected with HAZV at 0.1 MOI. Error 
bars represent data from 2 experimental repeats. Plotted using GraphPad Prism. b) 
Normalised COPI subunit RNA copy numbers isolated from SW13 cells previously 
transfected with siRNAs targeting COPA, COPB1 and COPB2. Error bars represent data 
from 2 experimental repeats. Plotted using GraphPad Prism. 
 
 
Figure 4.14, Western blot analysis shows siRNA knockdown of COPI components 
reduces HAZV N translation 
a) Western blot analysis of lysates collected from SW13 cells treated with siRNAs 
targeting COPA (C-A), COPB1 (C-B1), COPB2 (C-B2), a scrambled control (Scr.) was 
also included alongside a mock infected (- Inf) and infected (+ Inf) sample in which 
transfection reagent but no siRNA was added to both. Samples were probed for HAZV 
N and GAPDH as a loading control. b) Histogram displays normalised densitometric 
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analysis of western blot data from (a), calculated using the ImageJ software package, 
error bars represent data from 3 experimental repeats. Plotted using GraphPad Prism. 
 
4.8 Identifying the role of COPI in HAZV infection 
Due to the previously described dependence on membrane cholesterol by HAZV 
and the evidence that COPI components can influence the distribution of 
cholesterol on the plasma membrane, the role of COPI components in HAZV 
entry was first explored (Misselwitz et al., 2011; Charlton et al., 2019). A role for 
COPI complexes at this early stage of the lifecycle was supported by the data in 
Figure 4.13 and Figure 4.14, which revealed both mRNA transcription and 
translation were both affected by COPI knockdown, indicating a stage prior to 
these events, thus implicating virus entry. To confirm this, a 24 hour infection was 
set up using rHAZV(eGFP) to infect SW13 cells in which different COPI 
components had been knocked down, with eGFP expression measured at hourly 
intervals using the IncuCyte® live cell imaging system. SW13 cells were treated 
with either a scrambled siRNA or COPI specific siRNA according to the same 
protocol used in the initial siRNA screen and subsequent validations. Analysis of 
green cell count over time revealed initial detection of eGFP signal in the controls 
and COPB1 knockdown cells to occur at approximately 12 to 13 hpi (Figure 4.15, 
a), in line with previous observation for SW13 cells in section 4.5. In addition to 
the total green cell count in COPA, COPB1 and COPB2 knockdown cells being 
significantly lower at 24 hpi, detection of eGFP signal in COPA and COPB2 
samples occurred later, at 15 to 16 hours post infection, suggesting the 
knockdown of these genes to have delayed a phase in the viral lifecycle at a pre-
translation stage, or reduced the effectiveness of viral translation, leading to an 
increased duration until detection of eGFP. This is visible by eye when looking at 
images taken at 14 hours into the infection, with green cells visible in wells 
containing the controls and COPB1 knockdowns, but not visible in those wells 
containing COPA or COPB2 knockdowns (Figure 4.15. b). When visualising the 
same location in those wells at 24 hours, green cells become visible in all wells, 
with reduced numbers in the COPA and COPB2 wells versus the controls. This 
apparent disruption to viral infection by COPI has previously been documented 
for different pathogens. In vesicular stomatitis virus (VSV), an enveloped, 
negative sense, ssRNA virus, depletion of the COPI component -COP resulted 
in reduced VSV invasion (Misselwitz et al., 2011). This same study also identified 
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the mechanism of VSV dependence on COPI to be linked to the role of COPI in 
controlling the lipid composition of the membrane, specifically of sphingolipid 
GM1 and cholesterol. Cholesterol abundance within the plasma membrane has 
also been documented to affect HAZV among other viruses such as Semliki 
Forest virus, Andes virus and influenza virus (Phalen and Kielian, 1991; 
Kleinfelter et al., 2015; Chlanda et al., 2016). The role of cholesterol in HAZV 
entry was shown to be linked to formation of a K+ rich environment within 
endosomes that facilitated escape into the cytoplasm, demonstrated via depletion 
of cholesterol and K+ priming of HAZV virions in cholesterol depleted cells 
(Charlton et al., 2019). Therefore, one possible explanation of the dependence 
on COPI by HAZV in early stages of the life cycle is as a result of the native role 




Figure 4.15, COPI knockdown delays translation of HAZV N 
a) Total green cell count for each siRNA knockdown condition was determined using the 
IncuCyte® live cell imaging system software and plotted against time using GraphPad 
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Prism software with error bars representing two independent repeats. B) Representative 
images of siRNA treated infected SW13 cells by rHAZV(eGFP) at 0, 14 and 24 hours 
post infection taken on the IncuCyte® live cell imaging system. Scale bar represents 300 
µM  
 
If the role of COPI in HAZV entry was linked to its native role in cholesterol 
distribution, then infection with rHAZV should not require COPI to become 
redistributed compared to uninfected cells. To confirm this was the case, SW13 
cells were either mock infected or infected with rHAZV(eGFP) at an MOI of 0.1 
and imaged at 24 hpi using a confocal microscope. Analysis of eGFP, as an 
indicator of infected cells, and COPA demonstrated no significant difference in 
distribution of COPA between mock and infected cells, indicating HAZV was not 




Figure 4.16, rHAZV(eGFP) infection does not cause redistribution of COPA 
Immunofluorescent images of rHAZV(eGFP) infected SW13 cells taken on a Zeiss 
LSM880 confocal microscope using x40 magnification. Nuclei are shown in blue (DAPI), 
eGFP signal is shown in green, HAZV N is shown in red and a combined merged image 




To assess if the delay observed in translation of HAZV N had an impact on 
generation of infectious virions, titration of rHAZV collected from supernatant of 
infected SW13 cells, following knockdown of COPA, COPB1 and COPB2, was 
carried out. It was expected that due to the observed decreases in viral RNA 
(Figure 4.13) and translation products (Figure 4.14) all occurring within the range 
of a 10 fold reduction following a 24 hour infection, that a similar result would be 
observed with virus titre. As before, the experimental procedure followed the 
same concentrations and timings as previous experiments. Analysis of the 
number of infectious viruses present in the supernatant revealed a much higher 
decrease than initially expected. In the infected and scrambled controls, virus titre 
was estimated in the range of 104 copies per mL, versus titre in the range of 102 
for COPA, COPB1 and COPB2, representing a decrease of almost 100 fold 
following COPI knockdown (Figure 4.17, a, b).  
 
Comparison of the observed 2 fold change in N protein expression with the 100 
fold change in released infectious virus following COPA knock down strongly 
points towards COPA involvement in virus assembly. It is plausible that COPI 
vesicles also affect an additional part of the HAZV lifecycle. As mentioned in 
section 4.7, the HAZV glycoprotein Gc contains multiple KKXX motifs that can be 
recognised by COPI vesicles and therefore have the potential to interact with 
COPI at a post translational stage. Further evidence for this comes from CCHFV. 
CCHFV glycoproteins are extensively processed between the ER and Golgi 
apparatus (Vincent et al., 2003; Haferkamp et al., 2005; Sanchez et al., 2006), a 
detailed description can be found in section 1.4.2.1,. In a separate study, CCHFV 
Gc was identified to colocalise with -COP, at the time being used as a marker 
for the Golgi and was therefore not pursued further at the time (Erickson et al., 
2007). It is possible that COPI components perhaps play a more significant role 
in HAZV glycoprotein processing or transport during infection, however due to 





Figure 4.17, COPI knockdown results in reduced infectious virus production 
a) Histogram displays plaque forming units per mL (PFU / mL) of rHAZV released into 
supernatant following siRNA knockdown of COPI components COPA, COPB1 and 
COPB2 in SW13 cells. Both mock infected (Mock) and infected controls were included, 
alongside a scrambled siRNA control. Plotted using GraphPad Prism software, error bars 
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represent 2 independent repeats. b) Representative plaque assays used to determine 
the titre in part (a). SW13 cells were infected and fixed then stained 6 days post infection.  
 
As multiple roles of COPI in the HAZV lifecycle now seemed more likely, these 
alternate mechanisms were further explored. Multiple viruses have been shown 
to utilise COPI vesicles in formation of virus replication factories. Echo virus 11 
(EV11) infection of cells treated with BFA, a compound that blocks formation of 
COPI vesicles via inactivation of ADP-ribosylation factor (ARF) 1, led to a block 
in virus replication and RNA synthesis. Further studies also revealed 
colocalisation of sites of EV11 RNA synthesis with -COP early in infection 
(Gazina et al., 2002). In other viruses, a viral replication factory dependence on 
COPI but not COPII components has been documented. Depletion of COPI 
components inhibited formation of virus replication factories for both Drosophila 
C virus and polio virus, an effect not observed with COPII knockdown (Belov, 
Fogg and Ehrenfeld, 2005; Cherry et al., 2006). The prototypic bunyavirus, 
BUNV, is able to hijack the Golgi apparatus to form viral factories around the 
Golgi complex, incorporating Golgi stacks, mitochondria and rough ER elements 
(Fontana et al., 2008). Therefore, given the ability of COPI components to form 
tubular and vesicular structures in proximity of the Golgi, it is plausible HAZV and 
CCHFV may utilise COPI vesicles in virus replication factory formation.  
 
As it was observed that the natural distribution of COPA, and by extension COPI 
vesicles, was unchanged by rHAZV(eGFP) infection (Figure 4.16), whether 
HAZV forms replication factories around the Golgi was explored by using the 
COPA subunit as a marker. Viral components are normally concentrated in virus 
factories, due to the increased efficiency of replication afforded by having 
essential cellular components in a localised area (Novoa et al., 2005). Therefore, 
SW13 cells were infected with rHAZV at a 0.1 MOI and following a 24 hour 
infection, were stained for COPA and HAZV N then examined by 
immunofluorescence microscopy (Figure 4.18, a). It was hypothesised that a 
replication factory would have a high local concentration of HAZV N due to its 
association with RNP segments. However, confocal imaging of COPA and HAZV 
N localisation within SW13 cells was inconclusive. Line scans of COPA and 
HAZV N staining were analysed (Figure 4.18, b, i-iii) and suggest colocalisation 
in some infected cells, as indicated by coinciding peaks in COPA and HAZV N 
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signal (Figure 4.18, b, i). However, line scans in other cells suggested that no 
such colocalisation occurred (Figure 4.18, b, ii) thus if an interaction between 
HAZV N and COPA is required for virus growth, it may be transient, and only 
occurring at a specific stage of the HAZV replication cycle. Based on the evidence 
provided by the confocal microscopy it is unlikely COPA is involved in formation 




Figure 4.18, Confocal imaging of COPA and HAZV N localisation in SW13 cells 
a) Immunofluorescent images of WT rHAZV infected SW13 cells taken on a Zeiss 
LSM880 confocal microscope using x40 magnification. Nuclei are shown in blue (DAPI), 
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COPA signal is shown in green, HAZV N is shown in red and a combined merged image 
is displayed. Scale bar represents 20 µM. b, i-iii) intensity profiles of COPA and HAZV N 
signal along the white arrows indicated on the respective confocal panel. Plotted using 
GraphPad Prism software.  
 
4.9 Dependence on COPI vesicles by HAZV is ARF1 and GBF1 
independent 
COPI vesicle formation is a highly regulated and complex process. Initially COPI 
subunits are recruited to the Golgi membrane via the action of an Arf, a GTPase. 
Arf can be present in a GDP or GTP bound state, regulated via the action of 
guanine exchange factors (GEFs), which convert it to the GTP form, and GTPase 
activating proteins (GAPs), that return it to its GDP bound state (Donaldson and 
Jackson, 2000; Casanova, 2007; Inoue and Randazzo, 2007). Arf-GEFS 
therefore play a key role in the temporal regulation and distribution of Arf on the 
Golgi membrane, facilitated by a key Sec7 catalytic domain that enables the 
nucleotide transfer (Jackson and Casanova, 2000). GBF1 is a high molecular 
weight Arf GEF that acts on class I and II Arf proteins and is found localised in 
early Golgi compartments (Claude et al., 1999; Kawamoto et al., 2002). Once in 
its GTP bound state, ARF1 is able to recruit the coatomer to the membrane, 
where the KKXX motif is then able to associate with either the α-COP or β’-COP. 
Therefore, GBF1 plays a key role in the recruitment of ARF1 and subsequent 





Figure 4.19, Role of Arf1 and GBF1 in COPI vesicle formation 
Formation of COPI vesicles is initiated by the interaction of Arf1-GDP with GBF1 (step 
1). This interaction results in the activation of Arf1 by catalysing the exchange of GDP to 
GTP, exposing a myristoyl group that enables association of the protein with the 
membrane (step 2). Membrane bound Arf1-GTP recruits the pre-formed COPI coat (step 
3) which stimulates the recruitment and concentration of cargo (step 4), inducing 
curvature of the membrane into a vesicle (step 5). The formation of the vesicle completes 
with budding from the Golgi membrane (step 6). Vesicles are disassembled following 
hydrolysis of Arf1-GTP into Arf1-GDP by ArfGAP1 (step 7) 
 
Figure adapted from (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354614/)  
 
Both ARF1 and GBF1 were targeted by siRNAs during the membrane trafficking 
screen carried out in section 4.6. Due to the demonstrated dependence of HAZV 
on multiple subunits of the COPI complex, it was expected that ARF1 and GBF1 
would also demonstrate a similar effect. However, analysis of the TIIE following 
siRNA knockdown of ARF1 and GBF1 demonstrated no significant effect (Figure 
4.20) indicating that the use of COPI vesicles during the early phases of HAZV 
infection is in an ARF1 / GBF1 independent manner. However, it is important to 
remember that rHAZV(eGFP) in conjunction with the siRNA screen is only able 
to provide information up to and including viral translation. For CCHFV, 
translation of the GPC occurs on ER resident ribosomes, in contrast to the 
cytoplasmic ribosomes thought to translate N and the RdRp (Sanchez, Vincent 
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and Nichol, 2002). Therefore, it is likely that virus translation of the GPC and 
eGFP, expressed concurrently with HAZV N, occur in discrete locations to each 
other. The GPC, via a complex series of processing stages described in detail in 
section 1.4.2.1, is processed into the structural and non-structural glycoproteins. 
This occurs in the Golgi, where it is proposed CCHFV also assembles (Bertolotti-
Ciarlet et al., 2005; Sanchez et al., 2006). As COPI vesicle assembly occurs in 
the Golgi apparatus, it is likely that any effect on the virus by ARF1 and GBF1 
would not be observed until the viral lifecycle required the Golgi, i.e. during 
glycoprotein processing. 
 
Figure 4.20, ARF1 and GBF1 are non-essential to rHAZV(eGFP) infection 
Histogram of the relative fold change in total integrated intensity of eGFP signal in SW13 
cells infected with rHAZV(eGFP) at a MOI of 0.25 following independent reverse 
transfection of triplicate siRNAs (siRNA 1 – orange bars, siRNA 2 - green bars, siRNA 3 
- blue bars) against ARF1 and GBF1. Transfection reagent only and scrambled siRNA 
controls were included for reference. Error bars represent data from 4 experimental 
repeats. Plotted using GraphPad Prism. 
 
Further validation of the ARF1 and GBF1 independent nature of HAZV COPI 
dependence at a pre-translational stage was achieved via the use of BFA. BFA 
is a non-competitive inhibitor of GBF1 that functions via formation of an abortive 
ARF1-GBF1-BFA complex, preventing formation of COPI vesicles by stabilising 
GBF1 on Golgi membranes (Niu et al., 2005). Therefore, to validate the siRNA 
data in Figure 4.20, BFA was used to treat A549 cells prior to, and during, 
infection with WT rHAZV. Due to previous data supporting a role of COPI vesicles 
in influenza A virus (IAV) infection, IAV was used as a positive control to ensure 
BFA was functional. Western blot analysis of lysates collected following infections 
of the BFA treated A549 cells with WT rHAZV and rIAV displayed no significant 
reduction in HAZV N, whilst IAV N, as expected, was significantly reduced in a 
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dose dependent manner (Figure 4.21, a, b). A549 cells were chosen due to their 
ability to support replication of both rHAZV and rIAV, removing the need for 
multiple cell lines in the comparison. To rule out toxicity arising from BFA 
treatment of the A549 cells, an MTS viability assay was carried out using 
concentrations of 0-1000 ng / mL. Up until this point no significant effect was seen 
on cell viability by BFA, therefore it is assumed the decrease in IAV N is a BFA 
specific effect and that HAZV is unaffected by BFA at a pre-translational stage. 
 
Figure 4.21, WT rHAZV is not sensitive to brefeldin A treatment. 
a) Western blot analysis of lysates collected from A549 cells pre-treated with the 
indicated concentration of brefeldin A (BFA) for 45 minutes prior to infection with rHAZV 
or rIAV at a MOI of 0.1. Samples were probed for their respective nucleoproteins (HAZV 
N or IAV N) and GAPDH as a loading control. b) Normalised densitometric analysis of 
western blot data from (a), calculated using the ImageJ software package, error bars 
represent data from 3 experimental repeats, plotted using GraphPad Prism. c) Histogram 
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of the relative fold change in cell viability following treatment with BFA at a range of 
concentrations from 0 to 1000 ng / mL. Plotted using GraphPad Prism. 
 
4.10   Chapter summary and discussion 
In this chapter, the infectious clone system described in chapter 3 was modified 
to incorporate an eGFP ORF, upstream of the HAZV N protein, into the S 
segment expressing cDNA. Incorporation of this plasmid into the rescue protocol 
enabled the recovery of rHAZV(eGFP), which to the best of our knowledge 
represents the first recovery of a HAZV variant able to express a reporter protein. 
Expression of the eGFP reporter used a P2A linker, which promotes ribosome 
skipping and thus permits independent expression of HAZV N and eGFP from 
the same mRNA. Subsequently rescued rHAZV(eGFP) was shown to be a 
suitable model for studying HAZV, exhibiting a barely significant drop in multi-
step virus growth versus the parental rHAZV WT strain and no detectable loss of 
eGFP expression following repeated virus passage. 
 
The potential applications of such a reporter virus are many; one such use is in 
determining virus growth parameters. Use of rHAZV(eGFP) in conjunction with 
the IncuCyte® live cell imaging system reduced the workload and allowed real-
time comparison of virus growth in multiple cell lines, identifying different patterns 
of growth without the requirement for cell lysate sample processing techniques 
such as western blotting. A recent study using a similar CCHFV reporter virus 
allowed examination of CCHFV mediated pathology and disease progression in-
vivo using mouse models, successfully identifying the initial cells and organs 
targeted during CCHFV infection (Welch et al., 2019). 
 
In terms of examining the molecular and cellular virology of nairoviruses, the 
rHAZV(eGFP) system described here offers an important benefit compared to 
the CCHFV system. The rHAZV(eGFP) system is amenable to low CL-2 
containment facilities in comparison to the CL-4 facilities required for CCHFV 
experimentation, which are costly and represent a major barrier to experimental 
progress. This rHAZV(eGFP) system will allow a streamlined work flow in which 
results can initially be collected using HAZV, then based on these findings, 
selected experiments with CCHFV in high containment can be performed, thus 




The major application of rHAZV(eGFP) described in this chapter was screening 
a library of membrane trafficking components via siRNA knockdown. A total of 
142 genes were targeted by 426 unique siRNA primers and following infection 
with rHAZV(eGFP), were able to be analysed for beneficial or negative impact on 
virus replication at stages prior to and including translation. Targets were graded 
based on % reduction of TIIE and sorted in ascending order, quickly identifying a 
number of genes associated with COPI vesicles having a significant effect on 
viral replication when knocked down. Validation of these targets was achieved 
via qPCR and western blot analysis, confirming a role of COPI vesicles in HAZV 
infection. Further analysis revealed this role was initially likely to be linked with 
an early stage of the HAZV lifecycle, possibly in endosomal escape. This was 
hypothesised due to the recently described dependence of HAZV on 
membranous cholesterol and the ability of COPI components to regulate this 
(Misselwitz et al., 2011; Charlton et al., 2019). 
 
A further role of COPI components in HAZV infection was identified following 
titration of released virus following COPI knockdown in SW13 cells. A substantial 
increase in the fold reduction of infectious virus produced in COPI knockdown 
cells versus control cells could not be explained when combined with the fold 
reduction seen in the transcriptional and translational assays previously 
mentioned. This pointed to an additional role of COPI vesicles at a post-
translational stage of the HAZV life cycle. As previous evidence has supported 
an interaction between CCHFV Gc and the COPI component -COP (Erickson et 
al., 2007) and the observation of multiple KKXX motifs, required for transport of 
membrane bound proteins between the Golgi and ER, it is likely the additional 
role of COPI components occurs at a glycoprotein processing or transportation 
stage. 
 
Finally, the identification of an ARF1 / GBF1 independent mechanism of COPI 
dependence provided the most interesting finding. ARF1 is a well characterised 
component required for the formation of COPI vesicles, siRNA knockdown of 
ARF1 and GBF1, an activator of ARF1, resulted in no significant knockdown of 
TIIE following infection with rHAZV(eGFP). This was further supported via 
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treatment of cells with BFA, an inhibitor acting on ARF1, followed by infection with 
rHAZV. BFA displayed no inhibitory effects on translation of HAZV N. However, 
due to the limitations of rHAZV(eGFP) it was unable to rule out a post-
translational role for ARF1 or GBF1, which given the evidence around COPI 
vesicle formation, is most likely when ARF1 and GBF1 would have effect.  
 
Unfortunately, due to time constraints, further investigation into the role of the 
COPI components in virus infection was not pursued as extensively as hoped, 
with many potential validations and follow up experiments still to complete. 
Developing a method of exploring glycoprotein processing and trafficking, either 
via the generation of a tagged form of Gc / Gn or via specific antibodies against 
Gc, would enable more in depth understanding of the post-translational role of 
COPI vesicles in HAZV infection. Furthermore, examining the role of BFA on 
generation of infectious virus in a similar manner to the siRNA knockdown of 
COPI genes in Figure 4.17 would confirm whether the dependence of HAZV on 
COPI components is truly an ARF1 / GBF1 independent one. 
 
The reporter strain developed and utilised in this chapter successfully achieved 
the aims set out at the beginning of the project. rHAZV(eGFP) serves as an 
extremely valuable tool for furthering understanding into the lifecycle of HAZV, as 
evidenced by its identification of the importance of COPI vesicles and will no 
doubt be useful in uncovering more knowledge into HAZV infection. The uses of 
the system described in this chapter, in combination with the WT system 
described in chapter 3, are further explored in chapter 5, where mutations to the 






5 Exploring Hazara nucleoprotein cleavage during 
infection 
5.1 General introduction 
The development of the HAZV infectious clone system as described in chapter 3 
was used in subsequent experiments described in chapter 4 for the generation 
and use of a recombinant HAZV able to express eGFP. However, another key 
use of an infectious clone system is the ability to discover the role of nucleotides, 
amino acids or ORFs within the viral genome using the principles of reverse 
genetics.  
 
In this chapter, the highly-conserved caspase 3 cleavage motif, DQVD, in HAZV 
was selected as the initial target of mutagenesis. The DQVD motif is located at 
position 269 to 272, at the tip of the arm domain on HAZV N. (Surtees et al., 2015; 
Wang et al., 2015). CCHFV also expresses a similar site, DEVD, at position 266 
to 269 (Carter et al., 2012; Wang et al., 2015). The importance of the cleavage 
site in CCHFV has been previously demonstrated, however neither study 
confirmed the exact role of the cleavage event. A study in 2011 identified 
cleavage of CCHFV N by caspase 3 occurred during infection of mammalian cell 
lines, following activation of apoptotic pathways. Inhibition of caspases was 
shown to have a beneficial effect on viral infection, marked by an increase in titre 
of released virus, suggesting a protective role of the motif against the cellular 
immune response (Karlberg, Tan and Mirazimi, 2011). A recent study, published 
during the course of this project, identified the DEVD motif in CCHFV to be 
dispensable for infection of mammalian cells, but was required for efficient 
replication in cells of tick origin (Salata et al., 2018). Caspase mediated cleavage 
of viral proteins is not uncommon, the Junin virus (JUNV) encodes caspase 
cleavage motifs on its nucleoprotein as decoy substrates to subvert and delay 
the immune response (Wolff, Becker and Groseth, 2013). All human, but not 
avian, strains of influenza A and B also contain conserved caspase cleavage 
motifs within the nucleoprotein, with associated cleavage accompanied by 
increased caspase activity and development of apoptosis (Zhirnov et al., 1999; 
Lipatov et al., 2008). However, due to the previous lack of reverse genetics 
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systems for HAZV, the importance of the DQVD site in HAZV has never been 
fully explored.  
 
Caspases can be activated via three main pathways; the intrinsic pathway, the 
extrinsic pathway and the granzyme B pathway (Taylor, Cullen and Martin, 2008). 
However, regardless of the initial activation mechanism all three initiation routes 
lead to the activation of caspase 3 and result in DNA fragmentation, degradation 
of cellular proteins and ultimately cell death in a controlled manner (Elmore, 
2007). Caspases can be split into two groups, initiator and executioner. They are 
largely expressed as an inactive proenzyme which following activation can 
activate additional proenzymes, causing an activation cascade that amplifies and 
accelerates cell death. All caspases recognise and cleave proteins at aspartic 
acid residues, though the specificities vary between caspases as to the 
composition of neighbouring amino acids, most significantly with the 4 amino 
acids occupying the positions 1 to 4 (P1-P4) directly upstream of the cleaved 
aspartic acid. The preferential substrate site for caspase 3 has been well 
explored; the optimal cleavage sequence has been reported as DEVDG, though 
the caspase will cleave a DxxD sequence efficiently (Stennicke et al., 2000). 
Whilst highly inefficient, it has also been demonstrated that caspase 3 can 
tolerate alternate amino acids at P4 (Thornberry, 1997). Caspase 3 is widely 
regarded as the most important of the executioner caspases, it is able to activate 
caspase activated DNase (CAD) via cleavage of its inhibitor, ICAD (Sakahira, 
Enari and Nagata, 1998). CAD is then freely able to degrade chromosomal DNA 
and induce chromatin condensation. 
 
The immune response to viral infection therefore must be either prolonged or 
prevented in order for viral infection to be successful, premature cell death prior 
to completion of the viral life cycle would inhibit the ability of the virus to produce 
progeny virions. Therefore, viruses have evolved highly complex mechanisms to 
evade the immune system at multiple stages. A number of viruses target the Bcl2 
family of pro-apoptotic regulators, with examples including adenoviruses and 
Epstein-Barr virus (Henderson et al., 1993; Han et al., 1996). Caspases can also 
be directly targeted by direct interaction with the caspase active site by a viral 
protein or via competitive inhibition of signalling proteins (Skaletskaya et al., 
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2001; Filippova et al., 2007). As it has previously been shown that CCHFV is able 
to induce an immune response that results in the cleavage of CCHFV N, this 
chapter will focus on characterising the immune response and subsequent 
cleavage in relation to HAZV infection. 
 
The aims of this chapter were as follows; 
 
1. Determine the caspase cleavage characteristics of HAZV N in 
mammalian and tick cell lines 
2. Utilise the infectious clone to perform a reverse genetics analysis of 
caspase cleavage sites necessary for virus infection 
3. Identify the role of caspase cleavage sites in HAZV infection 
 
Identification of an essential conserved motif within HAZV N would provide an 
excellent target for antiviral therapy, due to the inability of the virus to evolve 
resistance. This would also underline the importance of the development of the 
recombinant system for HAZV in furthering research into the HAZV and CCHFV 
replication.  
 
5.2 Observation of multiple cleavage events in HAZV infection 
Previous studies have identified both HAZV N and CCHFV N to be cleaved by 
activated caspase 3 (Carter et al., 2012; Surtees et al., 2015; Wang et al., 2015). 
However, the importance of this cleavage event in relation to the HAZV life cycle 
has been poorly characterised to date. Therefore, to identify at what stage of virus 
replication this cleavage event was occurring, SW13 cells were infected at a MOI 
of 0.001 with rHAZV and total cell lysate was harvested at regular intervals 
between 0 and 96 hpi. Lysates were examined for HAZV N expression via 
western blotting and detection of GAPDH, using corresponding antisera, was 
used as a loading control. Interestingly, in addition to the expected cleavage 
products relating to caspase 3 cleavage at the DQVD site of approximately 30 
and 22 kDa, multiple additional HAZV N specific cleavage products were 
observed at variable timepoints throughout the infection (Figure 5.1, a). An initial 
cleavage event was observed resulting in generation of a product with a mass of 
approximately 45 kDa in the first 32 hpi following infection. This 45 kDa band then 
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decreased in abundance through the next 16 hpi, before becoming almost 
undetectable at 72 hpi. In contrast, the expected cleavage products resulting from 
caspase 3 cleavage at 30 and 22 kDa appeared following the decrease in 
abundance of the initial 45 kDa cleavage product. Levels of the 30 and 22 kDa 
products increased throughout the infection, with the most abundant levels seen 
at 48 to 72 hpi. This apparent switch in processing of the viral protein may 
correlate with activation or progression of a host cell defence mechanism, such 
as the progression from activation of initiator to executioner caspases, which 
target different motifs, during the apoptotic response to viral infection. This 
observation suggests HAZV N is cleaved in a much more complex manner than 
originally predicted, with the function and origin of these additional cleavage 
products unknown.  
 
As HAZV can replicate in both mammalian and tick vectors, whether HAZV was 
also cleaved in a similar manner in the tick cell line, HAE/CTVM9, was also 
explored. HAE/CTVM9 cells originate from the tick Hyalomma anatolicum and 
therefore provide an excellent physiologically relevant cell line for HAZV studies 
(Bell-Sakyi, 1991). Strikingly, despite strong detection of full length HAZV N, very 
limited N cleavage in these cells was detected, as judged from the lack of HAZV 
N specific bands of less than the full-length mass of 54 kDa (Figure 5.1, b). 
Detection of HAZV N in HAE/CTVM9 cells was also slightly delayed versus 
infection of the SW13 cell line, with first obvious detection of HAZV N occurring 
at 14 hpi compared to 10 hpi in SW13 cells. This demonstrates a striking 
difference in viral protein processing and duration of the attachment to translation 




Figure 5.1 Differential cleavage of HAZV N in infection of SW13 and HAE/CTVM9 
cell lines 
Monolayers of SW13 (a) or HAE/CTVM9 (b) cells were infected with an HAZV at a MOI 
of 0.001. At the indicated time points post-infection, total cell lysates were collected and 
analyzed for HAZV N expression by western blotting with HAZV N antisera. Detection of 
GAPDH in SW13 cells and actin in HAE/CTVM9 cells, using corresponding antisera, 
were used as loading controls.  
 
To identify the origin of these cleavage products, SW13 cells were pre-treated 
with the caspase inhibitors, Z-FA-FMK and Z-VAD-FMK then infected with rHAZV 
to identify if the additionally detected cleavage products were generated in a 
similar manner as the previously described 30 and 22 kDa products. Z-FA-FMK 
and Z-VAD-FMK are peptides that bind irreversibly to the catalytic site of 
caspases, inhibiting caspase-mediated apoptosis with minimal cytotoxic effects 
and are therefore useful tools for studying the role of caspases in virus infection 
(Van Noorden, 2001; Lawrence et al., 2006). Analysis of infected cell lysates via 
western blot demonstrated neither Z-FA-FMK (Figure 5.2, a) or Z-VAD-FMK 
(Figure 5.2, b) to have any major effect on full length HAZV N expression. 
However, Z-FA-FMK was able to block cleavage of the 45 kDa (*), 30 kDa (**) 
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and 20 kDa (***) products, as evidenced by failure to detect the corresponded 
bands in treated lysates versus untreated controls. Interestingly, Z-VAD-FMK 
was less able to block the cleavage of HAZV N, with similar levels of the 30 kDa 
(**) and 20 kDa (***) cleavage products detected in treated and untreated control 
lysates. Despite the inability of Z-VAD-FMK to prevent production of the caspase 
3 specific cleavage products, it was able reduce production of the 45 kDa (*) 
product, with lower abundance detected in treated lysates versus untreated 
controls. The ability of both caspase inhibitors to block detection of the 45 kDa 
product suggests the responsible host cell protease for the cleavage event 
resulting in generation of the 45 kDa product during infection to be a caspase.  
 
Figure 5.2, Caspases are responsible for HAZV N cleavage 
Monolayers of SW13 cells were pre-treated with either (a) Z-FA-FMK or (b) Z-VAD-FMK 
prior to infection with rHAZV at 0.01 MOI. At the indicated time points post-infection total 
cell lysates were collected and analysed for HAZV N expression and its specific cleavage 
products at 45 kDa (*), 30 kDa (**) and 20 kDa (***) by western blotting with HAZV N 




5.2.1 Incorporation of cleavage products into virions 
To assess whether these cleavage products were incorporated into infectious 
virions, rHAZV was purified across a 20 % sucrose cushion via ultracentrifugation 
at 150,000 RPM. An aliquot of the resuspended pellet containing virus was 
analysed via western blot for HAZV N specific products. In addition to detection 
of full length HAZV N, a range of smaller molecular weight products were also 
detected in the purified virions  
 
Figure 5.3, Caspase mediated HAZV N cleavage products are incorporated into 
infectious virions 
Left panel lysates collected from monolayers of SW13 cells infected with an rHAZV at a 
0.1 MOI. At the indicated time points post-infection, total cell lysates were collected and 
analyzed for HAZV N expression by western blotting with HAZV N antisera, detection of 
GAPDH, using antisera, was used as a loading control. Cleavage products were 
detected at approximately 45 kDa (*), 30 kDa (**) and 22 kDa (***). Purified rHAZV 
collected 72 hours post infection was denatured at 95C and analysed for HAZV N 
expression by western blotting with HAZV N antisera. 
 
5.3 Induction of apoptosis by HAZV 
Previous work has identified caspase 3 as the responsible protease for cleavage 
of HAZV N (Wang et al., 2015), however little work has been done to characterise 
this interaction in a live-cell model. To this end, SW13 cells were infected at 0.001 
MOI and total cell lysate was harvested daily at 24, 48, 72 and 96 hpi. As a 
negative control, a sample was also taken at 0 hpi. Lysates were first checked for 
HAZV infection and equal loading via detection of HAZV N and GAPDH (SW13 
cells) or actin (HAE/CTVM9 cells). As expected, no HAZV N was detected at the 
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0 hpi time point, but was detectable in all lysates collected 24 hr post infection 
and above. To determine whether the caspase pathway was activated in 
mammalian cells in response to HAZV infection, lysates were again analysed via 
western blot and probed for caspase 3, 7, 9 and PARP, along with their 
associated activated cleaved forms (Figure 5.4). Activation of caspases was 
detected in mammalian cell lysates at a minimum of 48 hpi, with all caspases 
having cleaved forms present in the lysates at 96 hpi (Figure 5.4, left panel). 
Strikingly, the same was not observed in the HAE/CTVM9 tick cell line, despite 
observation of caspases in the lysate, no activated forms were detected at any of 
the time points sampled (Figure 5.4, right panel). 
 
The inability to detect activated caspases in tick cells may provide an explanation 
for the lack of associated HAZV N cleavage observed previously during infection 
of tick cells in Figure 5.1. However, it is also possible that an unknown mechanism 
may delay apoptosis in tick cells, allowing the virus to persist longer in the vector. 
Delaying induction of apoptosis has been demonstrated by BUNV NSS, via 
detection of interferon activated apoptotic pathways earlier in NSS knockout 
BUNV vs WT BUNV infection (Kohl et al., 2003). However, following transfection 
of the CCHFV NSS into SW13 cells it was shown that this viral protein induced 
apoptosis via both intrinsic and extrinsic pathways. The ability of these proteins 
to induce or delay apoptosis may be dependent on the host cell type. It would 
make sense that in the cell line derived from the vector, HAE/CTVM9, that the 
virus would be unable to induce apoptosis, allowing persistence of the infection. 
However, in a cell line derived from the dead-end host, SW13, the virus induces 





Figure 5.4, Differential activation of caspases following rHAZV infection of SW13 
and HAE/CTVM9 cell lines 
Monolayers of SW13 cells (left column) or HAE/CTVM9 cells (right column) were infected 
with HAZV at 0.001 MOI. At the indicated time points post infection, total cell lysates 
were collected and analyzed for expression of HAZV N, Caspases 3, 7, 9, PARP and 
their associated cleavage products by western blotting with HAZV N antisera or 
purchased polyclonal antibodies. Detection of Actin, using antisera, was used as a 
loading control in both SW13 and HAE/CTVM9 cells.  
 
5.4 Generation of cleavage site deficient rHAZV 
In order to assess the importance of the individual cleavage motifs, a panel of 
mutations were introduced into the S segment rescue plasmid cDNA to knockout 
the ability of each of the motifs to be cleaved. This was achieved via SDM of the 
position 1 aspartic acid residue to either alanine or glutamic acid. Alanine was 
selected to completely knockout the cleavage ability, whereas glutamic acid was 
selected to knockout cleavage ability whilst maintaining a degree of structural 
integrity to the region.  
 
5.4.1 DQVD and ENKD sites 
It is well established that HAZV N contains a conserved caspase 3 cleavage motif 
at the tip of the arm domain, with the amino acid sequence 269DQVD272 (Surtees 
et al., 2015; Wang et al., 2015). However, it is often overlooked that the position 
4 aspartic acid residue also forms the position 1 residue in an overlapping 
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caspase motif, 266ENKD269. Whilst not the stereotypical DxxD motif that is 
preferred by active caspase 3, previous research has shown amino acid flexibility 
at the 2, 3 and 4 positions of caspases can be tolerated and indeed are described 
in the literature (Thornberry, 1997). Conservation of the motif exists between 
HAZV (DQVD) and CCHFV (DEVD), with the two sites occupying the same 
spatial position on the arm domain of their respective proteins, despite being 
located three amino acids apart (Figure 5.5). 
The DEVD motif is conserved in CCHFV across all fully sequenced isolates of 
CCHFV, both in its location on the apex of the protein and in sequence, 
suggesting a critical role of the motif in the viral lifecycle (Deyde et al., 2006).  
 
Figure 5.5, Location of DQVD and ENKD cleavage sites on HAZV and CCHFV 
nucleoproteins 
Schematic showing locations of caspase cleavage motifs DEVD/DQVD and 
ENKD/KHKD on the apex of the arm domains of HAZV (a) and CCHFV (b) respectively, 
with amino acid positions indicated numerically. 
 
In order to assess the importance of the overlapping ENKD and DQVD motifs, 
site directed mutagenesis was carried out, substituting the respective position 1 
aspartic acid residue for glutamic acid, rendering the motif uncleavable by 
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caspases. An additional mutant in which both position 1 residues were 
substituted for alanine, giving an AQVA motif, was also included to assess the 
effect of knocking out both caspase cleavage sites concurrently and also to 
permit a direct comparison to a similar mutation described using the recombinant 
CCHFV system (Salata et al., 2018). Recovery of rHAZV containing the ENKE, 
DQVE or AQVA motif was then carried out as described in section 3.4, 
substituting out the WT S segment cDNAs for the associated caspase cleavage 
site deficient S segment cDNAs. As previously described, following transfection 
of BSR-T7 cells, supernatants were harvested at 72, 96 and 120 hours post 
transfection and used to re-infect fresh monolayers of SW13 cells. Following a 
48 hour reinfection, total cell lysates were collected and analysed for expression 
of HAZV N as a marker of viral replication. Presence of HAZV N in the reinfection 
lanes of both rHAZV(ENKE) and rHAZV(DQVE) mutants suggested a non-
essential role for the ENKD and DQVD motifs independently; however, the 
inability to detect HAZV N in reinfections using the AQVA mutant S segment 
(Figure 5.6, a) suggests a requirement for at least one of the aspartic acid 




Figure 5.6, Recovery of caspase motif deficient rHAZV 
a) Detection of HAZV N protein for rHAZV(DQVE), rHAZV(ENKE), and rHAZV(AQVA) 
mutants in lysates collected post transfection (p.Tr) of BSR-T7 cells and 48 hours post 
infection (p.Inf) of SW13 cells, infected using supernatants harvested 72, 96, and 120 
hour post transfection. Recovery of all mutants was carried out alongside independent 
complete control recovery of WT rHAZV and a control in which transfection of L segment 
plasmid was omitted. detection of GAPDH, using antisera, was used as a loading control. 
b) Representative plaque assays of supernatants taken 120 h post transfection, 
displaying plaque morphology for recovered viruses. c) Comparison of titers of infectious 
WT rHAZV, rHAZV(DQVE) and rHAZV(ENKE) at 24 hour intervals following infection of 
SW13 cells at a MOI of 0.001 over a 4 day period, plotted using GraphPad Prism.  
 
Of note, recovery of the two mutants containing DQVE and ENKE motifs 
displayed similar plaque morphology to WT rHAZV, displaying the same clarity 
and bullseye characteristics (Figure 5.6, b). Comparison of fitness of mutants was 
achieved via a multistep growth curve over 4 days, the time at which titer of HAZV 
begins to decrease in supernatants from cell culture. Analysis of plaque assays 
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showed similarities in the growth profiles of WT rHAZV, rHAZV(DQVE) and 
rHAZV(ENKE) mutants, with peaks observed at approximately 106 PFU / mL at 
72 hpi (Figure 5.6, c). To confirm the cleavage site had been rendered redundant, 
western blot analysis of lysate collected from SW13 cells infected with WT, 
rHAZV(DQVE) and rHAZV(ENKE) was analysed. Surprisingly, despite the 
disappearance of the larger  32 kDa molecular weight product specific to HAZV 
N in the infection with rHAZV(DQVE), an alternate cleavage product was 
detected at a marginally larger molecular weight (Figure 5.7). In addition, the 
lower molecular weight product at  20 kDa remained unexplainably unchanged. 
No change to the cleavage products generated was observed with the 
rHAZV(ENKE) infection, suggesting the ENKD motif to be unassociated with 
caspase cleavage. Taken together, it suggests the entire DQVD motif may have 
an additional role to a caspase cleavage motif within HAZV infection. 
 
Figure 5.7, Knockout of caspase motifs results in alternate cleavage of HAZV N 
Western blot detection of full length HAZV N and its associated cleavage products at 30 
and 32 kDa (*) and 20 kDa (**) following a 48 hour infection of SW13 cells at a MOI of 
0.01 with WT rHAZV, rHAZV(ENKE) and rHAZV(DQVE). Relevant molecular sizes are 
indicated in kDa. 
 
To determine whether the caspase cleavage site was a requirement in cells 
originating from the natural tick vector, rather than mammalian cells, tick-origin 
HAE/CTVM9 cells were infected with WT rHAZV alongside rHAZV(ENKE) and 
rHAZV(DQVE) mutants. The time course displayed in Figure 5.1 identified a 
strong HAZV N band at 48 hpi and so this time point was used to determine 
whether the mutants were capable of expression of viral products. HAE/CTVM9 
cells were infected at a MOI of 0.001 and incubated for 48 hours. At this point 
total cell lysate was collected and analysed for HAZV N expression via western 
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blot. Actin was also detected as a loading control and mock infected HAE/CTVM9 
cells were also set up as a negative control. Visualisation of strong HAZV N 
specific bands in all infected wells of equal density demonstrates the ability of the 
rHAZV mutants rHAZV(ENKE) and rHAZV(DQVE) to bind, enter, uncoat, 
transcribe and translate viral products efficiently within HAE/CTVM9 cells 
suggesting the role of the HAZV caspase cleavage motif is not required for 
replication in these cells. 
 
Figure 5.8, Mutagenesis of the DQVD and ENKD sites does not affect ability of 
rHAZV to infect tick cells  
Western blot analysis of lysates collected 0 and 48 hours post infection (hpi.) of 
HAE/CTVM9 cells with WT rHAZV, rHAZV(DQVE) and rHAZV(ENKE) at 0.01 MOI via 
detection of HAZV N using anti HAZV N serum. Detection of Actin, using antisera, was 
used as a loading control. 
 
5.4.2 DVMA 
Caspase cleavage prediction software, GraBCas, identified an alternative motif 
to DQVD that may act as a substrate for caspase cleavage in HAZV. The DVMD 
motif at position 248-251 met the optimal consensus cleavage motif for caspase 
3, DxxD and was suitably located in an assumedly accessible region to permit 
interaction with the caspase and subsequent cleavage (Figure 5.9, a). 
Examination of related viruses revealed the site was very loosely conserved, with 
minimal conservation observed other than the P1 aspartate residue, which was 
located between positions 248-251 in CCHFV, NSDV, ERVE and TOFV (Figure 




Figure 5.9, Location of the DVMD predicted cleavage site and conservation in 
alternate species 
a) 3D representation of HAZV N, with the location of the DVMD motif indicated in red at 
position 248 to 251. Image generated using PyMOL. b) Conservation of the DVMD motif 
across related viruses within the Bunyavirales. 
 
In order to assess the importance of this domain in the HAZV life-cycle, a plasmid 
encoding a mutated DVMD motif, in which the P1 aspartate was replaced with 
alanine to generate an uncleavable DVMA motif (pMK-RQ-S-DVMA). Recovery 
of infectious rHAZV was attempted as previously described utilising a complete 
set of WT plasmids as a positive control. In the recovery attempt of the DVMA 
mutant the WT S segment pMK-RQ-S plasmid was replaced with the mutated 
version, pMK-RQ-S-DVMA, and transfected into BSR-T7 cells. Subsequent 
attempts to re-infect SW13 cells at 72, 96 and 120 hours post transfection 
resulted in no infection with rHAZV(DVMA), indicated by the lack of HAZV N 
signal following western blot analysis (Figure 5.10, a). Failure to recover 
rHAZV(DVMA) was shown not to be due to inefficiencies in the recombinant 
system as triplicate repeats ended with similar results, with WT rHAZV recovered 
in all cases, indicating the failure of rHAZV(DVMA) rescue to be a result of the 
mutation. Further validation that no mutant virus was recovered was provided by 
plaque assay, demonstrating recovery of WT rHAZV via observation of 
characteristic plaque morphology, with no detectable plaques in the 




Figure 5.10, Inability to recover rHAZV with a mutated DVMD motif shown via 
western blot and plaque assay 
a) Detection of HAZV N for the rHAZV(DVMA) mutant in lysates collected post 
transfection (p.Tr) of BSR-T7 cells and 48 hours post infection (p.Inf) of SW13 cells, 
infected using supernatants harvested 72, 96, and 120 hour post transfection. Recovery 
of the rHAZV(DVMA) mutant was carried out alongside independent complete control 
recovery of WT rHAZV and a control in which transfection of L segment plasmid was 
omitted. Detection of GAPDH, using antisera, was used as a loading control. b) 
Representative plaque assays of supernatants taken 120 h post transfection 
 
It is unknown why mutagenesis of the DMVD motif resulted in such a surprising, 
fatal phenotype. The minimal conservation of the motif, other than the P1 aspartic 
acid, suggests that caspase cleavage may not be the reason behind the failure 
to recover infectious virus. The limitation of the infectious clone system prevents 
the identification of any loss of cleavage product that would support the role of 
caspases associated with DVMD cleavage. Recovery of a defective virus, in 
which one of the cleavage products identified in Figure 5.1 was no longer present, 
would have provided strong evidence for the role of HAZV N cleavage during viral 
infection. However due to the poor conservation of the P2-P4 residues within the 
motif across multiple strains, it is unlikely that caspase cleavage at the DVMD 
site in HAZV would have such a critical role. The availability of a minigenome 
system could provide further understanding as to the role of DVMD during HAZV 
RNA synthesis, however such a system was not available during this project and 
attempts to generate one were unsuccessful. An alternative reason for the 
importance of the P1 aspartic acid residue may be structural. The location of the 
motif lies at the interface between the arm and globular domains of HAZV N, the 
conversion of D to A may result in an alteration in structure, such as the angle of 
the arm domain in relation to the globular domain that inhibits a critical function 
of HAZV N. Nevertheless, regardless of the way in which the DMVD motif affects 
HAZV infection, the infectious clone system was successfully used to 





5.4.3.1 Recovery of LFAA rHAZV 
Alignment of the amino acid sequences for the N protein of HAZV, CCHFV, 
NSDV, ERVEV and TOFV revealed the total conservation of a motif, LFAD, 
located at position 365 to 368 in HAZV that displayed 100 % conservation through 
the P1 to P4 positions. The motif is located on the globular domain of HAZV N, 
in an easily accessible position (Figure 5.11, a). Location of the motif was also 
similar, with the P1 aspartate residue located at position 360, 365 or 368, 
dependent on species (Figure 5.11, b). At the time of writing, no previous 
research describing the importance of such a well-conserved motif in HAZV or 
CCHFV has been reported and therefore presented an attractive area to 
investigate. Occurrence of a LFAD motif in a non-viral context is observed in the 
sorting nexin 1 (SNX1) protein. SNX1 is part of a larger family of sorting nexins, 
and contains a conserved phox homology (PX) domain that permits binding to 
phosphoinositide 3-monophosphate (PtdIns3P) (Carlton et al., 2005). In addition 
to a PX domain, SNX1 also contains a Bin/Amphiphysin/Rvs (BAR) domain that 
is able to sense and induce membrane curvature within endosomal 
compartments in the formation of transport vesicles (Peter et al., 2004). SNX1 
has previously been shown to have a role in endosomal sorting of epidermal 
growth factor receptor (EGFR) between endosomes, the Golgi and lysosomes as 
part of the retromer complex comprising vacuolar-protein-sorting proteins 5, 17, 
26, 29 and 35 (Vps5p, Vps17p, Vps26p, Vps29p, Vps35p) (Seaman et al., 1997). 
Critically, during the apoptotic response SNX1 is cleaved at the LFAD motif, 
preventing its ability to sort endosomal receptors, a process that might be 
required by HAZV and related viruses during infection (Duclos, Lavoie and 
Denault, 2017). To this end, it is possible that conservation of the LFAD motif in 
orthonairoviruses may be as a decoy substrate to prevent cleavage of SNX1 




Figure 5.11, Location of the LFAD predicted cleavage site and conservation in 
alternate species 
a) Model displays a 3D representation of HAZV N, with the location of the LFAD motif 
indicated in red at position 365 to 368. Image generated using PyMOL. b) Conservation 
of the LFAD motif across related viruses within the Bunyavirales. 
 
To assess the role of the LFAD motif in HAZV infection, the infectious clone 
system detailed in section 3.4 was modified to generate a rHAZV clone in which 
the LFAD motif was mutated to an uncleavable motif, LFAA. The mutated LFAA 
cDNA was generated via SDM of the pMK-RQ-S plasmid, converting the P1 
aspartate to alanine (pMK-RQ-S-LFAA). Recovery of mutant rHAZV was 
achieved as described in section 3.4, with pMK-RQ-S substituted for pMK-RQ-S-
LFAA. Recovery of rHAZV(LFAA) was carried out alongside recovery of WT 
rHAZV, in which WT encoding plasmids were used as a positive control for the 
recovery. Confirmation of successful recovery of rHAZV(LFAA) was achieved via 
the detection of HAZV N signal following western blot analysis of lysates taken 
from SW13 cells infected with supernatant harvested from BSR-T7 cells 120 
hours post transfection (Figure 5.12, a), as expected HAZV N signal was also 
detected in the rHAZV reaction.  
 
Despite recovery of both viruses, the intensity of HAZV N expressed following the 
48 hour reinfection of SW13 cells was markedly lower in the infection with 
rHAZV(LFAA) compared to rHAZV, with no recovery observed at all in infections 
established using supernatant collected 96 hours post transfection from 
rHAZV(LFAA), despite detection of rHAZV signal under the same experimental 
conditions (Figure 5.12, a). Further differences were observed between WT 
rHAZV and rHAZV(LFAA) upon analysis of plaque assays set up using 
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supernatant collected 120 hr post transfection. As in previous recoveries of WT 
rHAZV, plaques presented as clearly defined circles, with a ‘bulls-eye’ centre, 
however plaque morphology of rHAZV(LFAA) was substantially altered, with 
poorly defined plaques barely visible (Figure 5.12, b). This phenotype suggests 
severely reduced virus fitness, with this mutant virus unable to cause similar 
levels of CPE in SW13 cells as the WT equivalent. However, the extent of the 
decrease in fitness observed could not be experimentally determined effectively 
due to the inability to accurately determine the titre of the stock due to the issues 
surrounding detection of plaques, therefore a solution that enabled accurate 
titration of the viruses was required. 
 
Figure 5.12, Recovery of rHAZV containing a mutated LFAD motif displaying 
altered plaque morphology 
a) Detection of HAZV N for the rHAZV(LFAA) mutant in lysates collected post 
transfection (p.Tr) of BSR-T7 cells and 48 hours post infection (p.Inf) of SW13 cells, 
infected using supernatants harvested 72, 96, and 120 hour post transfection. Recovery 
of the rHAZV(LFAA) mutant was carried out alongside independent complete control 
recovery of WT rHAZV and a control in which transfection of L segment plasmid was 
omitted. Detection of GAPDH, using antisera, was used as a loading control. b) 




5.4.3.2 Recovery of fluorescent LFAA rHAZV 
To resolve the issues surrounding titration of rHAZV(LFAA), the eGFP infectious 
clone detailed in section 4.3 was used. The same SDM reaction used to generate 
pMK-RQ-S-LFAA was repeated, using pMK-RQ-S-eGFP as the template cDNA, 
generating pMK-RQ-S-LFAA-eGFP which was used to recover the mutant 
rHAZV(eGFP-LFAA) in the same way as described previously. As rHAZV(eGFP) 
had previously been shown to be comparable to WT rHAZV, it was expected that 
rHAZV(eGFP-LFAA) would be recoverable and demonstrate similar properties to 
rHAZV(LFAA). This was confirmed via western blot analysis of lysates taken from 
SW13 cells infected with supernatant harvested from BSR-T7 cells 96 and 120 
hours post transfection, with HAZV N and GFP signal detected in both complete 




Figure 5.13, Recovery of rHAZV-eGFP containing a mutated LFAD motif 
demonstrates reduced fitness 
a) Detection of HAZV N and GFP for the rHAZV(eGFP-LFAA) mutant in lysates collected 
post transfection (p.Tr) of BSR-T7 cells and 48 hours post infection (p.Inf) of SW13 cells, 
infected using supernatants harvested 72, 96, and 120 hour post transfection. Recovery 
of the rHAZV(eGFP-LFAA) mutant was carried out alongside independent complete 
control recovery of WT rHAZV and a control in which transfection of L segment plasmid 
was omitted. Detection of GAPDH, using antisera, was used as a loading control. b) 
Graphical representation of green cell count over time during the 48 hour re-infection of 
SW13s using supernatant harvested from BSR-T7 cells transfected for control, complete 
and rHAZV(eGFP-LFAA) 120 hours post transfection. Analysis was carried out using the 
IncuCyte® live cell imaging system and plotted using GraphPad Prism. c) Representative 
images of infected SW13 cells by rHAZV(eGFP-LFAA) at 0, 24 and 48 hours post 




As with the non-fluorescent mutant rHAZV(LFAA), the resulting rHAZV(eGFP-
LFAA) also appeared to demonstrate obvious reduced fitness issues following its 
recovery from cDNA. Abundance of both HAZV N and GFP signal via western 
blot were reduced versus the WT rHAZV(eGFP) controls in both 96 and 120 hour 
post transfection reinfections. This was supported by data collected from the 
incucyte scans of the 120 hour post transfection reinfection (Figure 5.13, b, c), 
with the time taken for GFP signal to be detected occurring between the 24 and 
48 hpi timepoints, versus a pre 24 hpi value for rHAZV(eGFP). 
 
5.4.3.3 Alterations to LFAD motif reduce viral fitness 
To determine whether the addition of eGFP expression to rHAZV(LFAA) would 
enable titration of the mutant form, a plaque assay was set up for both 
rHAZV(eGFP) and rHAZV(eGFP-LFAA) and imaged at 72 hpi. Observation of the 
patterns of infected cells, marked by eGFP expression, revealed a substantial 
difference in plaque morphology between rHAZV(eGFP) and rHAZV(eGFP-
LFAA). The most obvious difference was observed to be the diameter of the 
plaques, with the average diameter of a WT plaque being 534 m ( 27.85, n=13) 
versus an average diameter of 348.6 m (16.67, n=12) for rHAZV(eGFP-LFAA), 
giving a highly significant difference between WT and mutant (P = <0.0001) 
(Figure 5.14, a). In addition to the decreased diameter of plaques generated by 
rHAZV-LFAA(eGFP), the plaques appeared less “full” than those observed with 
WT rHAZV(eGFP) (Figure 5.14, b), which may explain why the plaques observed 
previously in rHAZV-LFAA (section 5.4.3.1) were much more poorly defined than 
the WT equivalents.  
 
Importantly, the visualisation of clear-cut foci of infection enabled titration of the 
rHAZV(eGFP-LFAA) virus stock. Using the EVOS microscope, which permits 
whole well fluorescence imaging, virus stocks of rHAZV(eGFP-LFAA) were able 
to be accurately titrated. A whole well image is generated via sequential imaging 
of the entire well, which are then stitched together by the EVOS software to create 
a final image (Figure 5.14, c). Plaques can then be counted as with a crystal violet 
plaque assay and the titre determined. The ability to accurately titre 
rHAZV(eGFP-LFAA) enables comparative infections at the same MOI as WT 
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rHAZV, allowing any difference in fitness to be attributed to the mutation rather 
than a different starting concentration of virus. 
 
Figure 5.14, Mutation of LFAD motif results in altered plaque morphology 
a) Histogram displays the diameter of the fluorescent plaques generated 72 hours post 
infection of SW13 cells by rHAZV(eGFP) or rHAZV(eGFP-LFAA). Minimum of 10 
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plaques were measured for each virus, significance determined by T-Test (P = <0.0001). 
Plotted using GraphPad Prism. b) Representative images of fluorescent plaques used to 
generate data in (a), imaged on the IncuCyte® live cell imaging system. c) Representative 
image of rHAZV(eGFP-LFAA) titration on EVOS microscope, taken 72 hours into 
infection of SW13 cells. 
 
Following the establishment of a means to calculate titres of rHAZV(eGFP) and 
rHAZV(eGFP-LFAA), an infection was set up in SW13 cells and imaged hourly 
on the IncuCyte® live cell imaging system. This enabled insight into the time taken 
between applying virus to cells and translation of viral transcripts. Plotting of 
green cell count versus time post infection identified a delay in detection of eGFP 
signal in rHAZV(eGFP-LFAA) infections compared to rHAZV(eGFP) infections 
(Figure 5.15, a). Whilst detection of eGFP in rHAZV(eGFP) occurred at 13 to 14 
hpi, in line with that observed previously in section 4.5, eGFP signal was detected 
much later in infections with rHAZV(eGFP-LFAA) at 25 to 26 hpi. This was evident 
from examining the images collected during the infections, with green cells barely 
visible in images taken 24 hpi for rHAZV(eGFP-LFAA), but multiple strong 
intensity green cells present for rHAZV(eGFP) (Figure 5.15, b). Whilst the initial 
translation event was delayed, the rate at which the green cell count increased 
following the initial detection of eGFP was similar for both viruses and reached a 
similar peak, indicating once rHAZV(eGFP-LFAA) had overcome the delay 
caused by the mutation, it did not hinder further stages of the viral life cycle. This 





Figure 5.15, rHAZV(eGFP-LFAA) displays delayed translation vs rHAZV(eGFP) 
a) Graphical representation of green cell count versus time post infection of SW13 cells infected with rHAZV(eGFP) or rHAZV(eGFP-LFAA) for 72 
hours. Analysis was carried out using the IncuCyte® live cell imaging system and plotted using GraphPad Prism. b) Representative images of infections 




This would support the relationship between the LFAD motif and virus entry and 
could be explained by the native role of SNX1. The inability of rHAZV(eGFP-
LFAA) to prevent cleavage of SNX1 during an apoptotic response to viral 
infection may impact the ability of rHAZV(eGFP-LFAA) to enter the cell. However, 
confusion arises regarding the timing of the delay in relation to SNX1. If the LFAD 
role is to protect SNX1 from apoptosis mediated cleavage, then it would follow 
that rHAZV had already entered and triggered apoptosis and therefore would not 
require the membrane receptors recycled by SNX1.  
 
To confirm whether SNX1 was a factor in rHAZV infections, siRNA knockdown 
was carried out. SW13 cells were pretreated with an siRNA targeting SNX1, using 
the same protocol as described in section 4.6. Following a 24 hour infection, 
SW13 cell lysates were collected and analysed for SNX1 and HAZV N expression 
via western blot (Figure 5.16, a). SNX1 levels were visibly reduced from the 
western blot analysis in lysates collected from SW13 cells that had been treated 
with either 15 or 30 nM siRNA. Analysis of normalised densitometric data of 
HAZV N revealed a trend in reduction of HAZV N expression with increasing 
concentration of the siRNA (Figure 5.16, b). The reporter rHAZV(eGFP) was also 
used to provide an alternative method of quantifying the effect of SNX1 on rHAZV 
infections (Figure 5.16, c). In this case analysis of the TIIE in SNX1 knockdown 
SW13 cells infected with rHAZV(eGFP) resulted in a similar trend observed in 
Figure 5.16, a. However, with the analysis this time carried out by the IncuCyte® 
live cell imaging system software the results were significant, indicating a role of 
SNX1 in HAZV infection at a stage including or prior to translation (Figure 5.16, 
d). Whether the role of SNX1 in HAZV replication is linked to the LFAD motif 
present in HAZV N was not confirmed experimentally in this project, though 





Figure 5.16, siRNA knockdown of SNX1 reduces rHAZV infectivity in SW13 cells 
a) Western blot analysis of SNX1 knockdown SW13 cells infected with WT rHAZV. Cells 
were pretreated with 15 or 30 nM of siRNA then infected with rHAZV at an MOI of 0.1 
for 24 hours. Total cell lysates were analysed for SNX1 and HAZV N, detection of 
GAPDH, using antisera, was also used as a loading control. A control in which SNX1 
was not targeted by siRNA and infected with rHAZV was also included (Control). b) 
Histogram displays normalised densitometric analysis of western blot data from (a), 
calculated using the ImageJ software package, error bars represent data from 2 
experimental repeats. Plotted using GraphPad Prism. c) Representative images of 
rHAZV(eGFP) infections taken 24 hours post infection, imaged on the IncuCyte® live 
cell imaging system. d) Histogram displays total integrated intensity of eGFP from 
images taken and analysed by the IncuCyte® live cell imaging system, error bars 
represent data from 2 experimental repeats. Plotted using GraphPad Prism. 
 
 
5.5 Chapter summary and discussion 
In this chapter, the infectious clone system developed as described in chapter 3 
then modified as described in chapter 4 was further utilised to explore the role of 
conserved cleavage sites within HAZV N. Initially, extensive cleavage of HAZV N 
was identified in SW13 cells, with multiple previously undocumented cleavage 
products identified. Critically cleavage of HAZV N was not observed in 
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HAE/CTVM9 cells, uncovering a stark difference in processing of the viral protein 
in two cell types with physiological relevance to the HAZV life cycle. Further 
characterisation of the cleavage products via inhibition of activated caspases 
identified the origin of the highest abundance products, specifically those at ≈ 45, 
30 and 20 kDa, to be caused by caspase cleavage. Interestingly, despite 
extensive conservation of the caspase cleavage motif on the tip of the arm 
domain of HAZV N and CCHFV N, inhibition of its cleavage had no effect on virus 
infection up to the point of translation. This would support the role of cleavage 
resulting in these specific cleavage products is as a decoy substrate, as the lack 
of the cleaved form of the protein did not appear to affect viral replication. 
 
The infectious clone system was then utilised to modify multiple proposed 
cleavage sites on HAZV N. Initially, the caspase 3 cleavage motif DQVD was 
mutated to change the P1 and/or P4 aspartic acids (which also formed the P1 
residue of an adjacent cleavage motif) to either alanine or glutamic acid, resulting 
in an ENKE motif, a DQVE motif and an AQVA motif. This was chosen to knock 
out the ability of the motif to be cleaved, whilst maintaining structural integrity. A 
previous study, published during the course of this project, attempted a similar 
task using the infectious clone model for CCHFV, in which the DEVD motif was 
converted to AEVA. They found that despite the motif being dispensable for 
replication in mammalian cell lines, the mutation of both P1 and P4 aspartic acid 
residues rendered the virus incapable of infecting tick cells (Salata et al., 2018). 
Therefore, it was a surprising and substantial discovery that the similar mutant 
generated in this project, AQVA, was unable to be recovered, despite multiple 
attempts. In both of the mutants where a single change to the DQVD motif was 
made, successful recovery of virus was achieved. The fact that both of the 
resulting viruses, rHAZV(ENKE) and rHAZV(DQVE), were viable and 
demonstrated multi step growth kinetics that were indistinguishable from those of 
WT rHAZV is a critical observation. As the DQVE mutant is cleaved at neither the 
DQVE site nor the adjacent ENKD site, as shown by the shifted band following 
western blot analysis, these findings show cleavage within the arm apex is not a 
requirement for virus viability. The alternative cleavage shown in infection with 
rHAZV(DQVE) shows that alternative cleavage sites exist that are amenable to 
cleavage once the dominant sites are removed. Deciphering the caspase 
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cleavage profiles of nairoviral N proteins is a complex task, as there are a total of 
28 aspartate residues that could potentially be cleaved in HAZV N alone. 
 
The failure to rescue the rHAZV-AQVA mutant despite repeated efforts suggests 
it is deficient in a critical function. The lack of rescue of rHAZV(AQVD), when 
contexed with the successful rescue of the cleavage deficient rHAZV(ENKE) and 
rHAZV(DQVE), shows it cannot be due to loss of cleavability of the arm apex. 
The results within this chapter show the DQVD site is important for rescue but 
not for caspase cleavage, which provides a starting point for studies to elucidate 
the critical role of this DQVD motif and provide insight into how CCHFV is able to 
remain viable following a similar mutation. A possibility is that the DQVD site is 
involved in an interaction with a host factor, and the availability of such a 
component may also explain the differential outcomes of CCHFV infection in 
mammalian and tick cells. 
 
In addition to the DQVD motif, the DVMD motif located between the arm and 
globular domains of HAZV was also investigated for its importance in HAZV 
replication. Again, mutagenesis of the motif to an uncleavable form rendered 
rescue of rHAZV(DVMA) impossible. Though as the location of this motif lies at 
an interaction site between two domains of the protein it may be due to the loss 
of structural integrity rather than any active role within infection. 
 
Finally, the role of a completely conserved motif, LFAD, was explored. Despite 
initial recovery of rHAZV(LFAA) containing a caspase cleavage deficient motif, 
the virus had severe fitness issues. Plaques generated by rHAZV(LFAA) 
displayed poor clarity and resulted in failure to accurately titrate viral stocks to 
permit comparisons. Incorporation of the LFAA mutation into rHAZV(eGFP) 
resolved this issue, permitting equal MOI infections of rHAZV(eGFP) and 
rHAZV(eGFP-LFAA) to be made. Further investigation into the role of the LFAD 
motif revealed a substantial delay in translation when the motif was knocked out, 
recovery of expression levels comparable to the WT motif following this delay 
suggested a pre-translational effect. SNX1, located within endosomes, is 
responsible for sorting of membrane receptors and inducing curvature of 
endosomal membranes (Peter et al., 2004; Carlton et al., 2005). Interestingly, it 
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is cleaved during the apoptotic response at an LFAD motif (Duclos, Lavoie and 
Denault, 2017), therefore it is plausible that HAZV N is also acting as a decoy for 
this protein as well. siRNA knockdown of SNX1 prior to infection with 
rHAZV(eGFP) demonstrated a slight effect on rHAZV, supporting this statement, 
however the scale of the reduction of rHAZV infection was not close to the loss 
of fitness displayed by rHAZV(LFAA), despite almost total knockdown of 
detectable SNX1. Further research into understanding the role of the LFAD motif 
in HAZV N may reveal a critical role of the lifecycle that could be targeted by anti-
viral drugs, due to the easily accessible location of the motif on the surface of 
HAZV N.   
 
The WT infectious clone system, in combination with the eGFP reporter virus 
have again proven to be extremely powerful tools in this chapter. The use of the 
system demonstrated significant differences between conserved motifs on HAZV 
N and CCHFV N and uncovered novel motifs of importance in relation to HAZV 
infection of mammalian cells. The ability to efficiently mutate multiple motifs within 
HAZV N demonstrates the utility of the recombinant system, allowing detailed 
experimentation into highly specific regions of the virus, which will no doubt prove 
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1.1. Nucleotide sequences 
 































































































































































































































































































































































































































Primer Orientation Sequence 
HindIII insertion Forward GGA TTA GCA AAG CTT GTT GAG CTA 
GAG GGG 
HindIII insertion Reverse CGT GGC CAA GAG AGG GTA CCC AGA 
TTT AC 
HindIII sequencer Forward TCG GCT TCT CCA TTG GGG AGT ACA C 
HindIII sequencer Reverse GCA TCA TCG GGA CTG GTG ACG G 
S segment EcoRI insertion Forward TCG TCC GAA TTC TCT CGC TGA TGT 
TGT GAG G 
S segment NotI insertion Forward TGC TGC GGC CGC ATG GAG AAC AAG 
ATT GTT GC 
S segment EcoRI deletion Forward ATG GTG AGC GGC GAG 
S segment EcoRI deletion Reverse TCT CGC TGA TGT TGT GAG G 
180 
 
S segment NotI deletion Forward ATG GAG AAC AAG ATT GTT GC 
S segment NotI deletion Reverse CGG TCC AGG GTT CTC TTC 
S segment DQVE substitution Forward GTC AAA GAG AAC AAA GAC CAA GTC 
GAA CAA GAC AAG GCA 
S segment DQVE substitution Reverse  
S segment ENKE substitution Forward GTC AAA GAG AAC AAA GAA CAA GTC 
GAC CAA G 
S segment ENKE substitution Reverse  
S segment AQVA substitution Forward AGA CCA AGT CGC CCA AGA CAA GG 
S segment AQVA substitution Reverse TTG TTC TCT TTG ACC CAT CC 
S segment DVMA substitution Forward AGA CGT GAT GGC CAA GGC CAA GG 
S segment DVMA substitution Reverse TTC CCC TCT AGC TCA ACC 
S segment LFAA substitution Forward ACT GTT TGC TAA CGA CTT CAC 
S segment LFAA substitution Reverse TCA ATG AGC CTT TTT CCC 
181 
 




Full Gene Name Sense siRNA Sequence Antisense siRNA Sequence 
AP2A1 adaptor-related protein complex 2, alpha 1 subunit GGCGGAAAUUAAGAGAAUCtt GAUUCUCUUAAUUUCCGCCtc 
AP2A2 adaptor-related protein complex 2, alpha 2 subunit CCACUUUAGCACAGAAGAAtt UUCUUCUGUGCUAAAGUGGtg 
AP1B1 adaptor-related protein complex 1, beta 1 subunit GCUUAUCUGCUACAUCGGCtt GCCGAUGUAGCAGAUAAGCtc 
AP2B1 adaptor-related protein complex 2, beta 1 subunit GCGGUAAAAGUCCUAAUGAtt UCAUUAGGACUUUUACCGCtg 
AP1G1 adaptor-related protein complex 1, gamma 1 subunit CGGCGUGCAAUGGAAUUGAtt UCAAUUCCAUUGCACGCCGtt 
ARF1 ADP-ribosylation factor 1 GGAACUGGUACAUUCAGGCtt GCCUGAAUGUACCAGUUCCtg 
CACNA1A calcium channel, voltage-dependent, P/Q type, 
alpha 1A subunit 
GGCGGCAACAACAGAUUGAtt UCAAUCUGUUGUUGCCGCCtc 
CACNA1B calcium channel, voltage-dependent, N type, alpha 
1B subunit 
GUGGCCUCCAUUCGAGUAUtt AUACUCGAAUGGAGGCCACtc 
CACNA1C calcium channel, voltage-dependent, L type, alpha 
1C subunit 
GGAGCACAUUCGAUAACUUtt AAGUUAUCGAAUGUGCUCCtc 
CACNA1D calcium channel, voltage-dependent, L type, alpha 
1D subunit 
GGACCAACUUCUCAGCCGAtt UCGGCUGAGAAGUUGGUCCtt 





CACNA1F calcium channel, voltage-dependent, L type, alpha 
1F subunit 
GGAUCUUUAAGGUCACCAGtt CUGGUGACCUUAAAGAUCCtg 
CACNA1S calcium channel, voltage-dependent, L type, alpha 
1S subunit 
GGGUCUCCCAGACAAGUCAtt UGACUUGUCUGGGAGACCCtt 
CAV1 caveolin 1, caveolae protein, 22kDa GGGACACACAGUUUUGACGtt CGUCAAAACUGUGUGUCCCtt 
CAV2 caveolin 2 GCACACAACGAUUAUAGUAtt UACUAUAAUCGUUGUGUGCtt 
CAV3 caveolin 3 GGAGAUGUGACGAAGGAACtt GUUCCUUCGUCACAUCUCCtg 
CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, 
p16, inhibits CDK4) 
CGUAGAUAUAUGCCUUCCCtt GGGAAGGCAUAUAUCUACGtt 
LYST lysosomal trafficking regulator CCUACCGCUCUCAGCAGAUtt AUCUGCUGAGAGCGGUAGGtt 
AP2M1 adaptor-related protein complex 2, mu 1 subunit GGAAAACAUCAAGAACAAUtt AUUGUUCUUGAUGUUUUCCtc 
AP1S1 adaptor-related protein complex 1, sigma 1 subunit CAAGGAACGGAAGAAGAUGtt CAUCUUCUUCCGUUCCUUGtc 
AP2S1 adaptor-related protein complex 2, sigma 1 subunit GGUCUUAAACGAAUAUUUCtt GAAAUAUUCGUUUAAGACCtc 
AP3S1 adaptor-related protein complex 3, sigma 1 subunit GGUAACUGGACUUCUAAAGtt CUUUAGAAGUCCAGUUACCtt 
CLTA clathrin, light chain (Lca) GGAAAGUAAUGGUCCAACAtt UGUUGGACCAUUACUUUCCtg 
CLTB clathrin, light chain B GGUCACGGAACAGGAAUGGtt CCAUUCCUGUUCCGUGACCtt 
CLTC clathrin, heavy chain (Hc) GCCACAGCUGGAAUAAUUGtt CAAUUAUUCCAGCUGUGGCtt 
COPA coatomer protein complex, subunit alpha GGCAUUGACUUCCAUAAGCtt GCUUAUGGAAGUCAAUGCCtc 
COPB1 coatomer protein complex, subunit beta 1 CCAACAUGGUUGAUUUAAAtt UUUAAAUCAACCAUGUUGGtg 
DNM1 dynamin 1 GGGAAAGAAAUUCACCGACtt GUCGGUGAAUUUCUUUCCCtt 
DNM2 dynamin 2 GCUCAUCUUCUCAAAAACAtt UGUUUUUGAGAAGAUGAGCtg 
183 
 
ENG endoglin (Osler-Rendu-Weber syndrome 1) GGUGUCAGCAAGUAUGAUCtt GAUCAUACUUGCUGACACCtg 
STX2 syntaxin 2 GGUGGAGGAGAUUAGAAACtt GUUUCUAAUCUCCUCCACCtg 
HPS1 Hermansky-Pudlak syndrome 1 CGGAAAAUGGCAACUUCCUtt AGGAAGUUGCCAUUUUCCGtg 
HSPA8 heat shock 70kDa protein 8 CGGAAAAGUCGAGAUAAUUtt AAUUAUCUCGACUUUUCCGtg 
ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of 
VLA-3 receptor) 
GGAGAUGCCACUUCUCACUtt AGUGAGAAGUGGCAUCUCCtc 
LMAN1 lectin, mannose-binding, 1 GGACAGAAUCGUAUUCAUCtt GAUGAAUACGAUUCUGUCCtt 
RAB3A RAB3A, member RAS oncogene family GGUCAAGACCAUCUAUCGCtt GCGAUAGAUGGUCUUGACCtt 
RASA1 RAS p21 protein activator (GTPase activating 
protein) 1 
GGCGUGUACGAGCUAUUCUtt AGAAUAGCUCGUACACGCCtt 
SNAP25 synaptosomal-associated protein, 25kDa GGGUAACAAAUGAUGCCCGtt CGGGCAUCAUUUGUUACCCtg 
STX1A syntaxin 1A (brain) GGUCAUGUCGGAGUACAACtt GUUGUACUCCGACAUGACCtc 
STX3 syntaxin 3 CGGCUUUUAUGGACGAGUUtt AACUCGUCCAUAAAAGCCGtg 
STX4 syntaxin 4 GCAGCUUGAACGCAGUAUUtt AAUACUGCGUUCAAGCUGCtg 
STX5 syntaxin 5 GGACAUCAAUAGCCUCAACtt GUUGAGGCUAUUGAUGUCCtg 
STXBP1 syntaxin binding protein 1 GGCUAUGAGUUAUGAUCUGtt CAGAUCAUAACUCAUAGCCtg 
STXBP2 syntaxin binding protein 2 GGUGCUUAUCAUGGAUCACtt GUGAUCCAUGAUAAGCACCtt 
STXBP3 syntaxin binding protein 3 GGUGUAUACUCUUGAUGUAtt UACAUCAAGAGUAUACACCtg 





VAMP2 vesicle-associated membrane protein 2 
(synaptobrevin 2) 
GCAUGUUAAUUAGCGUAUCtt GAUACGCUAAUUAACAUGCtg 
VAMP7 vesicle-associated membrane protein 7 GGUGACAGAGCAGAUUCUGtt CAGAAUCUGCUCUGUCACCtc 
SYT1 synaptotagmin I GCCAUGCAUUCCUAACACAtt UGUGUUAGGAAUGCAUGGCtg 
SYT4 synaptotagmin IV GGGAGUUGAUAUUUACCCUtt AGGGUAAAUAUCAACUCCCtt 
SYT5 synaptotagmin V GGUGCAGCCAGAAGUAGAGtt CUCUACUUCUGGCUGCACCtt 
AP3B2 adaptor-related protein complex 3, beta 2 subunit CGCCAUCCCUAAACUCUACtt GUAGAGUUUAGGGAUGGCGtg 
STX7 syntaxin 7 CCUGAAUUGAGGCAACAGUtt ACUGUUGCCUCAAUUCAGGtg 
AP3B1 adaptor-related protein complex 3, beta 1 subunit GGGAAAAAUGCAUCUGAACtt GUUCAGAUGCAUUUUUCCCtt 
VAMP8 vesicle-associated membrane protein 8 
(endobrevin) 
GGAUCUGGAAGCCACAUCUtt AGAUGUGGCUUCCAGAUCCtc 
VAMP4 vesicle-associated membrane protein 4 GGACAAAUCAGAAAGCUUAtt UAAGCUUUCUGAUUUGUCCtg 
STX16 syntaxin 16 GAAGCUGUUCAGUAUUAUAtt UAUAAUACUGAACAGCUUCtg 
STX11 syntaxin 11 GGAUGAAAACCAGCUGCUGtt CAGCAGCUGGUUUUCAUCCtg 
STX10 syntaxin 10 CCAUCGGUAUAGUGGAAGCtt GCUUCCACUAUACCGAUGGtc 
GBF1 golgi brefeldin A resistant guanine nucleotide 
exchange factor 1 
GCCCAAUGUAUUCCUUCGAtt UCGAAGGAAUACAUUGGGCtc 
SNAP23 synaptosomal-associated protein, 23kDa CCAACAGAGAUCGUAUUGAtt UCAAUACGAUCUCUGUUGGtg 
AP1S2 adaptor-related protein complex 1, sigma 2 subunit GCACUGUCUUAUCACAUCGtt CGAUGUGAUAAGACAGUGCtc 
AP1G2 adaptor-related protein complex 1, gamma 2 subunit GCCUGGCUCUGGUAAAUAGtt CUAUUUACCAGAGCCAGGCtt 
AP1M1 adaptor-related protein complex 1, mu 1 subunit GCCUUUGAUAUGGAUCGAGtt CUCGAUCCAUAUCAAAGGCtt 
185 
 
CACNA1I calcium channel, voltage-dependent, T type, alpha 
1I subunit 
GGAGCAGACAGCAAUACUUtt AAGUAUUGCUGUCUGCUCCtg 
CACNA1H calcium channel, voltage-dependent, T type, alpha 
1H subunit 
GUGCCUUUGUCAGGAACAAtt UUGUUCCUGACAAAGGCACtg 
CACNA1G calcium channel, voltage-dependent, T type, alpha 
1G subunit 
CCGAUGCUUCCUACCUGAGtt CUCAGGUAGGAAGCAUCGGtt 
AP3D1 adaptor-related protein complex 3, delta 1 subunit CCUUCAAGCGAAUUGGCUAtt UAGCCAAUUCGCUUGAAGGtg 
SYT7 synaptotagmin VII CGAGACCUUCCUCUUUGAAtt UUCAAAGAGGAAGGUCUCGtt 
AP4M1 adaptor-related protein complex 4, mu 1 subunit AUCCGGGUCGAUGAAGUCUtt AGACUUCAUCGACCCGGAUtc 
VAPB VAMP (vesicle-associated membrane protein)-
associated protein B and C 
GGGAAACCAUGAGUAAUGCtt GCAUUACUCAUGGUUUCCCtt 
COPB2 coatomer protein complex, subunit beta 2 (beta 
prime) 
GCGGAUGACAUGCAGAUUAtt UAAUCUGCAUGUCAUCCGCtc 
VAMP3 vesicle-associated membrane protein 3 GGUGGUGGACAUAAUGCGAtt UCGCAUUAUGUCCACCACCtc 
SNAP29 synaptosomal-associated protein, 29kDa CCCACACCUUCGAGCCUAUtt AUAGGCUCGAAGGUGUGGGtt 
STX8 syntaxin 8 CCUCUUGGAUGAUCUUGUAtt UACAAGAUCAUCCAAGAGGtt 
RGS6 regulator of G-protein signaling 6 GGUACUGACAUUGUGCAGUtt ACUGCACAAUGUCAGUACCtg 
RICS Rho GTPase-activating protein GGUUCUUCAAAGCUGCACAtt UGUGCAGCUUUGAAGAACCtg 
IQSEC1 IQ motif and Sec7 domain 1 GCAAGUCUGAGUCGGACUAtt UAGUCCGACUCAGACUUGCtc 
AP1M2 adaptor-related protein complex 1, mu 2 subunit GCGAAAUCGUCGGUACCAUtt AUGGUACCGACGAUUUCGCtc 
HUWE1 HECT, UBA and WWE domain containing 1 GCAAUGGCUGCCAGAAUUAtt UAAUUCUGGCAGCCAUUGCtg 
186 
 
PREB prolactin regulatory element binding GGCAUAAAGAAUGGCGUGCtt GCACGCCAUUCUUUAUGCCtg 
M6PRBP1 mannose-6-phosphate receptor binding protein 1 GGCUCUCAAAACGGGCAUCtt GAUGCCCGUUUUGAGAGCCtt 
STX6 syntaxin 6 GCCUUCAUUACAAGUACUCtt GAGUACUUGUAAUGAAGGCtt 
AP3S2 adaptor-related protein complex 3, sigma 2 subunit CCUGGAAACUUUGUGUCUGtt CAGACACAAAGUUUCCAGGtc 
SEC24B SEC24 related gene family, member B (S. 
cerevisiae) 
GCUCUUCUGUUGCGUCUCAtt UGAGACGCAACAGAAGAGCtg 
SEC23A Sec23 homolog A (S. cerevisiae) GGAAUCAGUUUCCACCUAGtt CUAGGUGGAAACUGAUUCCtt 
AP4B1 adaptor-related protein complex 4, beta 1 subunit GCGAGUGAUUAGGUACAUGtt CAUGUACCUAAUCACUCGCtg 
EHD1 EH-domain containing 1 GGUCCAUAAAGACUGAGCGtt CGCUCAGUCUUUAUGGACCtt 
AP3M2 adaptor-related protein complex 3, mu 2 subunit GCCAGUGAUCAAAGACAAUtt AUUGUCUUUGAUCACUGGCtc 
AP4S1 adaptor-related protein complex 4, sigma 1 subunit CGAGAUGGCUAUUUAUGAAtt UUCAUAAAUAGCCAUCUCGtt 
HPS5 Hermansky-Pudlak syndrome 5 GCAUAGCUGUGUCUCGGAAtt UUCCGAGACACAGCUAUGCtc 
AP1GBP1 AP1 gamma subunit binding protein 1 GCUCCUAUUCCAACUUUAAtt UUAAAGUUGGAAUAGGAGCtg 
COPE coatomer protein complex, subunit epsilon GGAGCUGAAGAGAAUGCAGtt CUGCAUUCUCUUCAGCUCCtt 
COPZ1 coatomer protein complex, subunit zeta 1 GCAUAUUUAGAUAAUAGGGtt CCCUAUUAUCUAAAUAUGCtg 
COPG1 coatomer protein complex, subunit gamma 1 GGAGAUGUCUUGCAUUGCAtt UGCAAUGCAAGACAUCUCCtt 
SEC31A SEC31 homolog A (S. cerevisiae) GAUGAGCACCUCAUUCUAAtt UUAGAAUGAGGUGCUCAUCtg 
SYT11 synaptotagmin XI GGUGGACGUAGGAACCUGUtt ACAGGUUCCUACGUCCACCtt 
AP4E1 adaptor-related protein complex 4, epsilon 1 subunit GCUGUUCUGGCAUUAUACAtt UGUAUAAUGCCAGAACAGCtt 
STX12 syntaxin 12 CCUAUGGAGACAGUAAUUAtt UAAUUACUGUCUCCAUAGGtc 
DNM3 dynamin 3 GGGACAGUUGCUCUCCAUAtt UAUGGAGAGCAACUGUCCCtg 
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VPS33B vacuolar protein sorting 33 homolog B (yeast) GCAACACGAAGUAGACAAGtt CUUGUCUACUUCGUGUUGCtt 
COPG2 coatomer protein complex, subunit gamma 2 CCAGGGUGAACACUUUGGAtt UCCAAAGUGUUCACCCUGGtt 
AP3M1 adaptor-related protein complex 3, mu 1 subunit GGAAUUACAGUGACAGUUCtt GAACUGUCACUGUAAUUCCtt 
STXBP6 syntaxin binding protein 6 (amisyn) GGUCAAGGCGAAUAUUUAAtt UUAAAUAUUCGCCUUGACCtc 
RACGAP1 Rac GTPase activating protein 1 GGACUUUGAGGAUUUCCGUtt ACGGAAAUCCUCAAAGUCCtt 
EHD4 EH-domain containing 4 GGGAAUGCUUUAGUCGUGGtt CCACGACUAAAGCAUUCCCtg 
EHD3 EH-domain containing 3 CCUCAUACUAUUCUCAGAAtt UUCUGAGAAUAGUAUGAGGtc 
EHD2 EH-domain containing 2 CCAUUCCAUAUUUAAGUGGtt CCACUUAAAUAUGGAAUGGtg 
SAR1B SAR1 homolog B (S. cerevisiae) GGAAAAACAACAUUGCUACtt GUAGCAAUGUUGUUUUUCCtg 
COPZ2 coatomer protein complex, subunit zeta 2 CCUCUUCCUAUACGUGGUGtt CACCACGUAUAGGAAGAGGtc 
SYT17 synaptotagmin XVII GGAUUUCGAGUCUUGAGUCtt GACUCAAGACUCGAAAUCCtc 
STX18 syntaxin 18 GCGACUAAUUGGUGAAAUGtt CAUUUCACCAAUUAGUCGCtg 
STX17 syntaxin 17 GGAUGACCUAGUACUUCUGtt CAGAAGUACUAGGUCAUCCtt 
C4orf16 chromosome 4 open reading frame 16 GGCAUUAUGAUUCCAUUGCtt GCAAUGGAAUCAUAAUGCCtt 
SAR1A SAR1 gene homolog A (S. cerevisiae) GGCAAAACCACUCUUCUUCtt GAAGAAGAGUGGUUUUGCCtg 
FAM62B family with sequence similarity 62 (C2 domain 
containing) member B 
CCCACCUUAGCACCUUUAGtt CUAAAGGUGCUAAGGUGGGtg 
SYT13 synaptotagmin XIII GGAGAGUUGUCUGUUAUGUtt ACAUAACAGACAACUCUCCtt 
TBC1D15 TBC1 domain family, member 15 CCAAUGACCAAGACGGCUUtt AAGCCGUCUUGGUCAUUGGtc 
ARHGAP10 Rho GTPase activating protein 10 GGCAGUCGAAGAGACAAGGtt CCUUGUCUCUUCGACUGCCtt 
HPS6 Hermansky-Pudlak syndrome 6 CGUUCUACUCAUCUGGAGCtt GCUCCAGAUGAGUAGAACGtg 
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PTGES2 prostaglandin E synthase 2 CCGAGUUCGGCAAUAAGUAtt UACUUAUUGCCGAACUCGGtc 
SYT15 synaptotagmin XV GGCAUUGUCAGUGUGUUUGtt CAAACACACUGACAAUGCCtc 
FAM62C family with sequence similarity 62 (C2 domain 
containing), member C 
CGGUGUCAAGGCACACACUtt AGUGUGUGCCUUGACACCGtt 
SYT16 synaptotagmin XVI GGAGAUAUGUUAUCUGCUUtt AAGCAGAUAACAUAUCUCCtg 
DTNBP1 dystrobrevin binding protein 1 GGCGAGUUUUGAGGAGGUAtt UACCUCCUCAAAACUCGCCtc 
SYT3 synaptotagmin III CGUUUCAAUUCUCGGUGCCtt GGCACCGAGAAUUGAAACGtc 
HPS3 Hermansky-Pudlak syndrome 3 GCGAGGCUGGAGAUUAUUUtt AAAUAAUCUCCAGCCUCGCtg 
HPS4 Hermansky-Pudlak syndrome 4 GCUAGUUGGAUUCUUUAAUtt AUUAAAGAAUCCAACUAGCtg 
SYT8 synaptotagmin VIII CUCCUGAAUGCACCACAUGtt CAUGUGGUGCAUUCAGGAGtg 
SYT12 synaptotagmin XII GGUACCUUCAGCAGAAGUAtt UACUUCUGCUGAAGGUACCtg 
STX1B syntaxin 1B GGUUCGGUCCAAAUUGAAAtt UUUCAAUUUGGACCGAACCtt 
SNX26 sorting nexin 26 GGCAACAAAGUGAUGGGAGtt CUCCCAUCACUUUGUUGCCtt 
SYT2 synaptotagmin II GAGUCAGGAGGACAUGUUUtt AAACAUGUCCUCCUGACUCtc 
AP1S3 adaptor-related protein complex 1, sigma 3 subunit AUAGAAAAUCAGGACAAUGtt CAUUGUCCUGAUUUUCUAUtg 
STXBP5 syntaxin binding protein 5 (tomosyn) GGCUACGUCAUUAUGUGGAtt UCCACAUAAUGACGUAGCCtg 
SYT9 synaptotagmin IX GGAUCGUUAUACGUCUUCAtt UGAAGACGUAUAACGAUCCtt 
SYT6 synaptotagmin VI CCCUGAUUGUGCGUAUCCUtt AGGAUACGCACAAUCAGGGtc 
VPS13B vacuolar protein sorting 13 homolog B (yeast) GCUCGAGUUAAAGUUGGAUtt AUCCAACUUUAACUCGAGCtt 
STXBP4 syntaxin binding protein 4 GCCCUGAGACAGCAAGUACtt GUACUUGCUGUCUCAGGGCtt 
SYT14 synaptotagmin XIV CCACCAUAUCAGGAUGACAtt UGUCAUCCUGAUAUGGUGGtg 
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SYT10 synaptotagmin X GCAAACCUGUGACUUCCAAtt UUGGAAGUCACAGGUUUGCtt 
STX19 syntaxin 19 GCAAGCUGUUAUUUAUGAAtt UUCAUAAAUAACAGCUUGCtg 
AP2A1 adaptor-related protein complex 2, alpha 1 subunit GGAGACAAAGCCUUGGAUGtt CAUCCAAGGCUUUGUCUCCtt 
AP2A2 adaptor-related protein complex 2, alpha 2 subunit GGCCAUCAGCUUAAUCAUUtt AAUGAUUAAGCUGAUGGCCtc 
AP1B1 adaptor-related protein complex 1, beta 1 subunit GGACGAGGAUCCAUAUGUGtt CACAUAUGGAUCCUCGUCCtt 
AP2B1 adaptor-related protein complex 2, beta 1 subunit GGACUGUGAAGAUCCUAAUtt AUUAGGAUCUUCACAGUCCtt 
AP1G1 adaptor-related protein complex 1, gamma 1 subunit GGCCAAUGAUUUAUUGGAUtt AUCCAAUAAAUCAUUGGCCtg 
ARF1 ADP-ribosylation factor 1 GGCAGUUUCUGGUACUCCUtt AGGAGUACCAGAAACUGCCtc 
CACNA1A calcium channel, voltage-dependent, P/Q type, 
alpha 1A subunit 
GGAUGCGUUUCUACAUCCGtt CGGAUGUAGAAACGCAUCCtc 
CACNA1B calcium channel, voltage-dependent, N type, alpha 
1B subunit 
GGCAGGGAUCAAAAUCAUCtt GAUGAUUUUGAUCCCUGCCtc 
CACNA1C calcium channel, voltage-dependent, L type, alpha 
1C subunit 
GGAUGACGAAAAUCGGCAAtt UUGCCGAUUUUCGUCAUCCtg 
CACNA1D calcium channel, voltage-dependent, L type, alpha 
1D subunit 
GGCAAACGAAAUACUAGCAtt UGCUAGUAUUUCGUUUGCCtt 
CACNA1E calcium channel, voltage-dependent, R type, alpha 
1E subunit 
GGCAAGGAGUCCUCUUCAGtt CUGAAGAGGACUCCUUGCCtt 





CACNA1S calcium channel, voltage-dependent, L type, alpha 
1S subunit 
GGUGCUACAUUCCCAAAAAtt UUUUUGGGAAUGUAGCACCtc 
CAV1 caveolin 1, caveolae protein, 22kDa CGAAAUACUGGUUUUACCGtt CGGUAAAACCAGUAUUUCGtc 
CAV2 caveolin 2 GGAUUGAAUACUUGGACCCtt GGGUCCAAGUAUUCAAUCCtg 
CAV3 caveolin 3 CGAAGGAACAAGGUCUAAUtt AUUAGACCUUGUUCCUUCGtc 
CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, 
p16, inhibits CDK4) 
CCAGAGAGGCUCUGAGAAAtt UUUCUCAGAGCCUCUCUGGtt 
LYST lysosomal trafficking regulator GCAGACGACAGCGUAAAAUtt AUUUUACGCUGUCGUCUGCtt 
AP2M1 adaptor-related protein complex 2, mu 1 subunit GGCACAGCUGAUGAAACAAtt UUGUUUCAUCAGCUGUGCCtt 
AP1S1 adaptor-related protein complex 1, sigma 1 subunit GGAACGGAAGAAGAUGGUGtt CACCAUCUUCUUCCGUUCCtt 
AP2S1 adaptor-related protein complex 2, sigma 1 subunit GGUUUACACGGUCGUGGACtt GUCCACGACCGUGUAAACCtt 
AP3S1 adaptor-related protein complex 3, sigma 1 subunit CCAUGCAGUUGUUUACCAAtt UUGGUAAACAACUGCAUGGta 
CLTA clathrin, light chain (Lca) GGAGCUAGAAGAAUGGUAUtt AUACCAUUCUUCUAGCUCCtt 
CLTB clathrin, light chain B GGCUUUCGUGAAGGAAUCCtt GGAUUCCUUCACGAAAGCCtc 
CLTC clathrin, heavy chain (Hc) GGUGGUAAUCAUUGAUAUGtt CAUAUCAAUGAUUACCACCtg 
COPA coatomer protein complex, subunit alpha CCUUGGAUCCUGACUAGUUtt AACUAGUCAGGAUCCAAGGtc 
COPB1 coatomer protein complex, subunit beta 1 GGAUCACACUAUCAAGAAAtt UUUCUUGAUAGUGUGAUCCtg 
DNM1 dynamin 1 GGUCAUGCUUCUCAUCGAUtt AUCGAUGAGAAGCAUGACCtg 
DNM2 dynamin 2 GCAGUCCUACAUCAACACGtt CGUGUUGAUGUAGGACUGCtc 
ENG endoglin (Osler-Rendu-Weber syndrome 1) GGUGACAUAUACCACUAGCtt GCUAGUGGUAUAUGUCACCtc 
STX2 syntaxin 2 GGAGAUUAGAAACAGUAUUtt AAUACUGUUUCUAAUCUCCtc 
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HPS1 Hermansky-Pudlak syndrome 1 GGUCCUCUUCUACUGGACAtt UGUCCAGUAGAAGAGGACCtc 
HSPA8 heat shock 70kDa protein 8 CCUAAAUUCGUAGCAAAUUtt AAUUUGCUACGAAUUUAGGtc 
ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of 
VLA-3 receptor) 
CGAGAUGUGCAAUAGCAACtt GUUGCUAUUGCACAUCUCGtt 
LMAN1 lectin, mannose-binding, 1 GGAAAUCUCUAAAAGAGGAtt UCCUCUUUUAGAGAUUUCCtc 
RAB3A RAB3A, member RAS oncogene family GGAAUCCUUCAAUGCAGUGtt CACUGCAUUGAAGGAUUCCtc 
RASA1 RAS p21 protein activator (GTPase activating 
protein) 1 
CCUAAUAGGUUAUUACAGUtt ACUGUAAUAACCUAUUAGGtc 
SNAP25 synaptosomal-associated protein, 25kDa GGUUGUACAUAGUGGUCAUtt AUGACCACUAUGUACAACCtt 
STX1A syntaxin 1A (brain) CCAAAGGUCUUGGUACAACtt GUUGUACCAAGACCUUUGGtg 
STX3 syntaxin 3 GCGGCAGCUCGAAAUUACUtt AGUAAUUUCGAGCUGCCGCtg 
STX4 syntaxin 4 CGCAGUAUUCGUGAGCUGCtt GCAGCUCACGAAUACUGCGtt 
STX5 syntaxin 5 GCGCAAGUCCCUCUUUGAUtt AUCAAAGAGGGACUUGCGCtt 
STXBP1 syntaxin binding protein 1 GGACUGUAUGAAGCAUUACtt GUAAUGCUUCAUACAGUCCtc 
STXBP2 syntaxin binding protein 2 GGGCAUCACCAUUGUUGAAtt UUCAACAAUGGUGAUGCCCtc 
STXBP3 syntaxin binding protein 3 GGGUAAAACUCAUUCACAGtt CUGUGAAUGAGUUUUACCCtt 
VAMP1 vesicle-associated membrane protein 1 
(synaptobrevin 1) 
GGAGGUGGUGGACAUCAUAtt UAUGAUGUCCACCACCUCCtc 
VAMP2 vesicle-associated membrane protein 2 
(synaptobrevin 2) 
CCUCUUGUACCCUCCUCUCtt GAGAGGAGGGUACAAGAGGtt 
VAMP7 vesicle-associated membrane protein 7 UGAGAGAACAAGGAGUUAAtt UUAACUCCUUGUUCUCUCAta 
192 
 
SYT1 synaptotagmin I GGAAAGGAAGAUGCAUUUUtt AAAAUGCAUCUUCCUUUCCtt 
SYT4 synaptotagmin IV GGUUUUCAAGAGAUGAUAUtt AUAUCAUCUCUUGAAAACCtg 
SYT5 synaptotagmin V GGCCAAAUAAAUAUUCAGCtt GCUGAAUAUUUAUUUGGCCtc 
AP3B2 adaptor-related protein complex 3, beta 2 subunit GGAGAUGCUGGACACCAACtt GUUGGUGUCCAGCAUCUCCtt 
STX7 syntaxin 7 GCAGCAGUAUACUAACCAGtt CUGGUUAGUAUACUGCUGCtt 
AP3B1 adaptor-related protein complex 3, beta 1 subunit GGACCCAAACCAACUAAUUtt AAUUAGUUGGUUUGGGUCCtt 
VAMP8 vesicle-associated membrane protein 8 
(endobrevin) 
GGGACAACCCUCCAUAAAUtt AUUUAUGGAGGGUUGUCCCtg 
VAMP4 vesicle-associated membrane protein 4 GCUUAUCGGAUAAUGCAACtt GUUGCAUUAUCCGAUAAGCtt 
STX16 syntaxin 16 GCAGAAGAUGAAAGAAUUGtt CAAUUCUUUCAUCUUCUGCtt 
STX11 syntaxin 11 CGUGUUUUCCGAGAACUUGtt CAAGUUCUCGGAAAACACGtc 
STX10 syntaxin 10 GGACCAUAUGGUCAGCCCAtt UGGGCUGACCAUAUGGUCCtt 
GBF1 golgi brefeldin A resistant guanine nucleotide 
exchange factor 1 
CCACCUUAUCAUCUAACCUtt AGGUUAGAUGAUAAGGUGGtt 
SNAP23 synaptosomal-associated protein, 23kDa GGAAUCAAGACCAUCACUAtt UAGUGAUGGUCUUGAUUCCtg 
AP1S2 adaptor-related protein complex 1, sigma 2 subunit GGUCAGUUUCUCUUAAUCUtt AGAUUAAGAGAAACUGACCtt 
AP1G2 adaptor-related protein complex 1, gamma 2 subunit GGUUUGCUCCAACCAAACGtt CGUUUGGUUGGAGCAAACCtc 
AP1M1 adaptor-related protein complex 1, mu 1 subunit GGUGGUGCAGGUGUUUUCCtt GGAAAACACCUGCACCACCtt 





CACNA1H calcium channel, voltage-dependent, T type, alpha 
1H subunit 
GGCUGGAUUUCUUCAUCGUtt ACGAUGAAGAAAUCCAGCCtg 
CACNA1G calcium channel, voltage-dependent, T type, alpha 
1G subunit 
GGAGAAGGCACUAGUAGAGtt CUCUACUAGUGCCUUCUCCtt 
AP3D1 adaptor-related protein complex 3, delta 1 subunit GGAUAUUGAUCGAGGACUCtt GAGUCCUCGAUCAAUAUCCtt 
SYT7 synaptotagmin VII GGAACAUCAUACAUAGUAGtt CUACUAUGUAUGAUGUUCCtc 
AP4M1 adaptor-related protein complex 4, mu 1 subunit CUAUGGCUAUGUACAGACCtt GGUCUGUACAUAGCCAUAGtc 
VAPB VAMP (vesicle-associated membrane protein)-
associated protein B and C 
CCGGAAGACCUUAUGGAUUtt AAUCCAUAAGGUCUUCCGGtt 
COPB2 coatomer protein complex, subunit beta 2 (beta 
prime) 
GCCUUUCAUUCUAACUAGCtt GCUAGUUAGAAUGAAAGGCtg 
VAMP3 vesicle-associated membrane protein 3 GGAAAUAUUGGUGGAAGAAtt UUCUUCCACCAAUAUUUCCtc 
SNAP29 synaptosomal-associated protein, 29kDa GCCUAUCACCAGAAGAUCGtt CGAUCUUCUGGUGAUAGGCtc 
STX8 syntaxin 8 CCUGCUCUCAAUAAAUUCCtt GGAAUUUAUUGAGAGCAGGtt 
RGS6 regulator of G-protein signaling 6 GGACCCAGUUGAAGCAAUAtt UAUUGCUUCAACUGGGUCCtc 
RICS Rho GTPase-activating protein GGACAUCCAUUCUGUGGGUtt ACCCACAGAAUGGAUGUCCtg 
IQSEC1 IQ motif and Sec7 domain 1 GGUCUCAGUGACUAACGACtt GUCGUUAGUCACUGAGACCtg 
AP1M2 adaptor-related protein complex 1, mu 2 subunit GGUCCACUUCCUAUGGAUCtt GAUCCAUAGGAAGUGGACCtg 
HUWE1 HECT, UBA and WWE domain containing 1 GAAUUAAGCAAAUCAAGCCtt GGCUUGAUUUGCUUAAUUCtg 
PREB prolactin regulatory element binding GCUGGCCUAAAGAUGCAAUtt AUUGCAUCUUUAGGCCAGCtg 
M6PRBP1 mannose-6-phosphate receptor binding protein 1 CCCUAUCAGUCAGUAGAGAtt UCUCUACUGACUGAUAGGGtg 
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STX6 syntaxin 6 GGCAUUAGCUGAAAGAAAAtt UUUUCUUUCAGCUAAUGCCtg 
AP3S2 adaptor-related protein complex 3, sigma 2 subunit GGGUUAGGGACUGCAUUGAtt UCAAUGCAGUCCCUAACCCtt 
SEC24B SEC24 related gene family, member B (S. 
cerevisiae) 
GGGAUUUCCCUCUACUUGUtt ACAAGUAGAGGGAAAUCCCtg 
SEC23A Sec23 homolog A (S. cerevisiae) GGUUCAUGAACUUGGAUGUtt ACAUCCAAGUUCAUGAACCtg 
AP4B1 adaptor-related protein complex 4, beta 1 subunit GCACUUAUUUGGCUACUUGtt CAAGUAGCCAAAUAAGUGCtt 
EHD1 EH-domain containing 1 GGCUCUGAAGAACCAUGAGtt CUCAUGGUUCUUCAGAGCCtt 
AP3M2 adaptor-related protein complex 3, mu 2 subunit GCCUCCUACCAUCCUUCGAtt UCGAAGGAUGGUAGGAGGCtt 
AP4S1 adaptor-related protein complex 4, sigma 1 subunit GGAACCAAUUGAUGAACUUtt AAGUUCAUCAAUUGGUUCCtg 
HPS5 Hermansky-Pudlak syndrome 5 GCCCUGAUCUGAAAGUGAGtt CUCACUUUCAGAUCAGGGCtc 
AP1GBP1 AP1 gamma subunit binding protein 1 GCCGAUAGUGUAUCACCACtt GUGGUGAUACACUAUCGGCtg 
COPE coatomer protein complex, subunit epsilon GGAGAACGACUUUGACAGGtt CCUGUCAAAGUCGUUCUCCtt 
COPZ1 coatomer protein complex, subunit zeta 1 GCCAGUUCCUAAAACUAAAtt UUUAGUUUUAGGAACUGGCtt 
COPG1 coatomer protein complex, subunit gamma 1 GCAGCCUAACAAAAGACAUtt AUGUCUUUUGUUAGGCUGCtg 
SEC31A SEC31 homolog A (S. cerevisiae) CAUUUGAGGAUCUUAUUCAtt UGAAUAAGAUCCUCAAAUGtg 
SYT11 synaptotagmin XI CCAUAUACUUGCAUGUCUAtt UAGACAUGCAAGUAUAUGGtt 
AP4E1 adaptor-related protein complex 4, epsilon 1 subunit GGAAGUUAUAGCUAAGCUCtt GAGCUUAGCUAUAACUUCCtc 
STX12 syntaxin 12 GGGUUGCUGGGCAUUUGAAtt UUCAAAUGCCCAGCAACCCtt 
DNM3 dynamin 3 GGUUACCAGUGAUUGUAUAtt UAUACAAUCACUGGUAACCtt 
VPS33B vacuolar protein sorting 33 homolog B (yeast) GCUAUACAAGGUGGAGAACtt GUUCUCCACCUUGUAUAGCtt 
COPG2 coatomer protein complex, subunit gamma 2 GGAUGGGUAUGAUGAUGAGtt CUCAUCAUCAUACCCAUCCtc 
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AP3M1 adaptor-related protein complex 3, mu 1 subunit GCCUCAACAUACAGUUUAAtt UUAAACUGUAUGUUGAGGCtc 
STXBP6 syntaxin binding protein 6 (amisyn) GGAGGACAAAGAAAAAGAUtt AUCUUUUUCUUUGUCCUCCtc 
RACGAP1 Rac GTPase activating protein 1 GGAUUUCCGUAAAAAGUGGtt CCACUUUUUACGGAAAUCCtc 
EHD4 EH-domain containing 4 GGAUCAUCCUGCUCUUUGAtt UCAAAGAGCAGGAUGAUCCtg 
EHD3 EH-domain containing 3 GGAACAGGACCUAUUCAGGtt CCUGAAUAGGUCCUGUUCCtc 
EHD2 EH-domain containing 2 GGAGAACAAGAAGAAGCAGtt CUGCUUCUUCUUGUUCUCCtt 
SAR1B SAR1 homolog B (S. cerevisiae) GGCUGUUAGAGUCAAAAGAtt UCUUUUGACUCUAACAGCCtt 
COPZ2 coatomer protein complex, subunit zeta 2 GGCUGUUUUCAUCCUAGAUtt AUCUAGGAUGAAAACAGCCtt 
SYT17 synaptotagmin XVII GCUGGUGCAUGGACUCAAAtt UUUGAGUCCAUGCACCAGCtg 
STX18 syntaxin 18 GGAUGACAGACACAGAACGtt CGUUCUGUGUCUGUCAUCCtc 
STX17 syntaxin 17 GGUCGACUACAUAAUGGAGtt CUCCAUUAUGUAGUCGACCtg 
C4orf16 chromosome 4 open reading frame 16 GCUUUAUACGCUGCACAGCtt GCUGUGCAGCGUAUAAAGCtt 
SAR1A SAR1 gene homolog A (S. cerevisiae) GGAAAGCUCUCCAACCAUGtt CAUGGUUGGAGAGCUUUCCtt 
FAM62B family with sequence similarity 62 (C2 domain 
containing) member B 
GGAUCAAUGGUGUUAAGGUtt ACCUUAACACCAUUGAUCCtg 
SYT13 synaptotagmin XIII GGAUGUCUGUGUCAUGGAGtt CUCCAUGACACAGACAUCCtc 
TBC1D15 TBC1 domain family, member 15 GGAUGCCGAAGUAAUAGUGtt CACUAUUACUUCGGCAUCCtt 
ARHGAP10 Rho GTPase activating protein 10 GGAUGUACAAACCUCCAGGtt CCUGGAGGUUUGUACAUCCtc 
HPS6 Hermansky-Pudlak syndrome 6 GGAAGGUCCUAAGUACAGAtt UCUGUACUUAGGACCUUCCtc 
PTGES2 prostaglandin E synthase 2 GGGCUGAGAUCAAGUUCUCtt GAGAACUUGAUCUCAGCCCtg 
SYT15 synaptotagmin XV CGAGCACUUCAUCUUUCAGtt CUGAAAGAUGAAGUGCUCGtc 
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FAM62C family with sequence similarity 62 (C2 domain 
containing), member C 
GGCACACACUAAUACGUGCtt GCACGUAUUAGUGUGUGCCtt 
SYT16 synaptotagmin XVI GGACUUAGAUAAUAUUCAGtt CUGAAUAUUAUCUAAGUCCtg 
DTNBP1 dystrobrevin binding protein 1 GGACUGUUCCAUUUUUGCCtt GGCAAAAAUGGAACAGUCCtg 
SYT3 synaptotagmin III GGAGUUCAAUGACCGAAUCtt GAUUCGGUCAUUGAACUCCtg 
HPS3 Hermansky-Pudlak syndrome 3 GCACCUGCUCUAUAGACGUtt ACGUCUAUAGAGCAGGUGCtg 
HPS4 Hermansky-Pudlak syndrome 4 GCCAUUAGUCUCCACGAGUtt ACUCGUGGAGACUAAUGGCtt 
SYT8 synaptotagmin VIII ACCAUGCAGGGUAGAAAGAtt UCUUUCUACCCUGCAUGGUtt 
SYT12 synaptotagmin XII GGCAGUCUCAGCAUUGAGGtt CCUCAAUGCUGAGACUGCCtt 
STX1B syntaxin 1B GGUAAUGACCGAAUAUAACtt GUUAUAUUCGGUCAUUACCtc 
SNX26 sorting nexin 26 GGGUCCUUGUACAGAAAUGtt CAUUUCUGUACAAGGACCCtc 
SYT2 synaptotagmin II GUCAGGAGGACAUGUUUGCtt GCAAACAUGUCCUCCUGACtc 
AP1S3 adaptor-related protein complex 1, sigma 3 subunit CAAGGGAAAUUACGGCUACtt GUAGCCGUAAUUUCCCUUGtc 
STXBP5 syntaxin binding protein 5 (tomosyn) GCCAUUGAACUGUCAUCUAtt UAGAUGACAGUUCAAUGGCtt 
SYT9 synaptotagmin IX GCUGCCAGGAUUUCAUUUAtt UAAAUGAAAUCCUGGCAGCtg 
SYT6 synaptotagmin VI GGCUAUUCAGAUCCCUAUGtt CAUAGGGAUCUGAAUAGCCtg 
VPS13B vacuolar protein sorting 13 homolog B (yeast) GGAACUGAAAUUACCAUUCtt GAAUGGUAAUUUCAGUUCCtg 
STXBP4 syntaxin binding protein 4 GGAUGGUCGUUUGAAGCCAtt UGGCUUCAAACGACCAUCCtt 
SYT14 synaptotagmin XIV CCUUGUUCUUCUACCUAUAtt UAUAGGUAGAAGAACAAGGtg 
SYT10 synaptotagmin X CGUGUGCAAAGACAAAUUAtt UAAUUUGUCUUUGCACACGtg 
STX19 syntaxin 19 GGAACUUGUUAAUUUGGAGtt CUCCAAAUUAACAAGUUCCtt 
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AP2A1 adaptor-related protein complex 2, alpha 1 subunit GGCUGUGAAUCUGUUGAGUtt ACUCAACAGAUUCACAGCCtc 
AP2A2 adaptor-related protein complex 2, alpha 2 subunit GCCACAAGUCUGAUCACCAtt UGGUGAUCAGACUUGUGGCtg 
AP1B1 adaptor-related protein complex 1, beta 1 subunit GGUGCUGAUGAAGUUCAUGtt CAUGAACUUCAUCAGCACCtt 
AP2B1 adaptor-related protein complex 2, beta 1 subunit GGAACAUCAACUUAAUUGUtt ACAAUUAAGUUGAUGUUCCtc 
AP1G1 adaptor-related protein complex 1, gamma 1 subunit GGAUUUUCCUAAAGUUACUtt AGUAACUUUAGGAAAAUCCtc 
ARF1 ADP-ribosylation factor 1 CCUCAGAACUGGUCUAUUUtt AAAUAGACCAGUUCUGAGGtt 
CACNA1A calcium channel, voltage-dependent, P/Q type, 
alpha 1A subunit 
GGCUGGAAUUAAAAUCAUUtt AAUGAUUUUAAUUCCAGCCtc 
CACNA1B calcium channel, voltage-dependent, N type, alpha 
1B subunit 
GGGAAGUUUUUCUACUGCAtt UGCAGUAGAAAAACUUCCCtt 
CACNA1C calcium channel, voltage-dependent, L type, alpha 
1C subunit 
GGAAGAAGAGUGUUUACAAtt UUGUAAACACUCUUCUUCCtc 
CACNA1D calcium channel, voltage-dependent, L type, alpha 
1D subunit 
GGACACUGCAUGACAUUGGtt CCAAUGUCAUGCAGUGUCCtt 
CACNA1E calcium channel, voltage-dependent, R type, alpha 
1E subunit 
GGUAUUUUGACUAUGUGUUtt AACACAUAGUCAAAAUACCtc 
CACNA1F calcium channel, voltage-dependent, L type, alpha 
1F subunit 
GUACGUAUUCCUGGUGAUUtt AAUCACCAGGAAUACGUACtc 
CACNA1S calcium channel, voltage-dependent, L type, alpha 
1S subunit 
GCUUCUAAUGUCAUUCAAAtt UUUGAAUGACAUUAGAAGCtc 
CAV1 caveolin 1, caveolae protein, 22kDa GGAGUUAGUGGAUUACUGCtt GCAGUAAUCCACUAACUCCtt 
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CAV2 caveolin 2 GGUCUUUUCAAAUAAUGCUtt AGCAUUAUUUGAAAAGACCtg 
CAV3 caveolin 3 GGAACAAGGUCUAAUUUGUtt ACAAAUUAGACCUUGUUCCtt 
CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, 
p16, inhibits CDK4) 
GCUUUUAAAAAUGUCCUGCtt GCAGGACAUUUUUAAAAGCtc 
LYST lysosomal trafficking regulator GCCCUAAUAAAUAGUGUGAtt UCACACUAUUUAUUAGGGCtt 
AP2M1 adaptor-related protein complex 2, mu 1 subunit CGUUAAGCGGUCCAACAUUtt AAUGUUGGACCGCUUAACGtg 
AP1S1 adaptor-related protein complex 1, sigma 1 subunit GGGACCUCAAAGUUGUCUAtt UAGACAACUUUGAGGUCCCtc 
AP2S1 adaptor-related protein complex 2, sigma 1 subunit GGUGCUGAAACAGCUGCUGtt CAGCAGCUGUUUCAGCACCtt 
AP3S1 adaptor-related protein complex 3, sigma 1 subunit GGAGGAUUAUUAAUUGGAGtt CUCCAAUUAAUAAUCCUCCtt 
CLTA clathrin, light chain (Lca) GCUACAGAAAACAAAAGCAtt UGCUUUUGUUUUCUGUAGCtg 
CLTB clathrin, light chain B UGCUGCAUCUAAGGUCACGtt CGUGACCUUAGAUGCAGCAtc 
CLTC clathrin, heavy chain (Hc) GGGCAAUUCAAAGAUAUCAtt UGAUAUCUUUGAAUUGCCCtt 
COPA coatomer protein complex, subunit alpha GGGCACAACCAUUAUGUGAtt UCACAUAAUGGUUGUGCCCtg 
COPB1 coatomer protein complex, subunit beta 1 GGAUCUUCAACAUCCUAAUtt AUUAGGAUGUUGAAGAUCCtt 
DNM1 dynamin 1 GGAGAACUGCCUCAUCCUGtt CAGGAUGAGGCAGUUCUCCtt 
DNM2 dynamin 2 GGGCUUCAUGUCCAACAAGtt CUUGUUGGACAUGAAGCCCtt 
ENG endoglin (Osler-Rendu-Weber syndrome 1) GGCAUCCAAGCAAAAUGGCtt GCCAUUUUGCUUGGAUGCCtg 
STX2 syntaxin 2 GGGUGAAAUGAUCAACAACtt GUUGUUGAUCAUUUCACCCtg 
HPS1 Hermansky-Pudlak syndrome 1 GGAGUACUUCACACCAGCUtt AGCUGGUGUGAAGUACUCCtc 
HSPA8 heat shock 70kDa protein 8 GGAGGUGUCUUCUAUGGUUtt AACCAUAGAAGACACCUCCtc 
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ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of 
VLA-3 receptor) 
GGAAACAGCUACAUGAUUCtt GAAUCAUGUAGCUGUUUCCtt 
LMAN1 lectin, mannose-binding, 1 GGCUCAGUGUGGACAAAGAtt UCUUUGUCCACACUGAGCCtc 
RAB3A RAB3A, member RAS oncogene family GAUUCUCAUCAUCGGCAACtt GUUGCCGAUGAUGAGAAUCtt 
RASA1 RAS p21 protein activator (GTPase activating 
protein) 1 
GGAGAUAUGUUCAUUGUUCtt GAACAAUGAACAUAUCUCCtt 
SNAP25 synaptosomal-associated protein, 25kDa CCCGUGUUCUCCUCCAAAUtt AUUUGGAGGAGAACACGGGtg 
STX1A syntaxin 1A (brain) GGAGAUUCGAGGCUUCAUUtt AAUGAAGCCUCGAAUCUCCtc 
STX3 syntaxin 3 GGGUGAGAUGUUAGAUAACtt GUUAUCUAACAUCUCACCCtg 
STX4 syntaxin 4 GGAGUUCUUCCACAAGGUCtt GACCUUGUGGAAGAACUCCtc 
STX5 syntaxin 5 GGAUUCCUACAUCCAGAGUtt ACUCUGGAUGUAGGAAUCCtg 
STXBP1 syntaxin binding protein 1 GGGCAUAACGAUUGUGGAAtt UUCCACAAUCGUUAUGCCCtc 
STXBP2 syntaxin binding protein 2 GGAGCUGAAUAAGUAUUCUtt AGAAUACUUAUUCAGCUCCtt 
STXBP3 syntaxin binding protein 3 GGGUUUAGAGAUUCUUACUtt AGUAAGAAUCUCUAAACCCtc 
VAMP1 vesicle-associated membrane protein 1 
(synaptobrevin 1) 
GGCAGGAGCAUCACAAUUUtt AAAUUGUGAUGCUCCUGCCtg 
VAMP2 vesicle-associated membrane protein 2 
(synaptobrevin 2) 
UUUGCGCCAUCAUCCUCAUtt AUGAGGAUGAUGGCGCAAAtc 
VAMP7 vesicle-associated membrane protein 7 CGGUUCAAGAGCACAGACAtt UGUCUGUGCUCUUGAACCGta 
SYT1 synaptotagmin I GGAAGAUGCAUUUUCUAAGtt CUUAGAAAAUGCAUCUUCCtt 
SYT4 synaptotagmin IV GGUAUACAUGUUUGAAGAAtt UUCUUCAAACAUGUAUACCtc 
200 
 
SYT5 synaptotagmin V GGACUGUCAGAUCCAUACGtt CGUAUGGAUCUGACAGUCCtc 
AP3B2 adaptor-related protein complex 3, beta 2 subunit GGAUCAGCUGAUAGAAGUCtt GACUUCUAUCAGCUGAUCCtt 
STX7 syntaxin 7 GCUAUUGUAUAAAGGAUGGtt CCAUCCUUUAUACAAUAGCtt 
AP3B1 adaptor-related protein complex 3, beta 1 subunit GGUUUACACUUGUCAACUUtt AAGUUGACAAGUGUAAACCtt 
VAMP8 vesicle-associated membrane protein 8 
(endobrevin) 
GGAGAGAAAAAAGAGAGAUtt AUCUCUCUUUUUUCUCUCCtt 
VAMP4 vesicle-associated membrane protein 4 GAAAUCUUUUGGAAGAUGAtt UCAUCUUCCAAAAGAUUUCtc 
STX16 syntaxin 16 CCAGCGAUUUGAUUUAUUGtt CAAUAAAUCAAAUCGCUGGtg 
STX11 syntaxin 11 GCUCAACGUACAAAAGACGtt CGUCUUUUGUACGUUGAGCtc 
STX10 syntaxin 10 CCAUAUGGUCAGCCCAACAtt UGUUGGGCUGACCAUAUGGtc 
GBF1 golgi brefeldin A resistant guanine nucleotide 
exchange factor 1 
GGCUCAGUGAGUUAUUGAGtt CUCAAUAACUCACUGAGCCtc 
SNAP23 synaptosomal-associated protein, 23kDa GGCUUGGACCAAAUAAAUAtt UAUUUAUUUGGUCCAAGCCtt 
AP1S2 adaptor-related protein complex 1, sigma 2 subunit CGUAGUGUUCUUGAAGAAAtt UUUCUUCAAGAACACUACGtg 
AP1G2 adaptor-related protein complex 1, gamma 2 subunit GAUUCACAGACAAGAGGGUtt ACCCUCUUGUCUGUGAAUCtg 
AP1M1 adaptor-related protein complex 1, mu 1 subunit GGAUGUGAAAUUUUUCCGUtt ACGGAAAAAUUUCACAUCCtt 
CACNA1I calcium channel, voltage-dependent, T type, alpha 
1I subunit 
GGAGAACUUCACCAUACAAtt UUGUAUGGUGAAGUUCUCCtc 





CACNA1G calcium channel, voltage-dependent, T type, alpha 
1G subunit 
GGAACAUCACCAAUAAAUCtt GAUUUAUUGGUGAUGUUCCtg 
AP3D1 adaptor-related protein complex 3, delta 1 subunit GGUCAUUUGUUGCGUUGAAtt UUCAACGCAACAAAUGACCtc 
SYT7 synaptotagmin VII CCAACUUGUAUCGAGUGGGtt CCCACUCGAUACAAGUUGGtt 
AP4M1 adaptor-related protein complex 4, mu 1 subunit GAGAUUGUCUGUACUGAUAtt UAUCAGUACAGACAAUCUCtc 
VAPB VAMP (vesicle-associated membrane protein)-
associated protein B and C 
GGUUAUGGAAGAAUGUAAGtt CUUACAUUCUUCCAUAACCtt 
COPB2 coatomer protein complex, subunit beta 2 (beta 
prime) 
GCUCUUAAUUAGAACUGGAtt UCCAGUUCUAAUUAAGAGCtc 
VAMP3 vesicle-associated membrane protein 3 GGUUCUGGAAAGAGACCAGtt CUGGUCUCUUUCCAGAACCtt 
SNAP29 synaptosomal-associated protein, 29kDa GCUUAUCGAACUAGACAUUtt AAUGUCUAGUUCGAUAAGCtt 
STX8 syntaxin 8 GGUGAAAAGGCACCAAAGCtt GCUUUGGUGCCUUUUCACCtt 
RGS6 regulator of G-protein signaling 6 GGUUAAAAAGUCCGUGUAUtt AUACACGGACUUUUUAACCtt 
RICS Rho GTPase-activating protein GGCUGAUAAAAAUCCACGAtt UCGUGGAUUUUUAUCAGCCtt 
IQSEC1 IQ motif and Sec7 domain 1 GGGAGUCCAGUACCUCAUCtt GAUGAGGUACUGGACUCCCtt 
AP1M2 adaptor-related protein complex 1, mu 2 subunit GGAGUACAUCACUCAGCAGtt CUGCUGAGUGAUGUACUCCtg 
HUWE1 HECT, UBA and WWE domain containing 1 GCAAAUCAAGCCUUUGUUAtt UAACAAAGGCUUGAUUUGCtt 
PREB prolactin regulatory element binding CCACGAUAAUACCCUGCUUtt AAGCAGGGUAUUAUCGUGGtt 
M6PRBP1 mannose-6-phosphate receptor binding protein 1 GCCUGUAGCUAAUGGACUUtt AAGUCCAUUAGCUACAGGCtg 
STX6 syntaxin 6 GGGAUUGUUUCAGAGAUGGtt CCAUCUCUGAAACAAUCCCtg 
AP3S2 adaptor-related protein complex 3, sigma 2 subunit GGGUGGAAGUUUGAUUGGUtt ACCAAUCAAACUUCCACCCtc 
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SEC24B SEC24 related gene family, member B (S. 
cerevisiae) 
GCCCUAUUAUAUACAUCAAtt UUGAUGUAUAUAAUAGGGCtg 
SEC23A Sec23 homolog A (S. cerevisiae) GGCAUUUCAAAAAGCUAUGtt CAUAGCUUUUUGAAAUGCCtt 
AP4B1 adaptor-related protein complex 4, beta 1 subunit GGAAGAACUAUUUGACAUUtt AAUGUCAAAUAGUUCUUCCtc 
EHD1 EH-domain containing 1 GCCUCACCAUUUCUCAAGGtt CCUUGAGAAAUGGUGAGGCtt 
AP3M2 adaptor-related protein complex 3, mu 2 subunit CCUACAGGAUUCUAAGGUUtt AACCUUAGAAUCCUGUAGGtt 
AP4S1 adaptor-related protein complex 4, sigma 1 subunit GGUACAGAAAACCUCCACGtt CGUGGAGGUUUUCUGUACCtt 
HPS5 Hermansky-Pudlak syndrome 5 GGAUGUGCUAUUAGUUAAUtt AUUAACUAAUAGCACAUCCtg 
AP1GBP1 AP1 gamma subunit binding protein 1 CCGAUUUUAAAACAGCCGAtt UCGGCUGUUUUAAAAUCGGtg 
COPE coatomer protein complex, subunit epsilon GCUGUUCGACGUAAAGAACtt GUUCUUUACGUCGAACAGCtc 
COPZ1 coatomer protein complex, subunit zeta 1 CCUUCCUGAGACUUAAGCAtt UGCUUAAGUCUCAGGAAGGtt 
COPG1 coatomer protein complex, subunit gamma 1 CCAAUCCCUCAAAGUACAUtt AUGUACUUUGAGGGAUUGGtg 
SEC31A SEC31 homolog A (S. cerevisiae) GACAAGUUCAGCAUAUUUUtt AAAAUAUGCUGAACUUGUCtg 
SYT11 synaptotagmin XI GGCAGUCUAUAAUUAACUGtt CAGUUAAUUAUAGACUGCCtt 
AP4E1 adaptor-related protein complex 4, epsilon 1 subunit CCUUCAUUGUUUGCUAAUAtt UAUUAGCAAACAAUGAAGGtg 
STX12 syntaxin 12 GGGCCCAAAUGCAUAAGUUtt AACUUAUGCAUUUGGGCCCtt 
DNM3 dynamin 3 GGUUACUCGUCUGAAUAUUtt AAUAUUCAGACGAGUAACCtt 
VPS33B vacuolar protein sorting 33 homolog B (yeast) GGAUUACCGAUCUCUGAAAtt UUUCAGAGAUCGGUAAUCCtt 
COPG2 coatomer protein complex, subunit gamma 2 GGCUGUCAACAAUAUCAUCtt GAUGAUAUUGUUGACAGCCtc 
AP3M1 adaptor-related protein complex 3, mu 1 subunit GGUAGUAAAAGGGAACAUUtt AAUGUUCCCUUUUACUACCtt 
STXBP6 syntaxin binding protein 6 (amisyn) GGACAAAGAAAAAGAUUCCtt GGAAUCUUUUUCUUUGUCCtc 
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RACGAP1 Rac GTPase activating protein 1 CCACAGACACCAGAUAUUAtt UAAUAUCUGGUGUCUGUGGtg 
EHD4 EH-domain containing 4 GGAUAAAAGCCUUUAUACAtt UGUAUAAAGGCUUUUAUCCtg 
EHD3 EH-domain containing 3 GGUGGUUUUAGUUCAUAGAtt UCUAUGAACUAAAACCACCtt 
EHD2 EH-domain containing 2 GGACAAGUCCAAAUACGACtt GUCGUAUUUGGACUUGUCCtt 
SAR1B SAR1 homolog B (S. cerevisiae) GGCUUACUCAGAGAUUUGAtt UCAAAUCUCUGAGUAAGCCtg 
COPZ2 coatomer protein complex, subunit zeta 2 GGAGCAGAUGGUUUUCGAGtt CUCGAAAACCAUCUGCUCCtt 
SYT17 synaptotagmin XVII GGAUCGUCAUUGGCCAGUAtt UACUGGCCAAUGACGAUCCtc 
STX18 syntaxin 18 GGGAAGAUCAUAGUUAAUAtt UAUUAACUAUGAUCUUCCCtg 
STX17 syntaxin 17 GGAGCUAAGGUUCAUUAGGtt CCUAAUGAACCUUAGCUCCtg 
C4orf16 chromosome 4 open reading frame 16 GCACUUAAGUAUAGCAACAtt UGUUGCUAUACUUAAGUGCtg 
SAR1A SAR1 gene homolog A (S. cerevisiae) GGUUAACAUCUGUAGCUUUtt AAAGCUACAGAUGUUAACCtt 
FAM62B family with sequence similarity 62 (C2 domain 
containing) member B 
GGGUGUUCUAAGGAUACAUtt AUGUAUCCUUAGAACACCCtt 
SYT13 synaptotagmin XIII GGAGGUGCUUAUUAAAUACtt GUAUUUAAUAAGCACCUCCtt 
TBC1D15 TBC1 domain family, member 15 CGAAAAUGUUGUCAUGACUtt AGUCAUGACAACAUUUUCGtc 
ARHGAP10 Rho GTPase activating protein 10 GGGAACUGUACUACUCGCAtt UGCGAGUAGUACAGUUCCCtt 
HPS6 Hermansky-Pudlak syndrome 6 GCUAUUUUUAAGAUGUGUGtt CACACAUCUUAAAAAUAGCtc 
PTGES2 prostaglandin E synthase 2 GGCAUCUCAUGGAAAAAAAtt UUUUUUUCCAUGAGAUGCCtg 
SYT15 synaptotagmin XV CCCAGAGCUGUACAAGUUCtt GAACUUGUACAGCUCUGGGtt 
CHR3SYT family with sequence similarity 62 (C2 domain 




SYT16 synaptotagmin XVI GGACUCAUGUUCCACAAUGtt CAUUGUGGAACAUGAGUCCtt 
DTNBP1 dystrobrevin binding protein 1 GGUAUGAGGAUACAUGGGCtt GCCCAUGUAUCCUCAUACCtg 
SYT3 synaptotagmin III GGAAAAAGCCAAACUCAUUtt AAUGAGUUUGGCUUUUUCCtc 
HPS3 Hermansky-Pudlak syndrome 3 CGUCAUUACAAGUAACAACtt GUUGUUACUUGUAAUGACGtg 
HPS4 Hermansky-Pudlak syndrome 4 CCUCAGUUCUAUUACGUUAtt UAACGUAAUAGAACUGAGGtt 
SYT8 synaptotagmin VIII CGCCGCUGCCUCAGAUCCCtt GGGAUCUGAGGCAGCGGCGtg 
SYT12 synaptotagmin XII GGAAGAUGAGCAAAAAGAAtt UUCUUUUUGCUCAUCUUCCtc 
STX1B syntaxin 1B GGAAGAAAAUCAUGAUCAUtt AUGAUCAUGAUUUUCUUCCtc 
SNX26 sorting nexin 26 GGUUUCUAACUUUGUAACUtt AGUUACAAAGUUAGAAACCtg 
SYT2 synaptotagmin II GAAAUAUGAGACCAAAGUCtt GACUUUGGUCUCAUAUUUCtt 
AP1S3 adaptor-related protein complex 1, sigma 3 subunit AUGGUACAUCACUCUCCCUtt AGGGAGAGUGAUGUACCAUtt 
STXBP5 syntaxin binding protein 5 (tomosyn) GGAGGUUUGUCAUAUGAUAtt UAUCAUAUGACAAACCUCCtg 
SYT9 synaptotagmin IX GACAACUCAACUUGUCAAAtt UUUGACAAGUUGAGUUGUCtt 
SYT6 synaptotagmin VI CCCUCGGUUGUGAUUUCAUtt AUGAAAUCACAACCGAGGGtt 
VPS13B vacuolar protein sorting 13 homolog B (yeast) GGAUUCAUGUACCAUGGACtt GUCCAUGGUACAUGAAUCCtc 
STXBP4 syntaxin binding protein 4 CCCAGUCUACUUGAAAAGGtt CCUUUUCAAGUAGACUGGGtg 
SYT14 synaptotagmin XIV GGUCAUGAAAUAGAAAGUUtt AACUUUCUAUUUCAUGACCtg 
SYT10 synaptotagmin X GCUAUUGAGCCUGCAAUAAtt UUAUUGCAGGCUCAAUAGCtt 
STX19 syntaxin 19 GGAUUUAAGGGAUCUUUUCtt GAAAAGAUCCCUUAAAUCCtt 
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1.4. Full siRNA screen results 
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